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Abstract 
This study investigates different modalities for achieving elective single embryo transfer in assisted 
reproductive technologies (ART) and developing protocols and policies that both permit maximum 
access to care as well as improving safety of ART by limiting the number of embryos that are 
transferred. 
The study includes 16 peer-reviewed journal articles and 1 book chapter published since 2001 and 
covering my career to date while working in two university affiliated IVF centres: McGill University 
and the University of Montreal, Canada. It includes research on: 
• Improving the clinical application of modified natural cycle IVF
A total of 134 MNCIVF cycles were compared with 370 IVF cycles using COS; in patients under 
the age of 35 years old the clinical pregnancy rate was 27% versus 47% however in patients older 
than 35 years old the benefits of MNCIVF did not support the poorer prognostic with a clinical 
pregnancy rate of only 8%.  
The addition of a NSAID, Indomethacin, further optimized the MNCIVF protocol by decreasing the 
premature ovulation rate from 16% to 6%, this in turn increased the potential of obtaining the oocyte 
at retrieval from 64% to 76%.  
The combination of MNCIVF and surgical sperm retrieval was demonstrated as a viable option in 
a case report describing a couple who did not want any risk of multiple pregnancy and the least 
invasive treatment possible to obtain their pregnancies. This treatment was confirmed with a study 
comparing 81 MNCIVF using ejaculated spermatozoa with 44 MNCIVF using surgically retrieved 
spermatozoa. There were no differences in the clinical pregnancy rate (31.0% versus 35.1%), 
however the chance of having an embryo transfer increased in the surgical group (65.9% versus 
45.7%). The age of the male partner in the surgical group was older (41.5 versus 36.5) perhaps 
associated with second relationships; a group for whom MNCIVF can be an interesting treatment 
option. 
The use of MNCIVF in young poor responders is suggested as well as an option for egg donation 
where the donor wants to avoid gonadotrophins. An analysis of over 1500 MNCIVF was carried out 
demonstrating a clinical pregnancy rate per embryo transfer of 32.5%. Patient cycles were stratified 
according to ovarian reserve and in younger patients this had little influence on outcome, however in 
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the patients over 35 years of age, the clinical pregnancy rate dropped significantly with a poor 
ovarian reserve (26.3% versus 6.3%) 
• Investigating the application of the protocol for in vitro maturation of oocytes
One hundred and seven IVM cycles in patients with polycystic ovarian syndrome were case matched 
with 107 IVF and COS cycles. There was no significant difference in the clinical pregnancy rate (28% 
versus 41%) although it came close to significance, however there were less oocytes (10.3 versus 14.9), 
less mature oocytes (7.8 versus 12.0) and less embryos available (5.8 versus 8.6). Importantly there 
were no cases of OHSS in the IVM group compared to 11% in the IVF with COS group.  
A case study describes the use of IVM in combination with PESA and the possibility to 
successfully obtain and mature oocytes in a PCOS patient and then fertilize those oocytes using 
spermatozoa retrieved using a simple procedure in an azoospermic partner. Additional more 
specialized uses of IVM are described including a case report of a young patient with FSH receptor 
mutation and falling ovarian reserve for whom IVM was used to obtain and mature ten oocytes for 
fertility preservation following a failed attempt to stimulate her ovaries.   
• Studying the implementation of legislation and funding related to ART and the impact on treatment 
in Quebec, Canada
An initial study after the introduction of funding demonstrated a reduction from 25.6% to 
3.7% in the multiple pregnancy rate following IVF, with an increase in the use of eSET from 1.6% 
to 50% of performed embryo transfers. This was followed by studies showing that although the 
pregnancy rate in IVF dropped under funding, the cumulative pregnancy rate would correct for 
this drop using a predictive calculation (29.7% versus 31.9%). This was confirmed with data 
analysis after the first complete year of funding in one clinic, indicating that the transfer of one 
fresh embryo followed by one frozen-thawed embryo gave equivalent pregnancy rates to DET 
(47.1% versus 47.1%).  
A financial analysis furthermore supported the fiscal benefits of funding showing that 
although funding in absolute terms costs the government more, the cost per baby is lower under 
funding than with a tax rebate system (49,517$ versus 43,362$) considering the costs of high 
order multiple pregnancies that are significantly reduced under funding with an eSET policy in 
place. 
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A final complete analysis of the totality of the funding program after it was shut down, comparing with 
the year prior to and the year post funding, clearly indicates that the design of funding can 
influence not only the fiscal burden but also clinical decision making and that this reflects in the 
results. The cancellation rate increased dramatically (17.0% versus 34.4%) and the live birth rate 
dropped in all treatment modalities (33.9% versus 23.7%). However, the multiple pregnancy rate 
dropped from over 25% to under 5% throughout the course of funding and remained under 5% 
even once funding was withdrawn.  
These publications form a tiny part of the enormous journey that ART has taken over the course of the 
last 40 years and continues to take on a daily basis. Additional research is required in all these and 
other areas related to IVF and embryology in order to further improve all aspects of ovarian 
stimulation, embryo culture and selection and implantation knowledge and application.   
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Chapter 1 – Introduction 
The birth in 1978 of Louise Brown signaled one of the greatest developments of reproductive 
medicine: the clinical application of many years of basic research in human reproduction and the 
beginning of numerous advances in the field (Steptoe and Edwards, 1978).  This first in vitro 
fertilisation (IVF) birth was the result of obtaining an oocyte during the natural menstrual cycle of the 
patient. The team of Edwards and Steptoe had previously worked unsuccessfully to perform IVF in 
combination with ovarian stimulation before returning to the natural cycle and it was not until 1981 
that the first IVF baby was born following ovarian stimulation and the recruitment of multiple follicles 
(Trounson et al, 1981). Over the course of the next fifteen years a number of important ‘firsts’ were 
associated with IVF treatment: birth after embryo cryopreservation (Trounson et al, 1983), the genetic 
analysis and selection of embryos for x-linked and monogenic disease (Handyside et al, 1990, 1992), 
intracytoplasmic sperm injection (ICSI): the microinjection of sperm into the egg to achieve 
fertilisation in cases with compromised sperm parameters (Palermo et al, 1992) and the application of 
surgically retrieved testicular spermatozoa in fertilisation using ICSI (Silber et al, 1994). 
For many reasons it was believed that IVF in combination with controlled ovarian stimulation (COS) 
would be the most effective use of the treatment and from 1981 the use of IVF with COS became the 
standard. Controlled ovarian stimulation was achieved initially with clomiphene citrate, a selective 
estrogen receptor modulator (Lopata et al, 1980) and then using human menopausal gonadotropin 
(hMG) (Trounson et al, 1981) along with gonadotropin-releasing hormone (GnRH) agonists (Fleming 
et al, 1982). IVF with COS in combination with embryo cryopreservation offered patients the ability 
to have multiple pregnancy attempts from one ovarian stimulation cycle and it also allowed for the 
transfer of multiple embryos which increased the chance of pregnancy. However, this option to transfer 
more than one embryo at a time also introduced the side-effect that would become arguably the biggest 
issue associated with in vitro fertilisation for many years; that is the increased risk of multiple 
pregnancies. The first multiple pregnancies resulting from IVF were reported in 1983 in Australia 
(Speirs et al, 1983). In North America by the start of the new millennium the multiple pregnancy rates 
from IVF were reported as 33% to 54% of all live births (Reports available on Centre for Disease 
Control and Prevention (www.cdc.gov) and Canadian Fertility and Andrology Society (www.cfas.ca) 
websites). 
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CANADA - CFAS USA - CDC 
Year Number 
of IVF 
cycles 
Live 
birth rate 
per cycle 
Multiple 
pregnancy 
rate 
Number 
of IVF 
cycles 
Live 
birth rate 
per cycle 
Multiple 
pregnancy 
rate 
2001 4292 21% 33% 107587 27% 54% 
2002 4896 20% 35% 115392 29% 53% 
2003 5380 23% 33% 122872 29% 51% 
2004 6502 24% 35% 127977 29% 36% 
 Table 1: Multiple pregnancy rates in USA and Canada from 2001-2004. (CDC, CFAS) 
Other than the availability of only one oocyte the major driving force away from using natural cycle 
for IVF was the inability to control the cycle. The first IVF cycles were performed by monitoring the 
natural luteinizing hormone (LH) surge of the patient and carrying out the oocyte retrieval based on 
this timing. The result of this approach is a requirement to have the operating room and laboratory 
available at all times of the day and night and an extremely high risk of premature ovulation and loss 
of the oocyte.  
The development of GnRH antagonists opened the opportunity to revisit the use of natural cycle IVF 
(Frydman et al, 1991). Unlike GnRH agonists that cause indirect suppression of the pituitary, the 
administration of GnRH antagonist results in immediate, dose-related inhibition of gonadotropin 
release by competing for GnRH receptors in the pituitary. This immediate short-term effect removes 
the need for pre-cycle down-regulation of the ovary and permits pre-ovulatory application. Despite 
being proposed in the early 1990s, it took over 10 years before GnRH antagonists started to be used 
regularly rather than GnRH agonist protocols as the standard for IVF with COS. 
In 2004 we started offering a controlled natural IVF cycle to patients at our clinic. In 2007, I published 
a paper describing a series of 134 controlled natural IVF cycles comparing them with 370 IVF cycles 
using COS in patients under-35 years of age (Phillips et al, 2007). The clinical pregnancy rate in these 
controlled natural cycles was 27% with no multiple pregnancies compared to a clinical pregnancy rate 
of 47% in the IVF with COS cycles but at the cost of a 37% multiple pregnancy rate. In addition, in 
this paper, I analysed the use of controlled natural cycle IVF in 108 patients over the age of 35 who 
requested controlled natural cycle IVF despite counselling to the contrary; these patients had a clinical 
pregnancy rate of only 8% as compared to 240 cycles of over-35-year-old patients with IVF and COS 
who had a clinical pregnancy rate of 37% with a multiple pregnancy rate of 36%. 
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For the under 35-year-old group of patients undergoing controlled natural cycle IVF, the 134 cycles 
were performed for 70 patients, with a clinical pregnancy rate per patient of 28.5%. In this paper I 
concluded that although the clinical pregnancy rate was lower for the controlled natural cycle IVF 
group, the benefits of a simpler protocol, fewer injections and medication, the ability to carry out an 
IVF month after month like intrauterine insemination cycles and no risk of multiple pregnancy was an 
interesting option for some patients. Based on this study patients were counselled to move to IVF with 
COS after three failed attempts of controlled natural cycle IVF since over 90% of patients who got 
pregnant did so on cycle one or two. Patients over the age of 35 were also counselled against controlled 
natural cycle IVF since the pregnancy rate in this group was particularly low.  
The application of hMG alongside GnRH antagonist in our protocol for controlled natural cycle 
certainly created some debate as to how ‘natural’ the protocol was. As journal referee after referee 
asked for clarification I published a letter outlining the basis for this use and why the cycle should still 
be considered ‘natural’ (Phillips et al, 2007). Kettel had demonstrated in 1991 that the application of 
a GnRH antagonist Nal-Glu, concomitantly with gonadotropin suppression, causes significant drops 
in estradiol levels leading to functional arrest in the dominant follicle (Kettel et al, 1991). This effect 
can be seen in temporarily plateauing estradiol levels in COS; however, the impact is more critical in 
natural cycles with only one follicle available for oocyte retrieval: the small dose of hMG given 
concurrently with the start of GnRH antagonist acts simply to limit the estradiol drop and support the 
follicle. We proposed the term controlled natural cycle IVF in our letter, and various other terms were 
used at the time. Consensus determined that the protocol is now referred to as ‘modified natural cycle 
IVF’ (Nargund et al, 2007). 
Now that control over the cycle could be assured there were still a disproportionately high number of 
cycles that ended with no embryo transfer. The use of ICSI could maximise the chance of fertilisation, 
but premature ovulation despite GnRH antagonist and failure to collect the oocyte at retrieval were 
still problematic. Follicle flushing and the use of 0.22 µm filters at egg collection, as used in in vitro 
maturation (to be discussed later), helped to maximise oocyte retrieval, however, the rate of premature 
ovulation was still high.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to affect ovulation likely through 
disruption of cyclooxygenase 2 (COX-2) which is the rate-limiting enzyme in prostaglandin 
production (Gaytan et al, 2006). A case report published in 1996 demonstrated that indomethacin, a 
NSAID (marketed in Canada as Indocid by Merck Frosst) could be used to delay ovulation for up to 
seven days. Patients from a community where the male partners were often absent for work 
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commitments were given the NSAID to delay ovulation in intrauterine insemination cycles until the 
male partner was available to produce a semen sample (Nargund and Wei, 1996). 
In 2008, I authored a publication with a series of modified natural cycles looking at the addition of 
indomethacin, demonstrating that the use of the NSAID in addition to our standard modified natural 
cycle protocol reduced the premature ovulation rate from 16% to 6% (OR 3.8 95%, CI 1.2-12.3) and 
increased the oocyte retrieval rate from 64% to 76% (p < 0.04) (Kadoch et al, 2008). The use of 
indomethacin had no impact on the pregnancy rate although there was a clinically interesting increase 
for those patients who took the drug (14% versus 21% p = 0.13). 
This approach was confirmed by a Japanese group who also used NSAID in modified natural cycle to 
reduce the risk of premature ovulation (Kawachiya et al, 2012). 
These papers demonstrated that a modified natural cycle IVF could be offered to patients with the 
associated benefits of an easier process for the patient, less costly, no risk of ovarian hyper-stimulation 
syndrome (OHSS), the possibility to perform cycles month after month and almost no risk of multiple 
pregnancy. Although clinical pregnancy rates were lower using modified natural cycle, ranging in the 
literature between 10% and 50%, for those patients opting for this protocol the benefits outweighed 
this limitation. 
Our work on modified natural cycle IVF was part of a movement at the time promoting a gentler 
approach towards IVF. Other researchers were also working with modified natural cycles as well as 
mild stimulation protocols for IVF. These different approaches were highlighted in a review editorial 
by Edwards in 2007 and underlined by the creation of a society directed entirely at the promotion of 
more physiological and mild IVF protocols; The International Society for Mild Approaches in Assisted 
Reproduction (ISMAAR) (Nargund and Frydman, 2007). 
In their 2007 paper, ISMAAR proposed terminology for ovarian stimulation protocols including the 
now accepted definition of modified natural cycle IVF. In addition, natural cycle IVF was defined as 
IVF carried out in a spontaneous menstrual cycle without the administration of any medication at 
any time during the cycle differentiating it from MNCIVF. In contrast mild IVF was 
defined as the application of FSH or HMG at lower doses than used in standard COS or for 
a shorter duration or when oral compounds are used in combination with gonadotropins. The aim of 
mild IVF is to collect between 2 and 7 oocytes. Studies have suggested that mild IVF reduces 
aneuploidy (Baart et al, 2007); in this randomized study the absolute number of euploid embryos 
was the same in the mild IVF group and the IVF with COS group, however proportionally the rate 
of aneuploidy was lower in the mild 
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IVF group. It has also been suggested that the use of mild IVF regimes can improve oocyte 
quality over IVF with COS in certain patients (Jamal et al, 2009). More recently a review of the use 
of mild IVF was published in 2009 (Verberg et al, 2009) as well as a debate on the subject (Fauser et 
al, 2010). These articles reference the fact that to date there are only a limited number of randomized 
control trial studies (RCT) comparing mild IVF with IVF using COS. However, some data 
is presented demonstrating reduced costs, safer treatment for patients and answering concerns 
around the milder IVF protocols in terms of potentially having lower cumulative pregnancy rates if 
fewer embryos are available: the data suggests that the overall number of available good quality 
embryos is the same thereby countering this argument. Both articles speak to the fact that mild IVF 
protocols have not been widely incorporated and suggest clinical resistance and patient characteristics 
(advanced maternal age) as primary reasons for this. Further research to demonstrate benefits are 
proposed going forward to underline the potential increased use of milder IVF protocols in ART. 
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Chapter 2 – Applications of modified natural cycle IVF 
Having improved the efficacy of the modified natural cycle for IVF (MNCIVF), it was clear that the 
benefits of this treatment were not apparent for all groups of patients: for example, my original study 
suggested significantly reduced pregnancy rates in patients using modified natural cycle IVF over 35 
years of age. Other studies looking at age related outcomes in MNCIVF confirmed this pattern; 
Tomazevic looked at patients less than and greater than 39 years of age and saw significant differences 
in the outcomes measures. Live birth rates were 55% versus 29% per embryo transfer in his study of 
397 cycles (Tomazevic et al, 2007). Another study of 947 MNCIVF cycles over 5 years confirmed the 
importance of age when three age groups were compared (≤ 35, 36-39 and ≥ 40), the authors reported 
clinical pregnancy rates that reduced by age group (10.6% versus 7.6% versus 3% respectively) 
(Gonzalez-Foruria et al, 2016). 
However, the ease of the protocol, reduced costs, minimal application of medication and no risk of 
multiple pregnancy are very appealing to certain patients. In 2005, I authored a case report for the use 
of MNCIVF in combination with percutaneous sperm aspiration (PESA) a relatively non-invasive and 
simple urological procedure to obtain sperm in men with an obstructive azoospermia (Kadoch et al, 
2005). In this case the couple had two children together; the male partner had undergone a vasectomy 
believing that their family was complete. When the couple decided that they wanted another child he 
underwent a failed vasovasostomy procedure. Since IVF presented the only option at this point but the 
couple were adamant that they did not want any risk of twins and wanted the simplest treatment 
available to them, MNCIVF fulfilled these requirements. Since second relationships where the male 
partner has undergone a vasectomy previously and where one or both of the couple already have 
children is a sub-group of patients presenting for care at IVF clinics, MNCIVF presents an alternative 
that can be offered to these patients. 
The application of surgical sperm retrieval in combination with MNCIVF was confirmed by a study I 
authored in 2012 which compared the outcomes of MNCIVF using ejaculated sperm with surgically 
retrieved sperm (Jamal et al, 2012). In this study no significant difference was seen in the clinical 
pregnancy rate for those cycles using surgically retrieved sperm when compared to ejaculated sperm 
as the source for ICSI (35.1% versus 31.0%, p = 0.71). No differences were seen in the female related 
parameters in the two groups although the men in the surgically retrieved sperm arm were significantly 
older; (41.5% versus 36.5%, p = 0.001) which may reflect a group as mentioned earlier; that is men in 
second relationships who have previously undergone vasectomy.  
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Another group that could benefit from MNCIVF are young patients who respond poorly to COS. In 
these cases, oftentimes high doses of gonadotropins are used in order to try to elicit a response from 
the ovaries, but despite the high doses perhaps only one or two follicles can be recruited. In this case, 
the use of MNCIVF can be a more physiologically appropriate, cost effective, and easier proposition 
for the patient. In addition, it avoids super-physiological doses of gonadotropins which may have a 
deleterious effect on the endometrium. This was proposed in two publications in 2009 demonstrating 
important differences in the gene expression profiles from the endometrium in natural cycles when 
compared to COS cycles in the same patients (Haouzi et al, 2009). Potential effects directly on the 
oocytes themselves have also been suggested in the mouse model (Edgar et al, 1987). We 
recommended the approach of using MNCIVF as a first line treatment for poor responder younger 
aged patients in a published letter to Fertility and Sterility in 2011 (Kadoch et al, 2011) outlining the 
benefits of MNCIVF and reduced risks to patients in particular to those who require high doses of 
gonadotropins for ovarian stimulation. This concept was supported by published data demonstrating a 
statistically significantly improvement in implantation rate using MNCIVF in poor responders in a 
randomised trial comparing to IVF with COS (14.9% versus 5.5%, p = 0.05) (Morgia et al, 2004).  
I also authored published case reports demonstrating the potential for the use of MNCIVF for specific 
patient cases further confirming the benefit of having MNCIVF as an additional protocol option for 
fertility clinics to offer. A 38-year-old patient with the rare condition of ovarian agenesis required 
oocyte donation to treat her infertility. Her sister offered to be the oocyte donor and since the patient 
and her sister wanted to minimise the impact on the donor and her life, it was proposed to use MNCIVF 
for the egg donation cycle. A successful cycle resulted in a healthy live birth (Kadoch et al, 2009). 
In another case report, a 33-year-old patient with idiopathic primary ovarian insufficiency and a 
familial history of premature menopause was pre-treated with dehydroepiandrostenedione (DHEA) to 
lower endogenous FSH levels and permit the patient to undergo a MNCIVF. Once again, a successful 
cycle resulted in a healthy live birth (Lehmann et al, 2014). 
Of course, not everyone was convinced about the benefits of MNCIVF and mild stimulation IVF 
protocols; a 2011 commentary in the journal, Reproductive Biomedicine Online questioned the 
application of these approaches in critiquing a specific publication but negatively referencing multiple 
publications on mild stimulation IVF, ISMAAR and MNCIVF including my 2007 paper (Gleicher et 
al, 2011). The authors’ principal arguments against these approaches hinged firstly on a lack of 
prospective randomised data as well as the importance of ensuring that patients are fully informed as 
to potential negative aspects of milder protocols; primarily that cumulative pregnancy rates are also 
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important and MNCIVF does not offer this possibility whilst mild stimulation significantly reduces 
the possibility. Clearly prospective randomised trials are the gold standard which are often not 
performed in the ART field for various reasons, and clear precise informed consent is an absolute 
requirement for any treatment ensuring that the patient understands the risks and negative aspects of 
any proposed treatment as well as the potential benefits. In our experience, at least at the time in 
question, many patients, but certainly not all, found the less invasive nature of MNCIVF to be a very 
attractive option for their fertility care. Of course, the patient input can be difficult to quantify 
scientifically and present in a published format, hence limiting the impact of this aspect on the 
arguments for or against a particular treatment. The use of MNCIVF in developing countries is an 
example of this; a study from Africa reviewed the reasons why so many patients cancelled their IVF 
cycles demonstrating that over 75% of cancellations were for financial reasons and these patients when 
given the choice between lower costs and simpler treatments such as MNCIVF would prefer these 
options even considering lower pregnancy rates (Shahin, 2007). 
In 2015, I authored the largest published series of MNCIVF cycles, analysing 1503 cycles performed 
in 782 patients over a period of six and a half years (Shaulov et al, 2015). Once again we stratified 
patients based on age (≤ 35 and ≥ 36) and in addition within the age groups by ovarian response 
according to the 2011 Bologna criteria (Ferraretti et al, 2011). Once again we confirmed that age is 
the major factor for the success of MNCIVF with higher cancellation rates in the older group of patients 
(23.8% versus 17.4%, p = 0.02) and lower clinical pregnancy rates per embryo transfer (23.5% versus 
34.5%, p = 0.02). When analysing by ovarian response, in the younger age group the clinical pregnancy 
rate was not affected by whether the patient had normal or poor ovarian reserve (35% versus 30%, p 
= 0.82) whereas in the older group the impact was more important (26% versus 6%, p = 0.06). This 
confirmed our previous proposition to offer MNCIVF to younger patients with anticipated poor 
ovarian response. In addition, we analysed the results per attempt number from first cycle to fifth 
MNCIVF attempt. Obviously, the number of cycles carried out reduced over time so 782 first attempts 
dropped to only 21 fifth cycles, however, the data indicated reasonably stable clinical pregnancy rates 
per embryo transfer (34.5%, 34.7%, 23.5%, 21.6%, 42.9%).  
The major limitation of this series was the retrospective nature of the study and the fact that patients 
who did not continue to undergo MNCIVF were not followed. These patients could have moved to 
other centres, converted to IVF with COS or achieved spontaneous pregnancy but these data were not 
recorded.  
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The benefits of MNCIVF have been somewhat reduced by the use of GnRH antagonist in combination 
with GnRH agonist trigger and freeze-all embryo strategies which can almost eliminate the risk of 
OHSS. Improved cryopreservation techniques and the use of vitrification in particular means that 
transferring a cryopreserved embryo offers the same potential as a fresh embryo transfer and therefore 
the importance of cumulative pregnancy rates becomes even more significant. However, our series of 
publications on MNCIVF demonstrates that it has a place in the arsenal of protocols that can be 
employed to treat patients and should be kept in mind for specific patients. 
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Chapter 3 – In vitro maturation of oocytes 
As already mentioned; other than multiple pregnancy, another major side-effect of IVF using COS is 
the risk of ovarian hyper-stimulation syndrome (OHSS). OHSS is an iatrogenic complication of COS, 
and although most OHSS is mild, when severe it can be associated with serious outcomes including 
reported cases of death. OHSS occurs in patients undergoing COS after an LH surge or exposure to 
human chorionic gonadotropin (hCG); used to trigger oocyte maturation prior to oocyte retrieval, or 
secondary OHSS in a pregnant patient following embryo transfer. The primary physiologic change 
that OHSS presents is a fluid movement from intravascular to third space areas, resulting in abdominal 
bloating, large ovaries, and in serious cases ascites, hemoconcentration, acute respiratory distress and 
thromboembolism. (Shmorgun and Claman, 2017) 
Polycystic ovaries are one of the risk factors for OHSS since these patients usually present with high 
antral follicle counts and often over respond to gonadotropin application resulting in multi-follicular 
response with extremely high levels of estradiol and associated increased risk of OHSS when triggered 
with hCG. Furthermore, the large number of oocytes retrieved in these patients often results in lower 
than average rates of maturation and thus increased numbers of immature oocytes which cannot 
fertilize.  
In vitro maturation of oocytes shares some of the benefits of MNCIVF, namely less medication, 
cheaper costs to the patient and greater patient convenience. In 2001 I authored a case report 
announcing the first case of in vitro maturation (IVM) in combination with percutaneous sperm 
aspiration (PESA) which was indicated due to diagnosis of obstructive azoospermia in the male partner 
(Abdul-Jalil et al, 2001). The female partner had 35 follicles between 4-6 mm on ultrasound on day 
3 of her menstrual cycle indicating a good candidate for IVM. A follow-up ultrasound on day 7 
confirmed no dominant follicle and hCG was given since previous work in our clinic had demonstrated 
the benefits to oocyte retrieval in IVM by giving hCG as used traditionally in an IVF cycle with COS 
(Chian et al, 2001). Twelve immature oocytes were obtained and cultured for twenty-four hours in 
specially designed in-house culture media including hMG and maternal serum, resulting in six mature 
oocytes which underwent ICSI. Four oocytes fertilised normally and three embryos were transferred 
to the patient on day 2 of embryo development. The patient became pregnant with a clinical twin 
pregnancy.  
IVM demands special consideration at the oocyte retrieval process in terms of both the clinical and 
laboratory elements. Since small follicles are to be punctured, a special larger gauge needle is required 
as is reduced pressure on the aspiration pump. On the laboratory side, immature oocytes do not have 
expanded cumulus granulosa cells complexes making them very much more difficult to visualise by 
the embryologist at the retrieval. In order to reduce the risk of missing oocytes at retrieval we added 
the use of 0.22 µm filters to the procedure and developed a technique of ‘sliding’ to assess oocyte 
maturity without denudation of the cumulus granulosa cells. In ‘sliding’, oocytes are examined in small 
volumes of media, tilting the dish in order to flatten the oocyte-cumulus complex, offering a better 
visual of the oocyte within and permitting an approximation of maturity.  
In 2002 I authored a study comparing IVM with IVF and COS for patients with polycystic ovarian 
syndrome (PCOS): 107 cycles of IVM were case matched with 107 cycles of IVF and COS (Child et 
al, 2001). Of 1102 oocytes that were retrieved for IVM, 835 matured to metaphase II (76%), 
fertilisation was achieved in 76% by ICSI as compared to 78% for IVF cycles (no significant 
difference). The number of retrieved oocytes (10.3 versus 14.9 p<0.01), the number of metaphase II 
oocytes (7.8 versus 12.0 p < 0.01) and the number of cleaved embryos available (5.8 versus 8.6 p < 
0.01) were all lower in the IVM group of patients. Furthermore the number of transferred embryos was 
lower in the IVF group (3.2 versus 2.7 p < 0.01), the pregnancy rate was not significantly different in 
the two groups (28% versus 41% p = 0.06) and the clinical pregnancy rate was not significantly 
different either (23% versus 36% p = 0.05), although both were close to statistical significance. There 
was a significant difference in the implantation rate (9.5% versus 17.1% p < 0.01) and probably 
associated with the fact that more embryos were transferred following IVM, the multiple pregnancy 
rate was higher in IVM although not significantly (41% versus 37%). There was also a significant 
difference in the incidence of OHSS between IVM and IVF groups (0% versus 11% p < 0.01). The 
technique succeeded in eliminating OHSS from these high risk patients however; clearly this technique 
did not achieve the advantage seen later with MNCIVF in removing the risks of multiple pregnancies. 
The benefits proposed in this study other than elimination of OHSS risk included less costs to the 
patients: the IVF group took an average of 31 ampoules of follicle stimulating hormone (FSH) during 
their controlled ovarian stimulation and only one ampoule of hMG was required for the IVM patients, 
as well as simplification of the cycle from the patients’ point of view with less clinic visits and blood 
tests requested. 
The findings of our study were confirmed in a more recent publication also comparing IVM with IVF 
using COS in patients diagnosed with PCOS. The researchers found no difference in the clinical 
pregnancy rates between the groups, however, lower live birth rates were seen in the IVM group 
(18.8% versus 31%, p = 0.021) although no significant differences were seen in results from 
subsequent frozen embryo transfer cycles (FET) between IVM and IVF (Walls et al, 2014) Similar 
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results indicating lower live birth rates but the elimination of OHSS were demonstrated in another 
study in 2012: live birth rates (44.3% versus 16.5%  p < 0.001) and development of OHSS (8.2% 
versus 0% p < 0.001) (Gremeau AS et al, 2012). 
There have been, however, some concerns raised regarding the use of in vitro maturation. Important 
epigenetic events in the latter stages of oocyte maturation have caused some researchers to question 
the safety of the technique. Indeed, the current American Society of Reproductive Medicine (ASRM) 
guidelines for IVM propose that it should only be used as an experimental technique and patients need 
to be advised that there is limited evidence related to its safety since relatively few babies have been 
born as a result of the technique. Some data had demonstrated abnormal methylation in in vitro matured 
oocytes however it is important to note that the oocytes used in the study were obtained from IVF 
using COS cycles which had not matured in response to maturation trigger in vivo.  These types of 
oocytes have subsequently been shown to be associated with high levels of DNA damage and poor 
embryonic development potential and as such are poor study substitutes for in vitro matured oocytes 
(Coticchio et al, 2015). 
As already discussed, hCG used to mimic the natural LH surge and trigger follicle maturation initiates 
OHSS due to its long half-life and luteotrophic action. The advent of the use of GnRH antagonists in 
IVF protocols permitting not only protocols such as the aforementioned MNCIVF but also allowed for 
the use of GnRH agonist application to trigger release of LH and FSH in an acute surge similar to that 
seen in the normal menstrual cycle. This form of action which was first suggested by a study in 2002 
(Fauser et al 2002) was not proposed specifically for OHSS avoidance until 2006 when a series of 
randomised controlled studies demonstrated that the use of GnRH agonist to replace hCG as the 
maturation trigger could effectively eliminate OHSS (Acevedo et al 2006, Babayof et al 2006, 
Engmann et al 2008) When information from these three studies is combined, in 78 patients triggered 
with GnRH agonist, no cases of OHSS were reported as compared with 25% OHSS in the group of 78 
patients triggered with hCG. This development, which remains as current practice today, effectively 
negated the major benefit of IVM leaving it on the sidelines of standard protocols used in assisted 
reproduction.  
However, it is important to note that it can still be used for specific cases, and similar to MNCIVF 
should be maintained in the options available for treatment of certain patients. I authored a case report, 
published in 2017 demonstrating the use of IVM for a very specific case in which other more standard 
ART protocols did not succeed (Pradervand et al 2017). A 19-year-old patient presented with a 
normal antral follicle count and anti-mullerian hormone (AMH) level (1.59 ng/mL) but with primary 
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amenorrhea and moderately developed secondary sex characteristics, small ovaries and uterus. Her 
FSH level was surprisingly high at 72.5 IU/L and FSH receptor (FSHR) mutation was suspected. The 
patient was found to have a rare variant mutation on exon 6 of the FSHR gene. One year later, her 
AMH dropped to 0.62ng/mL and her antral follicle count similarly reduced to a level associated with 
ovarian failure. An attempt to provide ovarian stimulation with the goal of fertility preservation was 
unsuccessful after the patient took 900 IU of recombinant FSH daily for 17 days with no ovarian 
response at all.  
IVM was offered as an alternative treatment; the patient underwent three IVM cycles over the course 
of several months achieving a total of 10 metaphase II oocytes and 2 metaphase I oocytes which were 
vitrified for future use. Based on her young age and a total of 10 metaphase II oocytes this patient 
should have a good chance to conceive in a future IVF cycle using her warmed oocytes (Doyle et 
al 2016). The normal process for reactivation of the oocyte maturation process explains how in this 
case immature oocytes could be matured in vitro despite the failure of ovarian response in 
vivo. The pathway that prevents germinal vesicle breakdown and further oocyte maturation 
involves signalling between the granulosa cells and the oocytes, that maintains high cyclic 
adenosine monophosphate (cAMP) within the oocytes. This communication is lost in vivo in 
response to the natural LH surge; however the physical removal of granulosa cells in vitro mimics 
the effect resulting in reducing cAMP and triggering the resumption of oocyte maturation. This 
technique has often been used experimentally in mammalian models to induce oocyte maturation 
(Jaffe and Norris 2010). 
The use of IVM for less common applications has been proposed by other authors including in 
fertility preservation for oncologic indications such as leukemia, for severe endometriosis as 
well as in combination with ovarian transposition prior to radiation therapy (Grynberg et al 2013). 
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Chapter 4 – Government funding of IVF 
Despite improving ovarian stimulation protocols and laboratory techniques the drive to replace 
multiple embryos continued and in 2010 the multiple pregnancy rate was still 29% in Canada (CFAS 
2010 report) and 30% in the USA (CDC 2010 report). Furthermore, in the USA, the use of elective 
single embryo transfer (eSET) was only reported in 10% of patients under the age of 35, and the 
average number of embryos transferred in this young, normally good prognostic, group of patients was 
2.0 (CDC 2010 report). 
The use of eSET varies dramatically around the world with several Scandinavian countries leading the 
way reaching 69.4% eSET rate in Sweden. The major factors that seem to impact the use of eSET are 
financial, cultural or social and legal. Certain countries have a legal imposition of eSET either in 
general or for specific cases such as patients less than 35 years of age and this may be associated with 
public funding as in New Zealand. There are also a number of countries where eSET is the standard 
even without a legal requirement such as Norway, Denmark and the Netherlands however IVF cycles 
are funded in these countries (Maheshwari et al, 2011).  
In Canada health care is provincially regulated and therefore the different provinces decide whether or 
not to cover specific treatments and medications. Prior to 2010, the province of Quebec did not include 
any fertility treatments under the government health insurance although a tax rebate was available for 
up to 20 000$Can per year of associated costs related to obtaining fertility treatments. In 2010 the 
government of Quebec introduced a programme of coverage for IVF and I authored a paper describing 
the effects of the first three months of the programme (Bissonnette et al, 2011). 
Assisted reproductive technology (ART) was included under the provincial health plan from August 
2010. The policy permitted any woman of reproductive age to have up to three cycles of IVF with 
COS or up to six attempts of MNCIVF. A cycle was counted at completion of embryo transfer. The 
cryopreservation of embryos and their subsequent transfer was also included but did not count against 
the total number of cycles and patients were obliged to use those embryos before carrying out an 
additional IVF cycle: so, embryo banking, for example, was not possible. The associated medications, 
required for COS and luteal support, in ART were also placed on the insured drug list for the province. 
Alongside the coverage, a law was enacted to limit the number of embryos that could be transferred in 
any one cycle. The law stated that only one embryo should be transferred however it set hard limits of 
a maximum of 2 embryos in a patient of 36 years of age or younger and up to three embryos (including 
no more than two blastocysts) in a patient of 37 years or older. Therefore, the option for multiple 
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embryo transfer remained available to clinicians and patients but clinics were asked to reduce the 
multiple pregnancy rate.  
I analysed the first three months of all IVF cycles started in Quebec from all the clinics. The average 
age of patients treated was 37 (range 22-46 years); all clinics applied their own parameters to select 
ovarian stimulation protocols and day of embryo transfer which ranged from day 2 until day 5. There 
were 1353 cycles performed resulting in 1103 embryo transfers. Of importance eSET was used in 50% 
of all embryo transfers and in the age group less than 35 years old, eSET was applied in 79% of embryo 
transfers. These transfers resulted in 32% clinical pregnancy rate overall and 50% clinical pregnancy 
rate in the younger group of patients. As a result of these transfers there were a total of 14 twin 
pregnancies (of which one was in the under 35 age group) and no triplet pregnancies: all the twin 
pregnancies were the result of double embryo transfer. The multiple pregnancy rate was therefore 
3.7%, as compared to 25.6% for the year 2009. We reported this data as indication of the success of 
the programme since the primary objectives were to encourage access to ART for all patients and to 
reduce the multiple pregnancy rate: this initial data seemed to support this finding. 
Interestingly this publication was not universally supported and in the same edition of the journal a 
commentary was published by one of the editors presenting the case against government intervention 
(Gleicher, 2011). In his commentary Gleicher argues that for many patients who wish to have two 
children, a twin pregnancy is, in fact, a less costly and less risky outcome. He further argues that the 
transfer of a single embryo reduces the pregnancy rate and therefore fails the patients that it is designed 
to help. This opinion gained some traction however other authors (Stillman et al, 2013) counter argued 
the four principle tenants of his argument for twin pregnancies, specifically: 
1. Patient autonomy – informed consent requires that patients have given all the appropriate
counselling prior to treatment and the medical team have a responsibility as the ‘experts’ to
guide patients.
2. DET is more efficient – there are studies that demonstrate that a double embryo transfer (DET)
results in higher pregnancy rates however other studies have shown that the transfer of a single
euploid blastocyst results in the same pregnancy rate. Furthermore, the importance of
cryopreservation must not be ignored with the potential for obtaining the desired two babies
from one COS but through two separate embryo transfers.
3. Two babies at a time is cheaper – there are multiple studies indicating that the costs associated
with multiple gestation and delivery even excluding the potential long-term care costs are
higher than those with singletons.
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4. Twin pregnancy is as safe as a singleton – there are risks associated with all pregnancies,
however, there is overwhelming evidence that multiple gestations are higher risk.
The authors’ concluded by quoting from the ASRM Practice Committee report that the optimal 
outcome of an IVF cycle is a healthy singleton and the majority view seems to be in agreement that 
one embryo-one baby at a time is preferable. 
In order to start to answer the cumulative pregnancy per cycle question I subsequently authored a study 
in 2013 which reviewed the implication of the Quebec policy change to eSET and the pregnancy rates 
per started COS. (Velez et al, 2013). In this study, IVF using COS cycles from one clinic in 2009 
before the funding was introduced, were compared to IVF using COS cycles from the first twelve 
months of funding. The first frozen embryo transfer (FET) cycle was included in the data set for the 
funded cycles in order to compare DET in the 2009 cycles with one plus one in the funded cycles. Four 
hundred and ninety-nine stimulated IVF cycles were started in 2009 compared to 815 for the first year 
after implementation of funding; a 64% increase in uptake. Patient ages did not differ (an important 
point to be discussed in more detail later) (35.2 versus 35.4 years). The clinical pregnancy rate was 
significantly different when the fresh embryo transfer was compared (31.9% versus 23.3% p = 0.001) 
however when the first FET was included and cumulative pregnancy rate was used for the funded 
group there was no difference (31.9% versus 29.7%, p = 0.41). Furthermore, the proportion of 
cryopreserved embryos available per cycle increased between the groups (31,5% versus 57.2% in 
patients under 37, p < 0.001 and 7.2% versus 35.1% in patients over 37, p < 0.001) which offers even 
greater potential for additional pregnancies and increasing the final cumulative pregnancy rate in the 
funded cycles.  
As previously mentioned, detractors of public funding and associated regulation on embryo number 
for transfer quote studies that demonstrate lower pregnancy rates when comparing SET with DET 
however these studies often include non-elective SET either exclusively or within the cohort of 
transfers. Studies which specifically analyse elective SET have shown similar results between eSET 
and DET outcomes (De Sutter et al, 2003). Clearly if eSET is the goal it is essential that the clinic has 
a strong embryo cryopreservation programme and the introduction of vitrification in human ART has 
permitted embryology laboratories to consistently produce survival rates in the high 90 percent with 
resultant clinical pregnancy rates that equal fresh transfer rates (Kuwayama, 2007). Vitrification was 
used exclusively for embryo cryopreservation for both the study groups in our analysis. 
In Canada, professionals who work in the field of ART meet under the auspices of the Canadian 
Fertility and Andrology Society (CFAS) which, since 2000, has managed a national registry of ART 
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cycles performed. This registry is known as the Canadian ART Registry (CARTR) and since 2014 has 
been managed by Better Outcomes Registry Network (BORN). BORN is an Ontario government 
funded independent organisation charged with collating data on all birth outcomes for the province of 
Ontario. In their role of managing CARTR, BORN are responsible for collating data from across the 
country however clinics in the province of Ontario no longer need to supply birth outcomes from their 
IVF cycles since this information is collected directly by BORN from the hospitals. Clinics in the rest 
of Canada are still required to provide complete cycle information until birth since BORN can only 
receive patient identifiable data from within their province. Participation in the CARTR is not 
mandatory but all IVF clinics provide data and the database management is maintained by fees paid 
from the ART clinics. The CARTR data is available on request to researchers. The data necessary to 
carry out the studies comparing Quebec IVF before and after funding was obtained from BORN on 
application and having demonstrated the validity of the research questions being posed.   
The other important element to consider with the government funding other than achieving a 
significant reduction in multiple pregnancy rate was to analyse the economic impact of the IVF 
coverage which I authored in 2014 (Velez et al, 2014). This study analysed the first complete calendar 
year of the programme, 2011, and compared the data with those cycles performed in the province 
during 2009 when patients had to self-fund their cycles and no legal limitations on treatment were 
applied.  
In the economic analysis a model was developed based on the 1875 cycles from 2009 and 5489 cycles 
from 2011 as well as projecting live births from cryopreserved embryos based on 177 FET cycles in 
2009 and 670 FET cycles in 2011. The financial comparison was made in consideration of the tax 
rebate given from 2009 as compared to the direct costs incurred by the government in 2011 with 
funding. In addition, costs associated with labour and delivery, preterm birth and neonatal care, as well 
as first year costs related to the child. Unsurprisingly the number of performed cycles increased by 
close to 200%, the age group representation of patients also changed with a reduction in patients under 
35 years old and increase in those over 40 years old (this was only a transient effect as will be discussed 
later). As already demonstrated the multiple pregnancy rate dropped significantly (29.4% versus 6.4% 
p < 0.001) as did the clinical pregnancy rate (39.9% versus 24.9% p < 0.001). The costs to the 
government relative to IVF funding compared to a tax-rebate system increased from CAD$7 million 
to CAD$26 million in the first year and the total cost including antenatal care, birth and complication 
costs relative to IVF increased from CAD$31 million to CAD$41 million. Per IVF cycle the costs 
increased from CAD$3,730 to CAD$4,759, however, when considering all downstream costs related 
to health these decreased from CAD$16,747 to CAD$8,960 and based on projected numbers of 
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children born from the 2011 cohort compared to the actual live births from IVF and FET cycles in 
2009, the cost per baby to one year of age actually decreased under the funding programme from 
CAD$49,517 to CAD$43,362 per live birth. This modeling suggested that in addition to reducing the 
multiple pregnancy rate or indeed perhaps because of its reduction the cost per cycle to the government 
per baby was less with funding than under a system of patient self-funding with a tax rebate in place. 
Our published model analysis did not take into account health care costs after a year of life which 
could arguably be more in the case of high order multiple deliveries, and it did not acknowledge the 
fiscal benefits brought by the children when they start to contribute to the economy themselves. 
Furthermore, it is important to note that the dramatic increase in cycles and therefore babies born, as a 
result of funding, balances somewhat the reduction in multiple births using neonatal intensive care 
facilities. 
As a result of this series of publications I was asked along with my colleagues to provide a chapter for 
a book: Screening the Single Euploid Embryo: Molecular Genetics in Reproductive Medicine. (Ed: E 
Scott Sills, 2015). This book includes chapters on genetic analysis of embryos, as well as ovarian 
stimulation, sperm analysis, embryo selection techniques, embryo transfer techniques and analysis of 
several mandated eSET programmes. In our chapter we argue that cumulative pregnancy rate should 
be used as the best measure of IVF success (Velez et al, 2015). In order to analyse this, the cycles 
using elective double embryo transfer (eDET) from 2009 were assessed against the eSET cycles from 
2011 plus the FET cycles using embryos created from those 2011 IVF cycles. Once again data was 
obtained from CARTR BORN. The patient ages were similar in the two periods (32.54 versus 32.52 p 
= 0.92), and age distribution was similar in the two groups, as was prior pregnancies and previous IVF 
attempts. There were some differences in the reason for treatment between the two groups with some 
indication that the eSET group was disadvantaged: lower mean number of oocytes retrieved, less 
cleaved embryos available, and fewer cryopreserved embryos. There were 514 eDET cycles performed 
in the province in 2009 with a pregnancy rate of 47.1%, and a multiple pregnancy rate of 35.1%. In 
2011, there were 1375 eSET cycles with a pregnancy rate of 33.9% leaving 909 women to have a FET 
cycle: of these women, 378 completed their FET cycle in 2011 and a further 21.2% achieved a 
pregnancy. The cumulative pregnancy rate of the eSET patients was therefore 39.7% at this point, 
however, 478 women were still waiting for their FET cycle; if we assume 90% survival rate of the 
cryopreserved embryos (which is conservative considering vitrification was used in all cases), then an 
additional 101 pregnancies should be expected from these cycles. Including these additional 
pregnancies, the cumulative pregnancy rate of the eSET cohort would be 47.1%. This is equal to the 
2009 eDET pregnancy rate, thereby demonstrating the argument that one embryo at a time achieves 
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the same outcome as DET and the importance of using cumulative pregnancy rate to assess success of 
eSET programmes.  
Previously a prospective randomised trial comparing live birth rates using eSET plus FET against 
eDET confirmed that the multiple pregnancy rate can be significantly reduced (33.1% versus 0.8% 
p<0.001) and that any reduction in the live birth rate is unlikely to exceed 11.6 percentage points 
(42.9% versus 38.8%, difference 4.1 percentage points 95% C.I. -3.4 to 11.6) (Thurin et al, 2004). Our 
data demonstrated higher clinical pregnancy rates but within the same range if we consider some 
clinical pregnancy loss to live birth.  
In 2015, after five and a half years, the Quebec government terminated the funding for IVF, and with 
the exception of fertility preservation for oncological reasons, IVF became patient-funded again in the 
province of Quebec. In 2018 I analysed the data from all the IVF cycles performed during the 
course of the programme and compared it to the combined 2009 and 2016 data: all data was again 
obtained from CARTR BORN (Bissonnette et al, 2019 in press). By combining data from 2009 
and 2016 as the control group data it ensures that changes and improvements in technology over the 
course of the study are reduced as variables in the results. Since there were legislative changes 
that affected maximum numbers of embryos that could be transferred over the time period it also 
allowed me to assess the direct impact of the funding on results. Since there is birth registry linked 
to the CARTR database for the births in Quebec, the ART clinics are responsible for following up 
and obtaining this information. However, it is not always possible to obtain this information and there 
were 1310 ongoing clinical pregnancies without live birth information for the 2010-2015 data. 
Using a 15% loss of pregnancy from 8 weeks, an additional 1113 live births were assumed in 
the calculations, with an additional 27 similar cases for 2009 and 124 cases in 2016. 
The total number of cycles increased dramatically as would be expected, averaging over 10000 for 
the funded years (reaching a maximum of 11900 in 2013) as compared to 2500 in 2009. In 2016 
there were a total of 5353 IVF cycles of which 56% were FET since embryos created under 
funding remained funded for the FET. Of interest and importance, the proportion of age groups 
of patients treated did not differ significantly over the two periods. The cancellation rate increased 
which was related to the design of the funding: an IVF cycle did not count for the patient until 
embryo transfer, therefore creating an environment which led to aggressive cycle cancellation (17% 
versus 34.4% p < 0.001). This increase was seen in every age group with the exception of the 
patients over 43 years of age; possibly due to the acceptation that in this age group a better future 
outcome may not be achievable and so embryo transfer was carried out even with suboptimal 
embryo parameters. The use of donor 
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eggs reduced during funding (4.5% versus 2.4% p<0.001), once again probably associated with 
funding design: the cost of donor eggs was not included in the programme and so unless a patient could 
find an altruistic donor herself, she needed to resort to purchasing eggs from USA based egg banks at 
great financial cost. The use of donor semen, which was covered, also decreased (4.5% versus 2.4%, 
p<0.001) most likely because all aspects of IVF were funded including surgical sperm retrieval and 
ICSI thereby eliminating a major reason for some patients to consider intrauterine insemination 
using donor semen when diagnosed with a severe male factor.  
The live birth rate per fresh embryo transfer decreased with funding confirming what we 
had previously published (33.9% versus 23.7% p < 0.001) however with this data set we did not 
calculate the cumulative or potential cumulative live birth rate. The live birth rate following 
treatment using MNCIVF also decreased (35.8% versus 25.2%, p=0.03) as did the live birth rate in 
FET (25.5% versus 21.9%, p<0.001). The use of eSET, which was a primary objective of the 
funding, increased in both the IVF with COS and the FET cycles (IVF 9.2% versus 64.3% p < 
0.001, FET 10.0% versus 73.5% p < 0.001) when comparing funding with 2009 data and 
unsurprisingly remained high in 2016 (IVF with COS 71.5%, FET 86.7%) since legislation brought 
in at the end of funding actually tightened the legislation related to the number of embryos at 
transfer. As a result, the multiple pregnancy rate dropped from 25.6% to range between 3.3% and 
7% during funding and remained under 5% in 2016.  
Overall as a result of funding for 64 months there were 9232 live birth events (some of which 
were still multiple pregnancies therefore more than 9232 babies were delivered from this 
programme.  
The major reason cited by the government for the closure of the programme was fiscal. It is difficult 
to obtain precise numbers concerning the actual costs however CAN$70 million to CAN$80 million 
per year were widely presented in the media. In our previous financial analysis of the programme in 
2014, we did not consider the contribution element of the children born from such an ART funding 
programme. If one considers that the average tax contribution lifetime by an individual in the province 
of Quebec is approximately CAN$330 thousand (StatsCan), then the more than 9232 babies will 
provide over CAN$3 billion during the course of their lives. The 64 months of funding cost 
the government CAN$400 million which translates into an 8-fold return in their investment.  
Clearly lessons can be learnt from the design of the funding programme which as mentioned 
encouraged cycle cancellation, for which the clinics were still paid and the patients did not lose 
their cycle. Providing a fixed number of cycles where the cycle counts once stimulation or at 
least egg collection is performed would provide for greater fiscal control while still giving access 
to treatment to all patients regardless of their socio-economic situation.   
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Chapter 5 – Conclusions 
The publications presented here demonstrate some different approaches to achieving the objective of 
single embryo transfer and to offering treatment techniques that maximise the potential to offer ART 
care to as wide a population of patients as possible. Worldwide, the multiple pregnancy rate remains 
one of the major negative side-effects of IVF however, many countries have managed to control this 
either with legislation or simply a culturally driven agreement amongst ART practitioners that eSET 
is the best embryo transfer policy.  
Clearly there have been a great number of developments that allow for eSET which have not been 
touched on in these publications. One of the most important amongst these is the significant 
improvements in IVF culture media permitting the possibility of prolonged culture and the transfer of 
a blastocyst rather than early cleavage stage embryos. Due to the natural selection process, being able 
to transfer a blastocyst increases the implantation rate per transfer thereby balancing to some degree 
the benefits of transferring more than one early cleavage stage embryo.  
Research into improving embryo selection such as with the use of time lapse technology and pre-
implantation genetic testing for aneuploidy (PGT-A), as well as other non-invasive assessments of 
culture media interaction and metabolomics have also allowed for greater understanding of the 
embryo and may improve selection parameters.  
Furthermore general improvements in the understanding of the construction of an IVF laboratory 
including the air quality and materials used, developments on the pharmacological side of ART, 
previously mentioned developments in culture media complexity and increased knowledge about 
important events in embryo development using morphological indicators have led to increased 
outcomes from IVF which itself permits the option for eSET whilst maintaining high clinical 
pregnancy and live birth rates. 
In terms of the impact that these publications have made; the number of citations for each publication 
is indicated on the cover page for each article at the end of this study. My publications and the ongoing 
use of MNCIVF at our clinic persuaded the government of Quebec to specifically include MNCIVF 
within the funding for IVF and based on our published data, permitting six cycles of MNCIVF as 
compared to three cycles of IVF with COS. This is the first government funding legislation to the best 
of my knowledge that specified MNCIVF within its terms. My publications on MNCIVF have been 
referenced in books such as the Development of In Vitro Maturation for Human Oocytes: Natural and 
Mild approaches to Clinical Infertility Treatment (2017, Springer International Publishing) and 
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Minimal stimulation and natural cycle in vitro fertilisation (2015, Springer Publishing) as well as 
reviews on the use of NSAID in gynecology: Role of non-steroidal anti-inflammatory drugs in 
gynecology (Livshits et al, 2010, Pharmaceuticals) and the use of ART in developing countries: 
Infertility and the provision of infertility medical services in developing countries (Ombelet et al, 2008, 
Human Reproduction Update). 
The publications that I authored on in vitro maturation have been cited in multiple peer-reviewed 
articles and also referenced in books (Infertility in Practice, Informa Healthcare 2008) and in a 
consensus analysis of the PCOS condition by two of the major ART societies: The ESHRE/ASRM 
consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis (Geisthovel et al, 
2007). 
My publications related to public funding of IVF within the province of Quebec, Canada have been 
referenced for policy proposal documents both in the U.K. and the U.S.A.: Elective single embryo 
transfer: an update to UK Best Practice Guidelines, (Harbottle et al, 2015, Human Fertility) and 
Preterm births, multiples, and fertility treatment: recommendations for changes to policy and clinical 
practices (Johnston et al, 2014, Fertility and Sterility) 
Further research is required to increase knowledge especially regarding improved embryo selection as 
well as investigating endometrial receptivity and thereby increasing implantation potential. These 
developments would permit eSET to become the standard for ART without risk of reducing live birth 
rates especially in combination with cryopreservation which already appears to have reached 
extremely high efficacy. 
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Abstract
A total of 134 controlled natural IVF (nIVF) cycles were reviewed retrospectively and compared with 370 stimulated IVF 
(sIVF) cycles. The clinical pregnancy rate per embryo transfer following nIVF was 27% and 47% in sIVF cycles for patients 
aged less than 35. However, natural cycle patients could attempt consecutive cycles with much less impact on their lives, 
both medically and ﬁ nancially. In patients under 35 years of age, the choice of controlled nIVF reduces the cost and risk to 
the patient, permitting her to have multiple, consecutive attempts, and cumulatively offers a clinical pregnancy rate which 
approaches that of sIVF. The multiple pregnancy rate in nIVF is signiﬁ cantly reduced compared with sIVF treatment cycles. 
In patients over 35 years of age the beneﬁ ts of nIVF were much less evident (clinical pregnancy rate: 8% per embryo transfer) 
and the opportunity to transfer multiple embryos in these patients seems to be advantageous.
Keywords: clinical pregnancy rate, IVF, multiple pregnancies, natural cycle
Over recent years, in-vitro fertilization has worked on the 
principle of stimulation of the ovaries and the production of 
multiple follicles in order to obtain many oocytes and, hopefully, 
several embryos. From these embryos, a choice is made as to 
which ones offer the best developmental potential, and these 
are then transferred to the patient’s uterus. However, the ﬁ rst 
IVF baby was conceived following a natural cycle (Steptoe and 
Edwards, 1978) and indeed natural cycle IVF (nIVF) was the 
method of choice for the ﬁ rst few years of IVF treatment.
The use of ovarian stimulation allowed an increase in the 
number of recruited oocytes and an increase in the pregnancy 
rates associated with IVF (Fishel et al., 1985). It also permits 
excess embryos to be cryopreserved in the event that the IVF 
attempt fails to result in a pregnancy or, indeed, to allow the 
patient to return for additional sibling attempts in the future 
without a need for further ovarian stimulation. However, 
due to the additional costs, risks and complexity of ovarian 
stimulation, there is pressure on both the patient and the care 
giver to increase the chance of the patient becoming pregnant 
and therefore it has become standard to transfer more than one 
embryo. A side effect of this is a dramatic increase in the rate 
of multiple pregnancies, which has been observed. Although 
some countries have acted by law to restrict the number of 
embryos that are permitted to be transferred, such as in the 
UK with the Human Fertilization and Embryology Authority, 
many countries leave the decision in the hands of the assisted 
reproduction professionals and their patients.
Although various different methods have been suggested as to 
how to choose the best embryos for embryo transfer, such as 
embryo morphology, nutrient uptake or pronucleus appearance, 
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Controlled natural cycle IVF: experience in a 
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Introduction
there is still no absolute method for determining which embryo 
has the best chance of developing into a successful pregnancy.
In a natural cycle, several follicles are recruited initially but it is 
only one that attains dominance and goes on to ovulate. Being 
able to control ovulation was one of the reasons why natural 
cycles were replaced with ovarian stimulation cycles, because 
the ﬁ rst oocyte retrievals had to be performed according to the 
natural LH surge and resulted in collections at any time of the 
day or night in order to collect the oocyte before ovulation.
Developments of gonadotrophin-releasing hormone (GnRH) 
antagonists allowed once again the possibility of using a natural 
cycle, by preventing the occurrence of a premature LH surge 
and thereby allowing better control (Rongières-Bertrand et al., 
1999). More recently, Trokoudes et al. (2005) published a series 
of controlled nIVF cycles (CONCIVF) in which he showed that 
CONCIVF could be a useful tool in the management of some 
patients presenting for fertility treatment.
Materials and methods
Patients under 39 years of age attending the OVO Fertility 
Clinic from January 2004 were offered the possibility of 
having IVF via a controlled natural cycle or stimulated IVF. 
Those choosing to accept controlled nIVF had a transvaginal 
ultrasound on day 6 and then serial ultrasounds to measure the 
leading follicle. It should be noted that patients who had their 
cycles cancelled before oocyte collection due to premature 
ovulation or abnormal follicular growth were excluded from 
the results.
Ultrasound scans were performed using a multifrequency 
transvaginal probe (Voluson 730 Expert, GE Medical Systems, 
Saint-Laurent, Quebec, Canada). Assessments were made by 
measuring the follicle in two perpendicular planes and taking 
the average diameter. Once the follicle reached 14 mm, GnRH 
antagonist (Ganirelix, Orgalutran, Organon Pharmaceuticals, 
Scarborough, Ontario, Canada) was administered (0.25 mg) 
as a s.c. injection daily until the day of human chorionic 
gonadotrophin (HCG) administration. Also patients received 
150 IU of human menopausal gonadotrophin (HMG) 
(Repronex, Ferring Canada, North York, Ontario, Canada) 
daily. The use of HMG was due to the study of Kettel et al.
(1991) to prevent an oestradiol drop in response to the GnRH 
antagonist. No stimulatory effect of HMG was seen: indeed no 
patient produced more than one follicle and patients only took, 
on average, two to three days of antagonist and HMG. Once a 
follicle of 17 mm was seen with an ultrasound scan, patients 
received an injection of 5000 IU of HCG (Pregnyl, Organon 
Pharmaceuticals), administered as an i.m. injection, to achieve 
ﬁ nal follicular maturation and oocyte retrieval took place 34 h 
later.
Oocyte retrieval was performed by vaginal ultrasound guidance 
using a 17G double lumen needle (Cook, Canada) and ﬂ ushing 
of the follicle was performed as necessary (Follicle Flush 
Buffer, Cook). Oocyte retrieval was performed without sedation 
or local anaesthetic. Oocytes were collected into fertilization 
media (Cook) at 37°C and 6% CO
2
. Semen was collected by the 
partner into a sterile container and processed using a gradient 
system (Puresperm, Nidacon, Sweden). When necessary, 
spermatozoa was retrieved by percutaneous sperm aspiration, 
usually performed before the IVF cycle, and cryopreserved 
(Sperm Maintenance Media, Irvine Scientiﬁ c, USA) for ease of 
scheduling and for use on the day of oocyte retrieval (Kadoch 
et al., 2005).
For stimulated IVF cycles, standard well-known protocols were 
used. In summary, patients were assessed by ultrasound after 14 
days of GnRH agonist (Suprefact, Aventis, Canada) to conﬁ rm 
pituitary suppression. Ovarian stimulation was commenced 
with daily injections of either recombinant FSH (rFSH) 
(Puregon, Organon, Canada; Gonal F, Serono, Canada) or HMG 
(Repronex, Ferring Canada) at a dose dependent on patient age 
and baseline ultrasound assessment of ovarian reserve. Patients 
started on 150 IU or 225 IU and adjustment was made following 
follicular assessment with ultrasound on day 6 of stimulation. 
Further ultrasound assessment of follicular growth was made 
as required and gonadotrophins adjusted accordingly. Once 
three follicles reached an 18 mm average of two perpendicular 
planes, 10,000 IU of HCG (Pregnyl; Organon Pharmaceuticals) 
was given and oocyte retrieval was scheduled for 36 h later.
Standard insemination or intracytoplasmic sperm injection 
(ICSI) was performed according to well-established sperm 
parameters. Fertilization was veriﬁ ed by the presence of two 
pronuclei and two polar bodies 18 h after insemination. All 
fertilized oocytes were transferred into cleavage media (Cook). 
Embryo transfer was performed under ultrasound guidance 
using a Wallace Sureview catheter (Smith Medical, UK) on 
day 2 after oocyte retrieval. Embryo transfer for stimulated IVF 
cycles was on day 2 or 3 after oocyte retrieval, depending on the 
numbers of embryos available.
Patients received two injections of HCG (2500 IU), on day 2 
and day 4 after collection, and took progesterone intravaginally 
600 mg daily (Prometrium, Schering, Pointe-Claire, Quebec, 
Canada), starting 2 days after oocyte retrieval, and continued 
until menstruation or for at least the ﬁ rst 8 weeks of pregnancy 
if the patient became pregnant.
Pregnancy was veriﬁ ed by serum HCG 15 days after oocyte 
collection and conﬁ rmed by the presence of an intrauterine fetal 
heartbeat by ultrasound at 6 weeks.
Results
Between January 2004 and October 2006, patients attending the 
clinic for IVF treatment were offered the possibility of sIVF or 
controlled nIVF. Patients over the age of 35 were counselled 
and advised to choose IVF in preference, although patients who 
insisted on trying nIVF were accepted. The data for the results 
with nIVF are reported in Table 1.
In summary, 134 cycles were performed for patients under 35 
years of age, with 75 resulting in an embryo transfer. The clinical 
pregnancy rate per embryo transfer was 27%. As a comparison, 
during the same time period, 370 cycles of sIVF were performed 
for patients under the age of 35 with 355 resulting in an embryo 
transfer. The clinical pregnancy rate per embryo transfer was 
47%. However, in the sIVF group the multiple pregnancy rate 
was 37% (Table 2).
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For those patients over 35 who insisted on attempting nIVF, 
there were 108 cycles resulting in 52 embryo transfers. The 
clinical pregnancy rate per transfer was 8%. In sIVF for the 
same age of patient, there were 240 cycles with 220 embryo 
transfers and the clinical pregnancy rate per embryo transfer 
was 37%. The multiple pregnancy rate in this group was 36%.
The cancellation rate or failure to reach embryo transfer was 
considerably higher in the controlled nIVF groups than in the 
sIVF groups. For the two treatment groups under 35, 59% of 
patients under 30 and 54% of patients between 31–35 reached 
embryo transfer as compared with 96% of patients in sIVF.
The 134 cycles of nIVF were performed for 70 patients. The 
clinical pregnancy rate per patient undergoing nIVF was 28.5% 
and 91% of the patients becoming pregnant did so on their ﬁ rst 
or second attempt, including cycles with no embryo transfer.
Conclusions
Although controlled nIVF does not reach the levels of 
pregnancy rate that can be obtained by transferring multiple 
embryos following ovarian stimulation, the authors believe 
that it can be a useful tool in the treatment of some couples 
presenting for infertility. The beneﬁ ts of controlled nIVF are 
obvious, in that the increasing problem of multiple pregnancy 
is removed, the patients do not need to inject themselves with 
expensive medications, and due to the reduced invasive nature 
of the procedure (no sedation or anaesthesia is used for the 
oocyte collections), patients can, if they choose, have a cycle 
each consecutive month. If it is also considered that, as with 
intrauterine insemination, patients can have three cycles of 
nIVF consecutively with minimal impact on their life schedules, 
then the cumulative pregnancy rate will approach that of sIVF 
cycles. Since it was found that the majority of pregnancies in 
nIVF occur on the ﬁ rst or second attempt (91%), including 
cycles with no embryo transfer, most patients are counselled to 
use sIVF after three unsuccessful attempts with nIVF.
Also it appears that the beneﬁ ts of transferring more than one 
embryo are increased in patients over the age of 35, since the 
pregnancy rate from nIVF was low (8%). In the sIVF group, 
patients over the age of 35 had a pregnancy rate that was 
comparable with the younger sIVF groups (37% for patients 
over 35 versus 53% for patients less than 30, and 44% for 
patients aged 31–35). It has been suggested that vaginal 
oestradiol supplementation may improve implantation rate 
(Wright et al., 2006); however, no beneﬁ t in controlled nIVF 
was seen in this clinic (unpublished data).
While laboratory researchers are trying to ﬁ nd the best method 358
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Table 1. Results of controlled natural cycle IVF (nIVF).
Patient age (years)
<31 31–34 35–38
Number of cycles 44 90 108
Number of embryo transfers 26 49   52
Cycles leading to embryo transfer (%) 59 54   48
Cycles with no oocytes retrieved (%) 23 24   32
Cycles with no fertilization (%) 18 21   19
Number of clinical pregnancies   7 13     4
Clinical pregnancy rate per embryo transfer (%) 27 27     8
Table 2. Results of stimulated IVF (sIVF).
Patient age (years)
<31 31–34 35–38
Number of cycles 145 225 240
Number of embryo transfers 139 216 220
Cycles leading to embryo transfer (%)   96   96   92
Number of clinical pregnancies   74   94   81
Clinical pregnancy rate per embryo transfer (%)   53   44   37
Multiple pregnancy rate (%)   38   35   36
Average number of embryos transferred 2.1 2.2 2.6
to select an embryo or embryos with the best developmental 
potential for embryo transfer, perhaps the role of natural 
selection of follicles should be considered. Further research 
is necessary to verify whether the aneuploidy rate, or perhaps 
nutrient uptake or output, in natural cycle embryos is improved 
over embryos resulting from stimulation cycles.
Since there is only one follicle in nIVF, there is a greater risk 
of cycle cancellation than in stimulated cycles, even in younger 
patients. This is an area of controlled nIVF that needs more 
attention and research, since there is certainly less chance of an 
embryo transfer following the commencement of a controlled 
nIVF cycle than a sIVF cycle. From the data presented here, 
slightly over half the cycles in controlled nIVF result in an 
embryo transfer (59%, 54%) as compared with nearly all cycles 
in sIVF (96%). The use of non-steroidal anti-inﬂ ammatory 
drugs (NSAID) has been proposed to improve the recuperation 
of oocytes by reducing the spontaneous ovulation rate (Nargund 
et al., 2001), and this is an area currently under investigation 
in the clinic’s programme. In addition, methods to improve 
fertilization rate with ICSI may provide helpful in ensuring that 
more patients complete their cycles (Wang et al., 2001; Hazout 
et al., 2006).
However, the choice to use nIVF can be incorporated into 
the ﬁ nancial aspect of the programme so that the impact on 
patients is reduced when an embryo transfer does not occur. For 
example, in this clinic, patients who do not obtain an oocyte at 
retrieval pay a much-reduced price simply to cover the costs of 
the retrieval only, and if the oocyte fails to fertilize, a signiﬁ cant 
rebate is also given on the cycle price. Patients who have their 
cycles cancelled before oocyte collection due to premature 
ovulation or abnormal follicular growth do not pay for their 
cycle at all, and so they have been excluded from these data. 
Therefore, only patients who have an embryo transferred pay 
the total cycle costs, which are still considerably less than a 
stimulated cycle. It is for this reason that clinical pregnancy 
rate per embryo transfer is reported, rather than the more 
traditional clinical pregnancy rate per cycle started. Whilst 
the authors realise that describing clinical pregnancy rates per 
embryo transfer may be construed as misleading, they feel that 
controlled nIVF is sufﬁ ciently different to sIVF in terms of 
impact on the patient’s life to warrant this. Perhaps in a situation 
where there is no or little ﬁ nancial implication on patients for 
fertility treatment, this argument is reduced; however, certainly 
in North America where, unfortunately, the ﬁ nancial burden of 
assisted reproduction falls on the patients and not governments 
or insurance companies, the authors feel that it is reasonable to 
present clinical pregnancy rates per embryo transfer as long as 
the patients are aware that the chance of failing to reach embryo 
transfer in a controlled nIVF is higher. During failed cycles, 
patients will, of course, take very little, if any medication, 
and undergo two or three vaginal ultrasounds at most, and the 
costs will be much reduced. Trokoudes et al. (2005) also used 
clinical pregnancy rates per embryo transfer in their controlled 
nIVF paper, suggesting that perhaps nIVF should be analysed 
in a slightly different way to sIVF. Patients initiating controlled 
nIVF at the centre are counselled about the risk of failing to 
reach embryo transfer, which may be up to 50% of those starting 
a cycle, although this rate is expected to improve with research 
involving NSAID, as mentioned previously, and with potential 
improvements to the protocol in the future.
The authors believe that, using the method that is described here, 
that a successful alternative to sIVF can be offered to patients 
and, in doing so, the various burdens that sIVF places on the 
patient and health care systems be considerably reduced.
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!BSTRACT
Recently there has been much discussion and presentation on IVF protocols using less stimulation or indeed none at all. Our 
experience with controlled natural cycle IVF over the last few years has convinced us that this is a powerful tool for many 
patients in the treatment of infertility. The protocol we employ has raised some questions as to whether it is natural cycle or 
stimulated cycle. We have reported a large series of cycles and seen no stimulatory effects of the medications used to control 
the cycle, thereby confirming our position that controlled natural cycle IVF is a valid option as an assisted reproduction 
treatment.
Keywords: controlled natural cycle IVF, IVF, minimal stimulation
There is a returning interest to natural cycle IVF and minimal 
stimulation regimes as well as in-vitro maturation. They are 
all useful tools in the treatment of infertility and, as recently 
suggested in this journal, may be the future of assisted 
reproduction technologies (Edwards, 2007; Nargund and 
Frydman, 2007; Ubaldi et al., 2007).
We have been working with controlled natural cycle IVF for 
several years and, indeed, have published articles on the subject 
in this journal (Reproductive BioMedicine Online) (Kadoch 
et al., 2005, 2007a,b; Phillips et al., 2007). One issue that has 
repeatedly arisen when articles are submitted is the question of 
whether the protocol we employ is truly natural cycle IVF. The 
terminology of the protocols has become a question of debate.
As discovered by IVF pioneers, such as Professor Edwards, 
truly natural cycle IVF is not an efficient treatment protocol 
due to the need for 24-hour oocyte retrieval and laboratory 
coverage, and the increased risks of premature ovulation. 
The advent of gonadotrophin-releasing hormone (GnRH) 
antagonists provided the opportunity to revisit the natural cycle 
in a more controlled manner; however, evidence of a negative 
effect on oestradiol concentrations once GnRH antagonists are 
administered throws up an additional complication. The use of 
small doses of human menopausal gonadotrophin (HMG) to 
counteract these negative effects of GnRH antagonist allows for 
a truly ‘controlled’ natural cycle protocol (Kettel et al., 1991).
In the protocol that we have been employing, HMG is 
administered at 150 IU upon commencement of GnRH 
antagonist. The patients, on average, only take HMG for 2 or 3 
days and, in nearly 400 cycles, we have never seen a stimulatory 
effect from the gonadotrophins.
The new protocols of minimal stimulation and ‘friendly IVF’ 
that have been proposed recently are also useful and interesting 
protocols. However, these protocols are designed to promote 
multi-follicular development and co-dominance, exactly the 
opposite of the intention of our controlled natural cycle protocol 
(Olivennes and Frydman, 1998; Macklon and Fauser, 2003). 
We believe that the ‘natural’ selection of a follicle, and thus an 
oocyte, is an important tool at a time when research to select the 
‘best’ embryo for transfer is ongoing.
Our studies with controlled natural cycle IVF have shown that 
it is a powerful protocol for use in patients less than 35 years of 
age. However, the minimal stimulation protocols may well be 
beneficial to older patients, who appear to need more than one 
embryo or, at least, perhaps a choice at embryo transfer.
We are confident in the terminology of our protocol as 
‘controlled natural cycle IVF’ rather than as a protocol of 
‘minimal stimulation’.
Nevertheless, regardless of the precise terminology used, the 
overall philosophy of moving towards less stimulation and less 
embryos transferred must be commended and encouraged.
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Abstract
The objective of this retrospective analysis was to evaluate the number of spontaneous ovulations occurring before oocyte 
retrieval in natural cycle IVF (nIVF) with and without the use of indomethacin. A total of 121 patients who underwent 
modified nIVF cycle between December 2003 and July 2006 were included in the study; 171 cycles without indomethacin 
and 84 cycles with indomethacin, started when the leading follicle reached 14 mm in size, were compared. The number of 
cycles with ovulation before oocyte retrieval and the number of cycles with no oocytes at retrieval were assessed with and 
without indomethacin. In addition, the pregnancy rates in the two groups of patients were analysed. There were 28 cycles 
(16%) in which ovulation occurred before oocyte retrieval in the group where no indomethacin was used and five cycles (6%) 
in which ovulation occurred before retrieval in the group where indomethacin was used. There was a statistically significant 
association between premature ovulation and indomethacin, with an odds ratio of 3.8 (95% confidence interval, 1.2–12.3). 
The oocyte retrieval per started cycle was 64% without indomethacin and 76% with indomethacin (P < 0.04). The clinical 
pregnancy rate per embryo transfer was 14% without indomethacin and 21% with indomethacin (not significant).
Keywords: human oocyte, indomethacin, modified natural cycle IVF, oocyte retrieval, premature ovulation
In recent years, natural cycle IVF (nIVF) has been largely replaced 
by conventional stimulated IVF. With ovarian stimulation, multiple 
follicles are recruited and many oocytes can be retrieved at the time of 
collection. This technique is advantageous, since multiple embryos 
are produced, which provides the opportunity to try to choose those 
that will give the patient the best chance of successful pregnancy. 
Conventional stimulated IVF has increased the pregnancy rates 
achieved, but since more than one embryo is usually transferred 
at a time, it has also increased the rate of multiple pregnancies. 
This is now considered a major complication, due to the increased 
morbidity and mortality associated with neonatal prematurity.
The search for ways to reduce multiple pregnancies resulting 
from assisted reproduction has renewed interest in nIVF. In nIVF, 
the selection of the dominant follicle is natural and devoid of 
any stimulation, so only one oocyte is retrieved and fertilized to 
produce a single embryo. This has several advantages: close to zero 
multiple pregnancy rate; avoids the risk of ovarian hyperstimulation 
syndrome; is less time consuming; physically and emotionally less 
demanding for patients; costs less than conventional stimulated 
IVF; and cycles can be done in consecutive months without a rest 
period as the ovaries are not stimulated.
Article
Spontaneous ovulation rate before oocyte 
retrieval in modified natural cycle IVF with and 
without indomethacin
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The efficacy of nIVF, however, is hampered by high cancellation 
rates of up to 30% because of premature LH rise and premature 
ovulation before retrieval, which is not seen in conventional 
stimulated IVF. There have been several attempts to prevent the 
premature ovulation associated with nIVF. Claman et al. (1993) 
administered human chorionic gonadotrophin (HCG) in 75 nIVF 
cycles in an effort to preempt the LH surge. This was unsuccessful, 
as the cycle cancellation rate was 47% due to ovulation. Another 
attempt to prevent the LH surge was made using a gonadotrophin-
releasing hormone (GnRH) anatagonist (cetrorelix) (Rongières-
Bertrand et al., 1999). This was done in a pilot study of 44 cycles 
with cetrorelix administered in the late follicular phase. The cycle 
cancellation rates due to premature ovulation were much lower 
than previously reported, at just 9%. This was evidence that 
GnRH antagonists may allow better control of the natural cycle, 
but did not eliminate the problem of premature ovulation.
There is evidence in the literature to support the use of 
indomethacin to reduce the incidence of spontaneous ovulation in 
nIVF. Nargund and Wei (1996) reported a case in which ovulation 
was successfully delayed for 1 week with the use of indomethacin 
at a dose of 50 mg three times a day for a total of 7 days. These 
workers later showed a lower spontaneous ovulation rate in a 
prospective trial comprising 42 nIVF cycles on indomethacin (50 
mg three times daily for 3 days), compared with 139 cycles in 
which no indomethacin was administered (Nargund et al., 2001). 
Although the difference was not significant between the two 
groups, the patients who took indomethacin were able to delay 
oocyte retrieval for up to 72 h.
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), 
has well known anti-prostaglandin effects. NSAID act mainly 
through the inhibition of cyclooxygenase, the enzyme that 
catalyses the synthesis of prostaglandins, which are essential 
mediators of ovulation, implantation and placentation of the 
conceptus. Prostaglandins induce the mobilization of granulosa 
and theca interna cells within the ovaries, and the cyclooxygenase-
2-dependent prostaglandins probably lead to the generation of 
proteolytic enzymes that rupture the follicles (Athanasiou et al., 
1996). Use of NSAID has been associated with the luteinized 
unruptured follicle syndrome (Mendonca et al., 2000).
Athanasiou et al., (1996) have shown that indomethacin 
administered at the time of a positive urinary LH can delay 
follicular rupture, with an associated reduction in intrafollicular 
blood flow but with no apparent effects on hormonal or menstrual 
status. The mechanism of action of indomethacin, therefore, 
is probably inhibition of the ‘inflammation’ associated with 
follicular rupture. Unlike GnRH antagonists it does not inhibit the 
LH surge. Furthermore, it is associated with much lower costs.
In this study, it is proposed that use of indomethacin in nIVF 
would reduce premature ovulation, therefore reducing cycle 
cancellations and improving the efficacy of nIVF.
Materials and methods
Patients
Between December 2003 and July 2006, 121 patients (255 
cycles) underwent nIVF at OVO Fertility Clinic. The database 
and charts were reviewed for details of the cycles. There were 
171 cycles without indomethacin and 84 cycles in which 
indomethacin was used. All patients had normal ovulatory cycles 
(27−31 days). Inclusion criteria included male factor infertility, 
tubal obstruction, implantation failure in conventional IVF, young 
women with reduced follicular ovarian reserve and history of 
previous hormone-dependant cancer.
Protocol
All patients were observed using serial transvaginal sonography 
starting from cycle day 6. Assessment of the leading follicle was 
made by taking the average of two perpendicular measurements. 
When the follicle reached 14 mm in size, all patients received 0.25 
mg subcutaneously of a GnRH antagonist (Ganirelix, Orgalutran; 
Organon, Ontario, Canada) daily until the day of HCG injection. 
Patients who were in the indomethacin group received 50 mg of 
indomethacin (Indocid; Merck Frosst, Quebec, Canada) three 
times a day until the day before oocyte retrieval. All patients also 
received 150 IU of human menopausal gonadotrophin (HMG; 
Repronex, Ferring Canada, Ontario, Canada) daily to sustain 
oestradiol concentrations. No stimulatory effect was seen from 
the administration of gonadotrophins, and their use was simply to 
prevent an oestradiol drop once GnRH antagonist was administered 
(Kettel et al., 1991). Once the follicular size reached 17 mm or 
greater, 5000 IU of HCG (Pregnyl; Organon) was administered 
subcutaneously. Oocyte retrieval took place 34 h later. On the 
day of retrieval, endovaginal sonography was performed prior 
to collection to confirm the presence of a follicle. Absence of a 
follicle was considered to be due to premature ovulation. Oocyte 
retrieval was performed under transvaginal ultrasound guidance 
using a 17G double lumen needle (Cook, Canada) and the 
follicle flushed as necessary (follicle flushing buffer, Cook). The 
procedure was performed without sedation or local anaesthesia. 
The oocytes were collected into fertilization media (Cook) at 
37°C, under 6% CO2. The partner’s semen was processed using a 
gradient system (Puresperm; Nidacon Ltd, Sweden). If necessary, 
spermatozoa were retrieved by percutaneous sperm aspiration 
(PESA), usually performed before the nIVF cycle and the 
spermatozoa cryopreserved (sperm maintenance media, Irvine 
Scientific, USA). Standard insemination or intracytoplasmic 
sperm injection (ICSI) was performed. Fertilization was verified 
by the presence of two pronuclei and two polar bodies 18 h post-
insemination or ICSI. All fertilized oocytes were transferred into 
cleavage media (Cook). Embryo transfer was carried out under 
ultrasound guidance using a Wallace Sureview catheter (Smith 
Medical, UK) on day 2 post-oocyte retrieval. Patients received two 
subcutaneous injections of HCG, 2500 IU each, on days 2 and 4 
post-collection. Patients were also given intravaginal progesterone 
(Prometrium; Schering, Quebec, Canada) 600 mg daily, starting 
2 days post-retrieval and continued until the pregnancy test. If 
the patient became pregnant, she was continued on Prometrium 
until the eighth week of pregnancy. Pregnancy was verified by 
serum HCG measurement 15 days post-oocyte collection and 
confirmed by the presence of a fetal heart at 6 weeks of gestation 
via transvaginal sonography.
Statistical analysis
Statistical analysis was performed using the SAS system. 
Parameters at baseline between the two groups were compared 
using Student’s t-test. The analysis of categorical data was 
by the chi-squared test and Fisher’s exact test. A multivariate 246
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logistic regression was used for outcome measures. The level of 
significance was set at P < 0.05 and two tailed tests were used.
Results
There were 84 cycles with indomethacin and 171 without 
indomethacin. The baseline characteristics between the two 
groups were similar for age of patients, attempt number, cause of 
infertility, reduced ovarian reserve, previous implantation failure, 
ICSI, IVF and sperm source (Table 1).
The primary outcome was the premature ovulation rate, which in 
the indomethacin group was 6% (5/84) as compared with 16% 
(28/171) in the non-indomethacin group. There was a statistically 
significant association between indomethacin and ovulation (P = 
0.02, OR = 3.8, 95% CI = 1.2−12.3), so that the odds of ovulation 
with no indomethacin were almost 4 times the odds of ovulation 
with indomethacin.
The oocyte retrieval rate per cycle was 76% (64/84) in the 
indomethacin group and 64% (109/171) in the no indomethacin 
group (P = 0.04), which was statistically significant. This is 
probably due to reduced premature ovulation as a result of 
indomethacin. The oocyte retrieval rate per retrieval procedure, 
however, was not altered significantly; 81% (64/79) and 76% 
(109/143) in the indomethacin and no indomethacin groups 
respectively. The adjusted odds ratio for no oocytes at retrieval per 
collection procedure with indomethacin versus no indomethacin 
was 0.9 (CI = 0.4−1.7), which was not statistically significant.
The embryo transfer rate per collection was not significantly 
altered by the use of indomethacin, being 52% (41/79) in the 
indomethacin group and 55% (78/143) in the no indomethacin 
group.
The clinical pregnancy rate per cycle, embryo transfer and oocyte 
retrieval procedure were increased in the indomethacin group, 
but the difference was not statistically significant between the 
two groups (Table 2). The clinical pregnancy rate per embryo 
transfer is the more important parameter to look at in nIVF, due to 
cycle cancellation secondary to premature ovulation. There was 
a lower pregnancy rate per embryo transfer in the group with no 
indomethacin as compared with the group on indomethacin. This 
difference was not statistically significant, however.
The pregnancy rate per embryo transfer was further analysed by 
age, as the cumulative pregnancy rate for all ages seemed to be 
low. The clinical pregnancy rate per embryo transfer for women 35 
years of age or less taking indomethacin was 31% (8/26), and 14% 
(7/50) for those not taking indomethacin (P = 0.08). For women 
over 35 years old, the clinical pregnancy rate was 6% (1/16) on 
indomethacin and 13% (4/30) without indomethacin. There was 
a non-significant trend towards an increase in the pregnancy 
rate per embryo transfer in these younger women as compared 
with women over 35 years of age. The adjusted odds ratio for 
the clinical pregnancy rate per embryo transfer was 0.6 (95% CI 
= 0.1–2.5) which was not statistically significant. The clinical 
pregnancy rate per patient was 20% (11/56) on indomethacin 
versus 17% (11/65) without indomethacin. Furthermore, 91% of 
the pregnancies occurred during the first two nIVF cycles in the 
non-indomethacin group and all pregnancies were in the first two 
nIVF cycles in the indomethacin group (Table 3).
There was no significant association between indomethacin and 
implantation. The implantation rate per embryo transfer with 
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Table 1. Comparison of patient characteristics in the indomethacin versus no 
indomethacin groups. 
Patient characteristic Cycles with Cycles without 
indomethacin indomethacin 
(n = 84) (n = 171)
Mean age ± SD (years) 34 ± 3.2 34 ± 3.5
Mean no. of attempts ± SD 1.8 ±1.3 2.0 ± 1.0
Cause of infertility n (%) 
  Unexplained 21 (25)   38 (22)
  Male factor 43 (51) 105 (61)
  Endometriosis   9 (11)   10 (6)
  Tubal factor 11 (13)   18 (11)
  Reduced ovarian reserve 14 (17)   31 (18)
Previous implantation failure (conventional IVF)   2 (2)     0 (0)
No. receiving ICSI 48 (57) 110 (64)
No. receiving IVF 36 (43)   61 (36)
Assisted hatching 
  Yes 17 (20)   71 (42)
  No 67 (80) 100 (58)
Sperm source 
  Ejaculate 53 (63) 103 (60)
  PESA 11 (13)   11 (6)
  TESA   3 (3)     3 (2)
ICSI = intracytoplasmic sperm injection; PESA = percutaneous epididymal sperm aspiration;  
TESA = testicular sperm biopsy.
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indomethacin was 13% (11/85) and without indomethacin was 
8% (14/184).
Discussion
One of the main disadvantages of nIVF, causing it to fall out 
of favour, is the associated high rate of premature ovulation 
and associated cycle cancellation, which results in a range of 
consequences, including time wastage and costs. The results 
obtained from this study, together with evidence from previous 
studies, suggests that the use of indomethacin may play an 
important role in overcoming one of the major obstacles in 
nIVF. In addition, the safety profile and the low cost of this 
medication make it attractive to use.
Results from this study show that the use of indomethacin in nIVF 
reduces premature ovulation from 16% (without indomethacin) 
to 6%. Patients who did not receive indomethacin had four times 
the odds of premature ovulation than those who had received 
indomethacin during the nIVF cycle. This led to a significant 
increase in oocyte retrieval rate per started cycle as a result of a 
reduction in cycle cancellation due to premature ovulation (P < 
0.04). These findings support the hypothesis that indomethacin 
reduces premature ovulation and cycle cancellation, therefore 
improving the efficacy of nIVF. In addition, the oocyte retrieval 
rate per procedure was not affected significantly by the use of 
indomethacin.
The embryo transfer rate was similar between the two groups 
studied, showing that indomethacin has no obvious effect on 
embryo development. The clinical pregnancy rate per cycle was 
increased in the indomethacin group but did not reach statistical 
significance which is possibly due to the small sample size. The 
clinical pregnancy rate per embryo transfer was not changed 
significantly by the use of indomethacin, as it did not affect 
embryo quality or implantation
The clinical pregnancy rate per embryo transfer for women 35 
years of age or less taking indomethacin was higher, but this 
was not statistically significant. On the other hand, women 35 
years of age and younger had higher pregnancy rates, which is 
most probably due to better oocyte and embryo quality. This 
finding suggests that conventional IVF cycles may be a better 
option for women over the age of 35 years, as reported in a 
previous publication (Phillips et al., 2007). This is because in 
conventional IVF cycles, more embryos can be transferred to 
overcome the lower implantation rates per embryo transferred 
in this group of women. In addition, findings from this study 
reveal that the majority of pregnancies in nIVF occurred within 
three cycles. Therefore, further nIVF attempts would not be 
advisable after three failed nIVF cycles.
Furthermore, this study did not show any effect of indomethacin 
on implantation, which is supported by the findings of a study 
that looked at the effect of indomethacin on implantation 
in oocyte recipients (Bernabeu et al., 2006). Although no 
differences were noted in terms of pregnancy rate in the two 
groups of patients, it is important to note that further studies 
should look at any effects of NSAID at the follicular level, in 
particular oocyte and granulosa cell effects potentially caused 
by the interruption of prostaglandin action on the follicle. 
Furthermore, due to the suggested association of NSAID with 
miscarriage, it will be important to follow the pregnancies 
obtained from modified nIVF cycles using indomethacin 
to ensure that there is not an increased rate of miscarriage. 
(Neilsen et al. 2001). Thus far, the data (unpublished) do not 
suggest any increase in miscarriage rate.248
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Table 3. Clinical pregnancy rate and natural IVF cycle attempt number. 
Natural IVF Clinical pregnancy rate (%) 
attempt With indomethacin No indomethacin
1 9/11 (82) 4/11 (36)
2 2/11 (18) 6/11 (55)
3 – 1/11 (9)
Table 2. Clinical pregnancy rates in the indomethacin treated versus 
no indomethacin groups. 
Clinical pregnancy rate Indomethacin No indomethacin
Per cycle (%) 11/84 (13) 11/171 (6)
Per embryo transfer (%) 9/42 (21) 11/80 (14)
Per retrieval procedure (%) 11/79 (14) 11/143 (8)
There were no statistically significant differences between the two groups.
A limitation of this study is its retrospective nature, which has 
inherent biases such as the selection of patients and observation 
bias. In addition, a multivariate logistic regression analysis 
was performed to overcome confounding variables with regard 
to the main outcomes. A prospective randomized controlled 
trial would be required to confirm findings obtained from this 
study.
In conclusion, so far as is known, this is the first study to show 
the impact of using GnRH antagonist in conjunction with 
indomethacin. Based on these data it has been demonstrated 
that the use of indomethacin significantly reduces premature 
ovulation before oocyte retrieval in modified nIVF. This is an 
interesting and potentially useful finding that demands further 
investigation.
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Introduction
The first successful IVF was performed in the natural cycle
of an infertile woman with tubal factor infertility (Steptoe
and Edwards, 1978).
Ovarian stimulation can increase oocyte and embryo
numbers as well as pregnancy rates (Fischel et al., 1985).
Hence, ovarian stimulation became a widely used method in
the treatment of infertility, and natural IVF (nIVF) was soon
abandoned in favour of stimulated IVF (sIVF). sIVF
increases the probability of obtaining more than one
fertilizable oocyte as well as that of conception. sIVF
treatment requires ovarian follicular stimulation to increase
the number of oocytes and the successful treatment outcome
(Healy et al., 1994).
However, improvements in laboratory techniques and methods
of follicular aspiration have created renewed interest in nIVF.
Gonadotrophin-releasing hormone (GnRH) antagonists induce
a reversible medical hypophysectomy, which prevents the
occurrence of premature LH surges and thus increases the
likely success of a cycle of nIVF (Rongieres-Bertrand et al.,
1999).
IVF with intracytoplasmic sperm injection (ICSI) has been
introduced as a potential treatment for severe male infertility,
and high rates of fertilization and pregnancy have been
reported (Palermo et al., 1992; Van Steirteghem et al., 1993).
In the absence of spermatozoa in the ejaculate (azoospermia),
the introduction of micro-epididymal and percutaneous
epididymal sperm aspiration (PESA) followed by
intracytoplasmic injection (ICSI) also appeared to be potential
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controlled natural cycle
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Abstract
The recovery of a mature oocyte from a natural cycle followed by IVF (nIVF) is an attractive alternative to conventional
IVF, involving ovarian stimulation, in the treatment of female infertility. Similarly, surgical recovery of spermatozoa from
the epididymis by percutaneous sperm aspiration (PESA) has simplified the treatment of men with obstructive azoospermia.
A couple sought treatment for diminished ovarian reserve and male factor infertility using IVF. A mature oocyte was
retrieved and was inseminated by intracytoplasmic sperm injection (ICSI), following recovery of spermatozoa by PESA. A
good quality embryo was transferred. A viable pregnancy was confirmed by ultrasound scan. A healthy baby boy was
delivered naturally at 37 weeks gestation. This study reports the first ongoing clinical pregnancy and subsequent birth
resulting from ICSI of spermatozoa retrieved by PESA into an oocyte recovered during a natural cycle. The use of a
combination of less invasive assisted reproductive techniques (PESA and nIVF) can overcome barriers to fertility.
Keywords: ICSI, IVF, natural cycle, PESA
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breakthroughs for the treatment of severe male infertility
(Shrivastav et al., 1994). The few drops of fluid obtained
during a PESA procedure may contain sufficient spermatozoa
to be frozen for several ICSI procedures.
Case report
A 35-year-old woman and her 43-year-old spouse were
referred for assisted reproduction due to decreased ovarian
reserve diagnosed by low antral follicle count on ultrasound
examination and male infertility. Semen analysis revealed an
ejaculate volume of 5.5 ml (normal >2 ml), a sperm
concentration of 23.1 mol/ml (normal >20 mol/ml) and
necrozoospermia.
The couple had had two children together previously and the
male partner underwent an unsuccessful vasectomy reversal.
A baseline ultrasound scan was performed on day 3 of menses
to exclude ovarian cysts and to ensure that the endometrial
lining was <5 mm thick. Serial transvaginal ultrasounds were
started on day 6. Follicular diameter was established by
calculating the mean value of the two largest measurements
perpendicular to each other. Subsequently, the patient was
monitored until the leading follicle reached a diameter >14
mm. As soon as the dominant follicle reached a mean diameter
of 14 mm, the patient received an antagonist (ganirelix,
Orgalutran; Organon Pharmaceuticals, Scarborough, Ontario,
Canada) (0.25 mg, s.c.) administered as an s.c. injection to
avoid a spontaneous LH surge. Recombinant gonadotrophin
(rFSH Puregon; Organon, 150 IU) was administered daily at
the time of the first injection of antagonist to prevent a fall in
the oestradiol concentration on the following day, and repeated
thereafter until human chorionic gonadotrophin (HCG)
administration. When the follicle had a diameter of 17 mm, the
patient received HCG (Pregnyl; Organon Pharmaceuticals,
5000 IU) administered as an IM injection to achieve final
follicular maturation. Transvaginal oocyte retrieval was
scheduled 34–36 h after HCG administration, and produced a
mature oocyte. Only the dominant follicle was aspirated.
Following retrieval of the oocyte, PESA was performed. A
volume of 0.3 ml of fluid was obtained with a sperm count of
13.5 mol/ml and motility of 30%. Spermatozoa were washed
in Cook fertilization media (Cook Canada, Toronto, Canada).
The oocyte was assessed for maturity and then ICSI was
performed according to standard protocols. The remaining
sperm specimen was frozen for future use.
Fertilization was confirmed 18 h later with the presence of two
pronuclei. Grading of the embryo was performed on day 2
after oocyte retrieval and before transfer. The embryo
transferred on day 2 after oocyte retrieval was four cells, of
good morphological quality with little fragmentation and
equally sized blastomeres. Zona thinning was performed using
the Hamilton Thorne ZILOS (Beverly, MA, USA). The
transfer of the embryo to the recipient uterus was completed
without complication on the first attempt. Unfortunately the
patient did not conceive on this cycle. A second cycle was
started from the patient’s next menses, following the same
protocol. A single oocyte was retrieved, fertilized by ICSI
using the frozen–thawed PESA sample. On day 2 after oocyte
retrieval a 2-cell embryo with even blastomeres and no
fragmentation was transferred. The luteal phase was supported
by HCG (Pregnyl; Organon Pharmaceuticals) and vaginal
natural P micronized progesterone (Prometrium; Schering,
Pointe-Claire, Quebec, Canada) (600 mg daily) starting 2 days
after oocyte retrieval and continued daily up to menstruation or
for at least the first 8 weeks of pregnancy if the patient became
pregnant. Serum HCG was collected 15 days after oocyte
retrieval. The first ultrasound was performed at a gestational
age of 6 weeks. A clinical pregnancy was defined as a
pregnancy in which a fetal sac with fetal heart activity was
visualized by ultrasound 8 weeks after HCG administration. A
healthy baby boy was delivered at 37 weeks’ gestation.
Discussion
An ESHRE consensus meeting report recently stated that the
essential aim of IVF/ICSI is the birth of one single healthy
child, with a twin pregnancy being regarded as a complication
(Land and Evers, 2003).
The collection of a mature oocyte from a naturally selected
follicle, followed by IVF, has received increasing attention as
an alternative to conventional sIVF treatment. The benefits of
nIVF compared with sIVF include reduced cost (fewer drugs),
reduced health risks (no hyperstimulation syndrome and
multiple pregnancies), and increased patient acceptability (no
blood tests). The financial benefits of nIVF as compared with
sIVF have been reported previously (Daya et al., 1995).
Although this protocol does require the patient to take some
medication, it is greatly reduced as compared with normal
stimulation protocols in sIVF, even mild controlled
stimulation. The oocyte retrieval procedure with only one
follicle is extremely quick and may be performed without
anaesthesia or sedation. Since only one oocyte and therefore
one embryo is obtained, there is no risk for multiple
pregnancy.
So far as is known, this report describes the first ongoing
clinical pregnancy and subsequent birth of a healthy baby
resulting from ICSI of frozen–thawed PESA-retrieved
spermatozoa and nIVF.
In summary, this study indicates that nIVF is a viable option
for infertile women who have normal ovulatory menstrual
cycles. If necessary, ICSI can be performed using spermatozoa
retrieved by PESA. This report illustrates the use of a
combination of fewer invasive assisted reproductive
techniques in overcoming barriers to infertility. These results
also indicate the importance of counselling regarding other
possible options, such as sIVF, in cases such as this.
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Introduction
Modified natural cycle IVF (mnIVF) is a treatment modality
that was of little interest for many years but has recently
been used increasingly as an alternative option to stimu-
lated IVF cycles (Aanesen et al., 2010; Reyftmann et al.,
2007; Ubaldi et al., 2004). This change has been made pos-
sible with the introduction of gonadotrophin-releasing hor-
mone (GnRH) antagonists and the development of
techniques to minimize premature ovulation in these cycles
(Kettel et al., 1991).
The benefits of mnIVF treatment are the use of minimal
amount of medication with almost no risk of ovarian hyper-
stimulation syndrome, the relatively easier oocyte retrieval
which can be done without sedation or local anaesthesia,
the lower financial burdens and the possibility to continue
with treatments on a monthly basis unlike stimulated IVF
(sIVF) where a break from treatment is required (Aanesen
et al., 2010; Pelinck et al., 2002). Furthermore, since mnIVF
almost always results in only one oocyte being aspirated,
single-embryo transfer will almost always be done, there-
fore reducing the risk of multiple birth (ESHRE, 2001;
Pandian et al., 2005).
Although the clinical pregnancy rates per cycle and per
embryo transfer in mnIVF may seem low, as reported in a lit-
erature review ranging from 0% to 18.8% and 0% to 50%,
respectively (Pelinck et al., 2002), cumulative pregnancy
rates with repeated mnIVF cycles, which are more accurate
for assessing the efficacy of mnIVF are encouraging.
Lifetime analysis from three published studies showed
cumulative pregnancy rates of 43% and 42% after three
and five oocyte aspirations (Aboulghar et al., 1995; Paulson
et al., 1992) and 46% after four started cycles (Nargund
et al., 2001). Furthermore, cancellation rates, the most
important drawback of mnIVF, have decreased after the
introduction of GnRH antagonists and indomethacin in the
late follicular phase of mnIVF without negative impact on
the clinical outcome (Paulson et al., 1994; Rongieres-Ber-
trand et al., 1999).
mnIVF has been proposed for various patient groups
including poor responders (Kadoch et al., 2011; Reyftmann
et al., 2007) and patients less than 37 years of age (Phillips
et al., 2007). Additionally, it has been offered in the study
centre as an alternative option to sIVF because of its lower
cost for eligible couples when medically indicated. More
recently, with the public funding of IVF in the province of
Que´bec, while up to three cycles of sIVF are covered by
Medicare, up to six cycles of mnIVF, along with all its
potential advantages, can be performed (Bissonnette
et al., 2011). Indeed, some studies have reported that the
cost of mnIVF is approximately 20% lower than that of sIVF,
including average cost of cancelled cycles and the costs
related to ovarian hyperstimulation syndrome (Aboulghar
et al., 1995; Nargund et al., 2001). More recently, Polinder
et al. (2008) conducted a randomized controlled trial eval-
uating the cost-effectiveness of mild ovarian stimula-
tion/GnRH antagonist co-treatment combined with
single-embryo transfer, compared with a standard stimula-
tion/GnRH agonist long protocol and the transfer of two
embryos. The authors reported that despite a significantly
increased average number of IVF cycles using the mild strat-
egy (2.3 versus 1.7 cycles), lower average total costs were
observed over a 12-month period. This was mainly due to
higher costs of the obstetric and post-natal period for the
standard strategy, related to multiple pregnancies.
There is limited information on the use of mnIVF in male
factor infertility. The use of intracytoplasmic sperm injec-
tion (ICSI) in sIVF protocols for the treatment of male infer-
tility has benefited many couples (Palermo et al., 1992).
Both ejaculate spermatozoa and those retrieved from the
testis (testicular sperm extraction, TESE) and epididymis
(percutaneous epididymal sperm aspiration, PESA) have
been utilized in insemination of oocytes using ICSI (Craft
and Shrivastav, 1994; Temple-Smith et al., 1985). This study
centre published a case report several years ago reporting
the use of surgically retrieved spermatozoa in combination
with mnIVF and the successful birth of a healthy boy (Kadoch
et al., 2005). Following that success, the objective of the
present study was to evaluate the ongoing results of mnIVF
in combination with surgical sperm retrieval in this clinic.
Materials and methods
mnIVF and ICSI cycles in women under 37 years of age per-
formed at OVO Clinic between December 2003 and Septem-
ber 2011 were included in this retrospective cohort study.
Only first cycles that underwent oocyte retrieval were
included in the analysis. The study recruited couples with
mild-to-moderate male factor (total motile sperm count,
TMC, 1–5 million in the pre-ICSI evaluation) with an indica-
tion for IVF–ICSI. The study excluded men with severe male
factor infertility (<1 million in the pre-ICSI evaluation) or
mild male factor infertility (>5 million in the pre-ICSI eval-
uation). On the day of ICSI, only cycles with mild-to-
moderate ICSI indication (motile spermatozoa between
0.1–5 million on IVF day) were included in the study
(Figure 1). Patients were not excluded if their TMC dropped
below 1 million (but remained above 0.1 million) on the day
of ICSI as this would have resulted in a substantial drop in
the total number of cases. It was felt that couples with a
drop in their TMC (on the day of ICSI) in the range of 0.1
to 1 million would have similar outcomes to couples with
a TMC between 1 and 5 million. Couples with diagnosis of
unexplained infertility, tubal factor, low ovarian reserve,
endometriosis, sperm donor or recurrent miscarriage were
excluded from the study (Figure 1).
The mnIVF protocol has been described previously
(Kadoch et al., 2008, 2011; Phillips et al., 2007). Patients
were seen on day 9 of their cycle for an initial ultrasound.
Follicular development was monitored and GnRH antagonist
(ganirelix, Orgalutran; Merck Frosst, Kirkland, Que´bec, Can-
ada) 0.25 mg s.c. was commenced when the dominant folli-
cle reached 14 mm; at the same time 50 mg indomethacin
(Indocid; Merck Frosst) was given three times a day until
the day before oocyte retrieval to reduce premature ovula-
tion. The use of indomethacin, a cyclooxygenase inhibitor,
has been associated with delayed follicular rupture, reduc-
ing premature ovulation (Athanasiou et al., 1996; Kadoch
et al., 2008; Morris et al., 2007; Nargund et al., 2001). Addi-
tionally, 150 IU human menopausal gonadotrophin (HMG)
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(Repronex, Ferring Canada, North York, Ontario, Canada)
were prescribed to counteract the oestradiol drop associ-
ated with GnRH antagonist use. The three medications are
started together and administered daily (average 2.7 days)
until the day of human chorionic gonadotrophin (HCG) trig-
ger, which is administered once the follicle attains
17–18 mm (5000 IU, Pregnyl; Merck Frosst). Transvaginal
oocyte retrieval was performed 34 h later.
Semen samples were produced by themale partner imme-
diately after oocyte retrieval into a sterile, sperm-tested
container. Semen was assessed at 37C after 30 min and
prepared using density gradients of Puresperm (Nidacon,
Sweden) and washed with Gamete Buffer (Cook, Canada).
Spermatozoa from men with obstructive azoospermia
were surgically retrieved by PESA or TESE prior to the ovar-
ian stimulation cycle. PESA samples were obtained several
weeks prior to the IVF cycle, cryopreserved using Sperm
Maintenance Media (Irvine, Somagen, Canada) and subse-
quently thawed on the day of oocyte retrieval. In cases
where the PESA sample was suboptimal (e.g. rare or nonmo-
tile spermatozoa) or could not be performed prior to the
ICSI cycle, TESE was performed 24–48 h prior to oocyte
retrieval to permit culture of the tissue at 37C (Morris
et al., 2007).
At oocyte retrieval, the oocyte was collected into Cook
Fertilization media (Cook), and prepared for ICSI by denuda-
tion of cumulus cells using cumulase (Origio, New Jersey
USA). Assessment of maturity for ICSI at metaphase II was
assessed by noting extrusion of the first polar body. In addi-
tion, birefringence technology was used to assess spindle
presence and location using a polscope (Oosight; CRi, USA).
Fertilization was confirmed by assessment of two pronuclei
18 h post-sperm injection and embryo transfer was per-
formed on day 2.
Biochemical pregnancy was assessed by serum bHCG con-
centration 15 days post-embryo transfer (bHCG higher than
25 IU) and confirmed by ultrasound evidence of an intrauter-
ine fetal heart at 8 weeks (clinical pregnancy). Live birth
rates were calculated for those patients with estimated
date of delivery before October 2011.
Statistical analysis was based on the assumption that
clinical pregnancy rates per embryo transfer in mnIVF–ICSI
cycles are approximately 30% and that the difference
between both groups of sperm source will be less than 25%,
Figure 1 Flow chart of study participants.
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a minimum of 41 cycles per group will have a power of 0.80
(alpha 0.05) to test the noninferiority of surgically retrieved
spermatozoa compared with ejaculated spermatozoa
(Blackwelder, 1982). Statistical analysis was performed
using STATA 10.0 (StataCorp, Texas, USA). Proportion com-
parisons were performed by chi-square or Fisher Exact
test. The Student t-test was used to compare means. A
P-value <0.05 was considered to be statistically significant.
The study was undertaken as a clinical quality control
evaluation and was properly reviewed and approved by
the scientific review committee (granted 15 February 12).
Results
A total of 726 first mnIVF cycles were performed in the study
centre between December 2003 and September 2011.
Ninety-two (12%) were cancelled before oocyte retrieval.
In the 634 cycles that underwent oocyte retrieval, at least
one oocyte was recovered in 553 cycles: an oocyte recovery
rate of 87.2% (Figure 1).
After excluding the noneligible couples, (Figure 1) 81
first mnIVF–ICSI cycles utilizing ejaculated spermatozoa
were compared with 44 cycles using surgically retrieved
spermatozoa (PESA, 30 cycles; TESE, 14 cycles). The ejacu-
lated sperm group comprised patients with mild-to-
moderate ICSI indication (mobile spermatozoa between
0.1–5 million on IVF day; mean ± SD 1.41 million ± 1.40 mil-
lion). All the patients in the surgically retrieved sperm group
had a diagnosis of obstructive azoospermia (prior vasec-
tomy, vasectomy reversal failure or congenital bilateral
absent vas deferens), except one with presumed obstructive
azoospermia (with a normal exam and serum FSH, and a nor-
mal karyotype and no Y chromosome microdeletion).
The descriptive characteristics of the two groups can be
seen in Table 1. There were no differences between the two
groups in terms of the female age, number of oocytes col-
lected or oocyte maturity. The male age in the surgically
retrieved sperm group was significantly higher than in the
ejaculated sperm group (41.5 versus 36.5 years, P = 0.001).
Cycle and obstetric outcomes are shown in Table 2.
There were no differences in terms of fertilization rate or
cleavage rate between the two groups. Assisted hatching
was performed equally in both groups. A higher rate of
embryo transfer was found in the surgically retrieved sperm
group (65.9% versus 45.7%; P = 0.03). Single-embryo transfer
was performed in all cases. There were no significant
differences between the biochemical pregnancy rate per
oocyte retrieval or per embryo transfer. Similarly, there
were no significant differences between the clinical preg-
nancy rate per oocyte retrieval or per embryo transfer. Only
singleton pregnancies were identified on the day of the via-
bility ultrasound.
Twelve out of 22 patients having a positive clinical preg-
nancy had an estimated date of delivery before 31 October
2011. In this group, live birth rates per embryo transfer
were similar between surgically and ejaculated spermato-
zoa respectively (5/31, 16.1% versus 7/27, 25.9%, P = 0.4).
Discussion
As far as is known, this is the largest retrospective cohort
study of couples with male factor infertility comparing the
clinical outcomes of mnIVF with ejaculated versus surgically
retrieved spermatozoa. The study found no differences in
terms of fertilization rate or cleavage rate between the
ejaculated and surgically retrieved sperm groups. However,
higher rates of embryo transfer were found in the surgically
retrieved sperm group. Single-embryo transfer was per-
formed in all cases. There were no differences in the bio-
chemical or the clinical pregnancy rate. Of note, all
ongoing clinical pregnancies at the 8-week ultrasound were
singleton pregnancies.
A few authors have evaluated the outcomes of mnIVF and
ICSI using ejaculated spermatozoa in cases of male factor
infertility. Ubaldi et al. (2004) assessed 157 couples with
severe male factor infertility and poor ovarian response
who underwent a total of 258 natural ICSI cycles. Thirty-two
cycles were cancelled before oocyte retrieval. In the 226
cycles that underwent oocyte retrieval, at least one oocyte
was recovered in 193 cycles with an oocyte recovery rate of
85.4%. The authors were able to perform an embryo transfer
in only 51.5% (133/258) of the started cycles. In the current
study, however, the proportion of embryo transfer was
lower in the ejaculated group (45.7%) and higher in the sur-
gically retrieved sperm group (65.9%), respectively. Ubaldi
et al. (2004) reported clinical pregnancy rates of 22.2%
per patient and 26.3% per embryo transfer. The current
study obtained similar results, with clinical pregnancy rates
Table 1 Demographic comparison between ejaculated spermatozoa and
surgically retrieved spermatozoa.
Ejaculation
(81 cycles)
Surgical
retrieval
(44 cycles)
P-
value
Female age (years) 31.7 ± 3.2 32.0 ± 3.2 NSa
Male age (years) 36.5 ± 6.2 41.5 ± 8.3 0.001b
No. of oocytes collected 1.06 ± 0.29 1.02 ± 0.15 NSb
Oocyte maturity 94 (80/85) 100 (45/45) NSc
Data are mean ± SD or % (n/total oocytes).
NS = not statistically significant.
at-test equal variances.bt-test unequal variances.
cFisher Exact test.
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of 16.0% and 20.5% per oocyte retrieval and 35.1% and 31.0%
per embryo transfer in the ejaculated and the surgically
retrieved groups, respectively. These results are comparable
to studies of poor responders (Bassil et al., 1999) and nor-
mally responding younger women (Janssens et al., 2000;
Ng et al., 2001).
Recently, Jones and Liu (2011) published a case report of
a 35-year-old woman with significantly elevated FSH con-
centrations, regular menses and severe male factor infertil-
ity who conceived after her third mnIVF attempt with ICSI,
recommending mnIVF as an option prior to considering
oocyte donation when a secondary cause of infertility
necessitates ICSI. In this study centre’s previously published
case report, a 35-year-old woman and her 43-year-old
spouse diagnosed with secondary infertility were referred
for assisted reproduction due to decreased ovarian reserve
and male factor infertility with unsuccessful vasectomy
reversal (Kadoch et al., 2005). Following the previously
described mnIVF protocol, oocyte retrieval was performed
and PESA was conducted thereafter. Transfer of a
good-quality embryo was accomplished in this first cycle;
however, no pregnancy was achieved. Subsequently, a sec-
ond mnIVF cycle was performed with successful oocyte
retrieval and fertilization using a sample of the remaining
frozen spermatozoa obtained with PESA. As result of this
second mnIVF cycle, a healthy baby boy was delivered at
37 weeks’ gestation. Supported by this initial case report,
it was suggested considering mnIVF as an alternative option
for infertile women who have normal ovulatory menstrual
cycles; and when necessary, ICSI could be performed using
spermatozoa retrieved by PESA (Kadoch et al., 2005).
In most studies to date, the source of spermatozoa (ejac-
ulated, epididymal or testicular) used in ICSI cycles has had
no significant impact on clinical outcomes and this is also true
within the context of single-embryo transfer (Nagy et al.,
1995; Nilsson et al., 2007). Moreover, there is no difference
in reproductive outcomes whether fresh or frozen spermato-
zoa are used in ICSI (Nagy et al., 1995). Nonetheless, the
mnIVF represents a unique IVF scenario in that a single oocyte
is obtained and a single spermatozoon is used. Although there
are no data to show even amodest impact of sperm source on
ICSI outcomes, if there were such an effect it would poten-
tially be best demonstrated in the context of a single oocyte
injection (as in a mnIVF). Therefore, this study assumed that
the use of a single, surgically retrieved spermatozoa (i.e. epi-
didymal or testicular) would adversely impact reproductive
outcomes when compared with the use of a single ejaculated
spermatozoa. The fact that this study observed no effect of
sperm source on mnIVF outcomes further supports the pre-
mise that the source of spermatozoa has no significant
impact on ICSI reproductive outcomes in general.
The primary limitation of this study is its relatively small
sample size. This limited its ability to adjust for a broad
range of potential covariates, including female factors,
although the selection of women younger than 37 years
would decrease confounding by female age. Although the
sample size is large enough to indicate that the use of sur-
gically retrieved spermatozoa does not have an important
and significant adverse impact on reproductive outcomes
following mnIVF (i.e. >25% reduction in clinical pregnancy
rates), we cannot exclude the possibility that the use of sur-
gically retrieved spermatozoa could have a more modest
adverse effect on clinical outcomes.
Additionally, while only first mnIVF cycles were included
in this study, some couples had previously undergone stim-
ulated cycles at the study clinic or in another institution.
In fact, while most of the patients (78.5%) did not have a
prior stimulated cycle, 15.6% had one and 5.9% had between
three and six previous stimulated cycles (data not shown).
Nonetheless, since the distribution was similar in both
groups, if this would introduce a bias, it would not have
an impact on the interpretation of the results.
These results allow the conclusion that, for couples with
obstructive azoospermia, mnIVF could be a reasonable
alternative to conventional sIVF where occasionally one
may have a larger number of oocytes than spermatozoa
Table 2 Comparison of outcome measures between ejaculated spermatozoa and
surgically retrieved spermatozoa.
Outcome Ejaculation
(81 cycles)
Surgical retrieval
(44 cycles)
Fertilization rate 48 (59.3) 30 (68.2)
Cleavage rate 43 (53.1) 30 (68.2)
Cycles with embryo transfera 37 (45.7) 29 (65.9)
Cycles with assisted hatching 15 (18.5) 9 (20.5)
Biochemical pregnancy
Per oocyte retrieval 14/81 (17.3) 10/44 (22.7)
Per embryo transfer 14/37 (37.8) 10/29 (34.5)
Clinical pregnancy
Per oocyte retrieval 13/81 (16.0) 9/44 (20.5)
Per embryo transfer 13/37 (35.1) 9/29 (31.0)
Data are n (% per cycle) or n/total (%).
aSignificantly higher for surgical retrieval (P = 0.03, t-test).
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for the IVF cycle. mnIVF may be considered in couples
where the man has had a vasectomy, if the partner is
eligible for mnIVF. The data demonstrates that the need
to surgically retrieve spermatozoa should not be a contrain-
dication to using mnIVF.
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The use of modified natural-cycle in vitro fertilization (IVF) is a valuable alternative to controlled ovarian hyper-
stimulation in young poor responders and should be considered in patients who require IVF and demonstrate en-
docrinologic evidence of ovarian aging and in those who have had one or two canceled controlled ovarian
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Although the first pregnancy obtained by in vitro fertilization (IVF)
with embryo transfer was achieved with a natural cycle—and indeed
natural-cycle IVF was the method of choice for the first few years of
IVF treatment (1)—this procedure was soon abandoned in favor of
gonadotropin-stimulated protocols in controlled ovarian hyperstim-
ulation (COH). The use of COH allowed an increase in the number
of recruited oocytes and an increase in the pregnancy rates associ-
ated with IVF (2). It also has permitted excess embryos to be cryo-
preserved in the event that the IVF attempt fails to result in
a pregnancy or when the patient desires additional sibling attempts
without a need for further ovarian stimulation. However, due to the
additional costs, risks, and complexity of ovarian stimulation, both
the patient and the caregiver feel the pressure to increase the chances
of the patient becoming pregnant; therefore, it has become standard
to transfer more than one embryo.
In some patients, the induction of multiple follicular growth is not
achieved with IVF in a stimulated cycle. Diminished ovarian reserve
is the main reason for poor ovarian response in these patients. Some
tests are considered as primary markers of poor ovarian response: an
increased serum baseline follicle-stimulating hormone (FSH) level,
a decreased value of antim€ullerian hormone (AMH), or a significant
reduction in the antral follicle count.
Over time, oocyte quality decreases in parallel with progressive
follicle loss. The combination of decreases in both the quality and
number of oocytes explains declining fecundity in females. The
diminution of follicle count in women younger than their midthirties
is the main limiting factor, and quality is preserved.
In a natural cycle, several follicles are recruited initially, but it is
only one that attains dominance and goes on to ovulate. Being able
to control ovulation was one of the reasons why natural-cycle IVF
was replaced with stimulated-cycle IVF; the first oocyte retrievals
had to be performed according to the natural leuteinizing hormone
(LH) surge, which resulted in collecting the oocyte at any time of
the day or night before ovulation.
Amounting interest in natural-cycle IVF has challenged the med-
ical community to better understand the mechanisms controlling the
follicular phase and ovulation in particular, in an effort to optimize
this procedure and its outcome. Improvements in laboratory tech-
niques and methods of follicular aspiration have created renewed in-
terest in natural-cycle IVF. Gonadotropin-releasing hormone
(GnRH) antagonists induce a reversible medical hypophysectomy,
which prevents the occurrence of premature LH surges and thus in-
creases the likely success of a cycle of natural-cycle IVF (3). Indo-
methacin use during the late follicular phase has also been shown to
decrease the rate of spontaneous ovulation and hence provide
a higher oocyte retrieval success rate in modified natural-cycle
IVF (4).
In fact, the use of modified natural-cycle IVF minimizes physical
and emotional stress for the patient and significantly reduces the cost
of drugs and laboratory tests for the assisted reproduction unit. Al-
though modified natural-cycle IVF does not reach the levels of preg-
nancy rate that can be obtained by transferring multiple embryos
after ovarian stimulation, we believe that it can be a useful, easy,
and cheap tool in the treatment of young poor responders. The ben-
efits of modified natural-cycle IVF are obvious: the increasing prob-
lem of multiple pregnancy is removed, the patients do not need to
inject themselves with large quantities of expensive medications,
and the less invasive nature of the procedure (no sedation or anesthe-
sia is used for the oocyte collections) allows patients to have a cycle
each consecutive month. Therefore, as with intrauterine insemina-
tion, patients can have three cycles of modified natural-cycle IVF
consecutively with minimal impact on their life schedules.
In our center, modified natural-cycle IVF protocol is performed as
follows. A baseline transvaginal ultrasound scan is performed on
day 3 of menses to exclude ovarian cysts and to ensure that the en-
dometrial lining is<5 mm thick. Serial ultrasound examinations are
started on day 6. The follicular diameter is established by SonoAVC
(Voluson E8), calculating automatically the mean value. Subse-
quently, the patient is monitored until the leading follicle reaches
a diameter >14 mm. Clinicians, therefore, use surrogate markers
of follicular maturation such as estrogen production and follicular
size. As soon as the dominant follicle reaches a mean diameter of
15 mm and the endometrium a thickness of 6 mm, the patient re-
ceives 0.25 mg SC of GnRH antagonist (Ganirelix, Orgalutran;
Merck Canada). Indomethacin (Indocid; Merck Frosst) at a dosage
of 50 mg orally three times a day is also started on the same day
to prevent spontaneous ovulation. Both are continued until the hu-
man chorionic gonadotropin (hCG) is administered. Human meno-
pausal gonadotropin (hMG, Repronex; Ferring Canada), 150 IU
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SC, is administered daily at the time of the first injection of GnRH
antagonist to prevent a fall in the estradiol concentration on the fol-
lowing day, and it is repeated thereafter until hCG administration.
When the follicle has a diameter of 17 mm, the patient receives
5,000 IU IM of hCG (Pregnyl; Merck Canada) to achieve final fol-
licular maturation. Transvaginal oocyte retrieval is scheduled 34
hours after hCG administration.
Modified natural-cycle IVF has recently received renewed atten-
tion and has been used for patients who have shown a poor response
in previous attempts with COH. It has been suggested in recent years
that natural-cycle IVF may be a promising alternative for poor re-
sponders (5, 6). The biological advantages of natural-cycle IVF
may provide a single oocyte of better quality and thus allow the
transfer of a healthier embryo into a more receptive endometrial en-
vironment (7). Overall, these data suggest that poor responders may
benefit from natural-cycle IVF, and it should be offered in those
young patients with a diminished ovarian reserve. In our clinical ex-
perience, modified natural-cycle IVF should be considered as a first
approach and not as a consequence of a previous treatment failure.
Unfortunately, modified natural-cycle IVF is rarely proposed and
only then as a last chance after previous standard attempts have
failed. Reasonable pregnancy rates have been reported in several
prospective studies where modified natural-cycle IVF was per-
formed in poor responder patients (8–10). Although no large
controlled prospective studies are available, we achieve
a relatively satisfactory pregnancy rate per cycle compared with
studies focused on poor responder patients undergoing different
protocols for multiple ovulation induction. Better embryo quality
as a consequence of natural oocyte selection, better endometrium
receptivity, and monthly repeatability of the procedure can
balance the relatively low chance of obtaining an embryo transfer.
For practical reasons, the advancement of the follicular phase in
the menstrual cycle is commonly timed according to the onset of last
menses. Shorter cycles in poor responders can be explained by the
intercycle basal FSH signal. Efforts should be diverted toward con-
trolling when it takes place, either with exogenous estrogen or with
oral contraceptives (11). Practically, the prescription of ethinyl es-
tradiol, 4 mg orally, during the 2 or 3 first days of themenstrual cycle
can be useful in these conditions to delay follicular maturation and
to synchronize with the endometrium.
While laboratory researchers are trying to find the best method to
select an embryo or embryos with the best developmental potential
for embryo transfer, perhaps the role of natural selection of follicles
should be considered. Further research is necessary to verify
whether the aneuploidy rate or gene expression of cumulus cells
in natural-cycle embryos are improved over embryos resulting
from stimulation cycles.
Because there is only one follicle in natural-cycle IVF, there is
a greater risk of cycle cancellation than in stimulated cycles, even
in younger patients. This is an area of natural-cycle IVF that needs
more attention and research, as there is certainly less chance of an
embryo transfer after the commencement of a natural-cycle IVF cy-
cle when compared with a stimulated IVF cycle.
The number of women over 35 years of age attempting to con-
ceive has increased significantly in the last decade. Although it is
well established that a woman’s reproductive success dramatically
declines with age, the underlying physiologic changes responsible
for this phenomenon are not well understood. Many studies show
that the risk of childlessness increases at higher ages as a conse-
quence of ovarian aging. It is well known that the considerable in-
crease in aneuploidy in embryos from older women contributes to
these women’s inability to conceive, increasing both implantation
loss and pregnancy failure (12, 13). Many studies have shown that
oocyte quality has the greater impact on the reduction of fertility
than oocyte number. The concept of using natural-cycle IVF for
older patients has been previously suggested and has had very
poor outcomes (14).
Because the pregnancy rate from modified natural-cycle IVF is
lower (15), it appears that the benefits of transferring more than
one embryo are increased in patients over the age of 35 years. Fur-
thermore, in older patients, achievement of multiple follicle growth
remains a challenge. Indeed, poor ovarian responses are common-
place after the age of 35 years in any assisted reproduction unit.
The management of these patients is a challenge, and whatever pro-
tocol is used their clinical outcome remains poor compared with
both young patients and those with normal response. The overall
pregnancy rates achieved with modified natural-cycle IVF in older
patients are low, and they are reduced with the transfer of a single
embryo.
Apart from oocyte donation, there is no established intervention
to improve the pregnancy outcome of older patients. Although the
factors responsible for diminished oocyte quality remain to be elu-
cidated, recent data focus on the potential role of mitochondria dys-
function in reproductive aging (16). In this context, the use of
coenzyme Q10 as a mitochondria energy substratum has been pro-
posed to reduce the aneuploidy rate and enhance the prognosis of
modified natural-cycle IVF in older poor responders. This is an
area currently under investigation in our clinic’s program.
The use of modified natural-cycle IVF is a valuable alternative to
COH in young poor responders and is in line with the increasing in-
terest in single-embryo transfer and the resultant reduction in multi-
ple pregnancies. This alternative should be considered in patients
who require IVF, who demonstrate endocrinologic evidence of ovar-
ian aging, and who have had one or two canceled COH cycles.
Hence, we suggest that modified natural-cycle IVF should be con-
sidered as a first approach in young poor responders. Furthermore,
the increasing interest in the concept of the potential rejuvenation
of ovarian reserve in mammalian females poses the question as to
whether modified natural-cycle IVF could become a future option
for older patients who have reduced ovarian reserve.
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Abstract
The recovery of a mature oocyte from a modified natural cycle followed by in-vitro fertilization (nIVF) is an attractive 
alternative to conventional IVF, involving ovarian stimulation, in the treatment of female infertility. Ovarian agenesis is a 
rare disorder resulting in primary amenorrhoea and infertility in affected females. A couple sought help for infertility due to 
ovarian agenesis of the female partner and decided to pursue treatment utilizing oocyte donation. Modified natural-cycle egg 
retrieval was carried out on the donor; one mature oocyte was retrieved and underwent IVF using a sperm sample from the 
male partner. A good-quality embryo was transferred. A viable pregnancy was confirmed by ultrasound scan and resulted in 
the delivery of a healthy baby boy at 36 weeks’ gestation. This is the second published report of an ongoing clinical pregnancy 
and subsequent birth resulting from oocyte donation recovered during a modified natural cycle. The use of less invasive 
assisted reproduction techniques such as nIVF can be used in oocyte donation cycles successfully.
Keywords: egg donation, IVF, modified natural cycle IVF, natural cycle, oocyte donation, ovarian agenesis
The first successful IVF was performed in the natural cycle of an 
infertile woman with tubal factor infertility (Steptoe and Edwards, 
1978). Ovarian stimulation can increase oocyte and embryo 
numbers as well as pregnancy rates (Fishel et al., 1985). Hence, 
ovarian stimulation became a widely used method in the treatment 
of infertility, and natural IVF was soon abandoned in favour of 
conventional (stimulated) IVF. Conventional IVF increases the 
probability of obtaining more than one fertilizable oocyte as well 
as that of conception and requires ovarian follicular stimulation to 
increase the number of oocytes and improve treatment outcome 
(Healy et al., 1994).
However, improvements in laboratory techniques and methods 
of follicular aspiration have created renewed interest in natural 
IVF. Gonadotrophin-releasing hormone (GnRH) antagonists 
induce a reversible medical hypophysectomy, which prevents 
the occurrence of premature LH surges and thus increases the 
likely success of a cycle of natural IVF (Rongieres-Bertrand et 
al., 1999). Indomethacin use during the late follicular phase has 
also been shown to decrease the rate of spontaneous ovulation and 
hence higher oocyte retrieval success rate in modified natural IVF 
cycles (Kadoch et al., 2008).
The clinical pregnancy rate per embryo transfer following 
modified natural IVF was reported to be 27% compared with 47% 
in conventional IVF cycles for patients aged less than 35 years 
old (Phillips et al., 2007). However, natural-cycle patients could 
attempt consecutive cycles with much less medical and financial 
Case report
Successful pregnancy in an ovarian agenesis 
patient after modified natural cycle IVF oocyte 
donation
Introduction
Case report - Pregnancy for an ovarian agenesis patient - IJ Kadoch et al.
impact on their lives and in this age group the choice of modified 
natural IVF reduces the cost and risk to the patient, permitting 
her to have multiple consecutive attempts and offers a cumulative 
clinical pregnancy rate which approaches that of conventional 
IVF (Pelinck et al., 2007; Phillips et al., 2007).
Gonadal agenesis with a 46,XX chromosome complement is 
an extremely rare disorder affecting females with only 11 cases 
reported in the literature; 10 of them were discussed in a report 
by Mutchinick et al. (2005) and one was recently published by 
Dede et al. (2008). Out of those reported cases; only eight of them 
reached the age of puberty and exhibited primary amenorrhoea, 
lack of secondary sexual development and hypergonadotrophic 
hypogonadism. Variable forms of Müllerian anomalies were 
observed in all of these patients. Treatment of these cases would 
involve administration of hormone replacement therapy in the 
form of oestrogen to achieve puberty along with secondary sexual 
development and maximum potential bone growth, in addition 
to progesterone to oppose the oestrogenic effect on the uterus, if 
present, and induce menstruation.
Case report
This report describes the case of a 38-year-old female and her 
38-year-old partner who presented to the fertility centre for 
treatment. The female partner was a known case of ovarian 
agenesis which was diagnosed during her pubertal years when 
she presented with primary amenorrhoea and lack of secondary 
sexual development. She was found to have a normal 46,XX 
karyotype, absent ovaries and present normal Müllerian organs 
(vagina, cervix, uterus and tubes) and had been started on 
oestrogen/progesterone hormone replacement therapy which 
was later changed to combined oral contraceptive for the last 
15 years. The patient experienced normal withdrawal menstrual 
bleeding. The patient was otherwise healthy with no history of 
any other medical or surgical disease and she didn’t use any other 
medication. On physical examination she had normal secondary 
sexual characteristics including normal vagina, cervix and 
palpable uterus. The male partner was a non-smoker and healthy 
with no history of any medical or surgical disease or the use of 
any medication. He had not previously fathered any pregnancies 
in the past.
The couple was seeking advice on fertility treatment using oocyte 
donation and the female partner’s sister had offered to donate to 
her sister. Basic work-up for the couple included viral serology 
(hepatitis B, hepatitis C, cytomegalovirus [CMV], human 
T-lymphocyte virus types I and II, and human immunodeficiency 
virus types I and II) and results were negative except for CMV 
immunoglobulin G, which was positive for both partners. 
Venereal Disease Research Laboratory (VDRL) and Chlamydia 
cultures were negative for the couple and the female was immune 
to rubella and had a normal cervical smear. Semen analysis for 
the male partner was normal.
The donor was a healthy, married 35-year-old, with two previous 
spontaneous pregnancies and the delivery of two healthy children. 
She had no history of any medical or surgical disease and has a 
regular menstrual cycle. Her hormonal workup indicated a normal 
profile including a day-3 FSH 6.6 IU/l, oestradiol 73 pmol/l and 
baseline day-3 transvaginal ultrasound study (TV-US), which 
showed a normal ovarian reserve with an antral follicle count 
of 16. VDRL and cervical swab for chlamydia cultures were 
negative, cervical smear was normal; the patient was rubella 
immune and had a negative viral serology for the same profile 
mentioned above.
A meeting with a psychologist was carried out for the couple 
and the donor, separately and together on different occasions. 
The female partner expressed her wish to minimize the risks 
and side effects of conventional IVF on the donor as well as the 
costs of medications, so modified natural IVF was offered as a 
plausible alternative to pursue the treatment. Informed consent 
was obtained from all participants in the cycle.
Modified natural IVF protocol was carried out on the donor as 
follows. A baseline TV-US was performed on day 3 of menses 
to exclude ovarian cysts and to ensure that the endometrial lining 
was <5 mm thick. Serial TV-US were started on day 6. Follicular 
diameter was established by calculating the mean value of the two 
largest measurements perpendicular to each other. Subsequently, 
the donor was monitored until the leading follicle reached a 
diameter >14 mm. As soon as the dominant follicle reached a mean 
diameter of 14 mm (day 11 of donor’s cycle), the donor received 
0.25 mg, s.c. GnRH antagonist (Ganirelix, Orgalutran; Schering-
Plough Canada, Pointe-Claire, Québec) administered to avoid 
a spontaneous LH surge. Indomethacin (Indocid; Merck Frosst, 
Kirkland, Québec) at a dose of 50 mg p.o. three times a day was 
also started on the same day to prevent spontaneous ovulation and 
both would be continued until human chorionic gonadotrophin 
(HCG) administration. Recombinant gonadotrophin (rFSH, 
Puregon; Schering-Plough Canada) 150 IU s.c. was administered 
daily at the time of the first injection of GnRH antagonist to 
prevent a fall in the oestradiol concentration on the following 
day, and repeated thereafter until HCG administration. When the 
follicle had a diameter of 17 mm (day 13 of donor’s cycle), the 
donor received 5000 IU i.m. HCG (Pregnyl; Schering-Plough 
Canada) administered as to achieve final follicular maturation. 
Transvaginal oocyte retrieval was scheduled 34–36 h after HCG 
administration (day 15 of donor’s cycle) and produced a mature 
oocyte. Only the dominant follicle was aspirated.
The recipient protocol at the study centre involved the use of 
a GnRH agonist (nafarelin acetate; Synarel, Pfizer Canada, 
Kirkland, Québec) 1 puff intranasally twice daily along with 
micronized 17-B-oestradiol (Estrace; Shire BioChem Inc., Saint 
Laurent, Québec) 2 mg p.o. and 2 mg p.v. once daily and aspirin 
(Asaphen EC; Pharmascience, Montréal, Québec) 81 mg p.o. 
once daily. The GnRH agonist was used in the recipient protocol 
to avoid any possibility of LH triggering caused by the continuous 
daily use of micronized 17-B-oestradiol.
This protocol was followed for 12 days after which the GnRH 
agonist was stopped, a TV-US was performed to assess 
endometrial thickness (7.7 mm at that point) and then the 
recipient continued with Estrace and aspirin until the day of HCG 
injection of the donor when a second TV-US was performed 
to assess endometrial thickness and ensure that it was at least 
8 mm. In this case the recipient responded well to the protocol 
and her endometrial thickness was at 10 mm. Luteal support on 
the recipient was started on the same day of HCG injection of 
the donor in the form of micronized progesterone (Prometrium; 
Schering-Plough Canada) 300 mg p.v. twice daily, and would 
continue along with Estrace and aspirin for 12 weeks. In addition 
for luteal support, HCG 2500 IU s.c. (Profasi; EMD Serono 222
RBMOnline®
Canada, Mississauga, Ontario) was administered to the recipient 
once every other day for a total of three doses starting on the same 
day as the HCG injection of the donor. The recipient also took 
ciprofloxacin 250 mg p.o. twice daily for 5 days; starting on the 
day of HCG injection of the donor.
A single oocyte was retrieved from the donor and was inseminated 
using a washed sperm sample from the male partner. Fertilization 
was confirmed 18 h later by the presence of two pronuclei and two 
polar bodies. The embryo cleaved 24 h later, resulting in a good-
quality embryo, which was transferred on day 2 as a 5-cell grade 
II embryo. The embryo transfer was uneventful. The patient had a 
positive serum pregnancy test 2 weeks after embryo transfer and 
a TV-US 2 weeks later confirmed the viability of an intrauterine 
single viable pregnancy with gestational age of 6 weeks.
The pregnancy progressed uneventfully, and the patient gave 
birth at gestational age of 36 weeks to a healthy male fetus of 
2.46 kg. Both mother and baby are in excellent condition.
Discussion
An ESHRE consensus meeting report stated that the essential aim 
of IVF/ICSI is the birth of one single healthy child, with a twin 
pregnancy being regarded as a complication (Land and Evers, 
2003). The collection of a mature oocyte from a naturally selected 
follicle, followed by IVF, has received increasing attention as an 
alternative to conventional IVF treatment. The benefits of natural 
IVF compared with conventional IVF include reduced cost (fewer 
drugs), reduced health risks (no hyperstimulation syndrome and 
multiple pregnancies) and increased patient acceptability (no 
blood tests). The financial benefits of natural IVF as compared 
with conventional IVF have been reported previously (Daya et 
al., 1995).
Although this protocol does require the patient to take some 
medication, it is greatly reduced as compared with normal 
stimulation protocols in conventional IVF, even including mild 
stimulation. The oocyte retrieval procedure with only one follicle 
is extremely quick and may be performed without anaesthesia 
or sedation. Since only one oocyte and, therefore, one embryo is 
obtained, there is no risk for multiple pregnancy.
The International Society of Mild Approaches in Assisted 
Reproduction (ISMAAR) is an organization recently founded 
to promote a more physiological, less drug-oriented, lower risk, 
less expensive and more patient-friendly approach to assisted 
reproduction technology and this includes natural IVF, especially 
with more recent research suggesting an advantage in embryo 
implantation and a decrease in oocyte abnormalities (Nargund 
and Frydman, 2007).
Gonadal agenesis with a 46,XX chromosome complement 
is an extremely rare disorder affecting females with only 11 
cases reported in the literature. Out of those reported cases; 
only eight of them reached the age of puberty and exhibited 
primary amenorrhoea, lack of secondary sexual development and 
hypergonadotrophic hypogonadism. Variable forms of Müllerian 
anomalies were observed in all of these patients.
As far as is known, this report describes the first case of a female 
patient with ovarian agenesis and normal Müllerian organs 
who was able to carry a pregnancy and have a live birth using 
oocyte donation. In addition, it is the second published report 
of a clinical pregnancy and live birth utilizing natural IVF in 
an oocyte donor cycle, the preceding publication reported two 
ongoing pregnancies in five recipients with natural-cycle oocyte 
donation from five donors using a GnRH antagonist (Meldrum 
et al., 1994).
In summary, this report indicates that natural IVF is a viable 
option for infertile women who seek treatment through oocyte 
donation with the advantage of less medication, less risk of 
multiple gestations and significant financial advantage for the 
concerned couple.
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INTRODUCTION
With the lack of  evidence‑based medicine, primary ovarian 
insufficiency (POI) patients are often rapidly oriented toward 
egg donation. The hypergonadotropic hypogonadism exposes 
patients to chronically elevated levels of  follicle‑stimulating 
hormone (FSH) that down regulate FSH receptors on the 
surface of  granulosa cells. The follicle is therefore desensitized 
to FSH. By lowering endogenous FSH, it would be possible 
to restore ovulation and possibly to obtain a spontaneous 
pregnancy. There are many options to lower endogenous FSH.
Our team has developed and implemented a multidisciplinary 
approach centered on patient care. Modified‑natural in vitro 
ABSTRACT
Patients with primary ovarian insufficiency (POI) are classically oriented to egg donation due to the lack of currently available 
efficient treatments. In response to this shortcoming, modified natural in vitro fertilization cycle (mnIVF) combined with 
dehydroepiandrostenedione (DHEA) neoadjuvant treatment is an original therapeutic tool at our disposal. A 33‑year‑old patient 
with idiopathic POI was prescribed DHEA neoadjuvant treatment. She rapidly recovered her menstrual cycle and after 3 months of 
DHEA, basal follicle‑stimulating hormone has decreased drastically. Then, a mnIVF was performed. The patient got pregnant and 
gave birth to a healthy girl. She became pregnant a second time under DHEA only. Coupled with DHEA neoadjuvant treatment, 
a mnIVF could be a useful therapeutic tool for extremely poor prognosis patients with POI.
Key Words: Androgen, dehydroepiandrostenedione, modified natural in vitro fertilization, ovarian rejuvenation, primary 
ovarian insufficiency
www.ivflite.orgCASE REPORT
Quick Response Code
About the Author
Dr. Pierre Lehmann completed his medical studies at the Faculty Lariboisière St-Louis in Paris (France). Then, he 
realises his residence in Nice Hospital (France). After spending, with the congratulations of  the Jury, the study Specialist 
Diploma of  Obstetrics and Gynecology, he has focused his training in the field of  fertility. Dr. Lehmann holds a Diploma 
of  Specialised Complementary Study in Reproductive Medicine (DESC), which marks its qualities as an expert in this 
field. During two years he was attached to the fertility center of  Aix en Provence (france). Dr. Lehmann has realised a 
subspecialization in Gynaecological Endocrinology of  Reproduction and Infertility at the University of  Montreal and 
his clinical interest is the ovarian aging and primary ovarian insufficiency. He is actually professor of  University of  Montreal and Mc 
Gill University  and practices at the Sacré Cœur hospital of  Montreal and Fertility center of  CHUM.
IVF Lite Foundation Published by Medknow. All rights reserved.
Please cite this article as: Lehmann P, Himaya E, Phillips S, Kadoch I. Ovarian rejuvenation with dehydroepiandrostenedione prior to a modified natural in vitro 
fertilization cycle: A new hope in premature ovarian insufficiency. IVF Lite 2014;1:110‑2.
DOI: 10.4103/2348‑2907.140129
[Downloaded free from http://www.ivflite.org on Tuesday, June 12, 2018, IP: 67.68.28.47]
Lehmann, et al.: Ovarian rejuvenation in premature ovarian insufficiency
IVF Lite | March-April 2014 | Vol 1 | Issue 2 111
fertilization  (mnIVF)  cycle  combined  with  adjuvant 
dehydroepiandrostenedione (DHEA) administration is an 
original therapeutic option.
CASE REPORT
A 33‑year‑old woman presented to the clinic with a history of  
primary infertility for 18 months. She gradually had shorter 
cycles in the past year, going from 28 to 23 days cycles. For 
the past 5 months, she had a secondary amenorrhea.
Of  interest, her family history revealed that her mother had 
a premature menopause at the age of  39. The patient’s FSH 
was 67 IU/L and 60.8 IU/L on two samples at a 1‑month 
interval. Her anti‑Müllerian hormone (AMH) was measured 
at  0.2  ng/mL. A  vaginal  ultrasound  (GE Voluson E8) 
showed a surprising total antral follicle count of  13 between 
2 mm and 9 mm (10 follicles on the right: 3, 3, 4, 5, 5, 5, 
7, 7, 8, 8 mm, and 3 on the  left: 3, 6, 7 mm). The POI 
workup including a karyotype, an FMR1 mutation screen 
and an autoimmune investigation (anti‑21‑hydroxylase and 
anti‑thyroid antibodies) was negative. She was  therefore 
diagnosed with idiopathic POI.
After beginning a treatment of  DHEA 75 mg daily, the patient 
rapidly re‑established a regular menstrual cycle. Three months 
after the treatment, the basal FSH dropped from 60.8 IU/L to 
10.85 IU/L. However, the AMH remained low at 0.16 ng/mL. 
Then, mnIVF cycles were started using the following usual 
protocol in our center. Ultrasound monitoring is started on 
cycle day 9 for patients with regular cycles between 28 and 
30 days. Shorter cycles are seen sooner. Vaginal ultrasound is 
used in order to closely examine the endometrium and the 
ovaries. Once follicular size reaches 15 mm with an endometrial 
thickness  of   at  least  6 mm,  a  gonadotropin‑releasing 
hormone  (GnRH)  antagonist  (Ganirelix, Orgalutran; 
Merck Canada)  is  introduced at  a daily dose of  0.25 mg. 
We combine the GnRH antagonist with 150 IU of  purified 
urinary human menopausal gonadotropin (hMG) daily (hMG, 
Repronex; Ferring Canada) until the leading follicle reaches 
18 mm. Indomethacin at a dose of  50 mg orally 3 times a 
day (Indocin, Merck Frosst) is also added until the day after 
human chorionic  gonadotropin  (hCG)  administration  to 
reduce the risk of  premature ovulation. We then administer 
5000 IU subcutaneous of  hCG (Ferring Canada) to achieve 
final follicular maturation.
Egg retrieval was performed 34 h after hCG and a mature 
oocyte was collected. A good morpholological embryo 
was  transferred  on  day  2  after  assisted‑hatching was 
performed.  Luteal  phase  support  consisted  of   vaginal 
progesterone (endometrin 200 mg by day, Ferring Canada) 
until the 10th gestational week. The patient gave birth to 
a healthy girl after a pregnancy without incident.
One  year  later, wishing  another  pregnancy,  she became 
pregnant a second time under DHEA only, before even 
starting mnIVF.
As usual, an informed written patient consent was obtained 
to present her case.
DISCUSSION
The first pregnancies after IVF were obtained in the late 
1970s with oocytes retrieved from natural cycles. In the 
1980s,  stimulated  cycles  grew  in  popularity with more 
oocytes retrieved and more flexible protocols. At present, 
interest has grown toward mnIVF that offer a reduction 
in costs, in ovarian hyperstimulation syndrome, in multiple 
pregnancies and their complications.
Primary  ovarian  insufficiency  affects  1‑5% of  women. 
Eighty  percent  of   POI  remains  idiopathic  after  a 
well‑established workup.[1] For a long time, patients with 
POI were considered irreversibly infertile. Many therapies 
was used  (clomiphene citrate,  gonadotropins,  estrogens, 
GnRH,  binations  of   these  and  egg  donation)  but  only 
6.3% of  those patients become pregnant.[2]
Dehydroepiandrostenedione  is  an  endogenous  steroid 
produced by both theca cells from the ovarian zona reticula 
and the adrenal cortex. It is the main source of  androgens 
in women  through  its  conversion  to  testosterone.  It’s 
then transformed into estradiol under the action of  the 
aromatase. Finally, DHEA is a prohormone essential  to 
ovarian follicle steroidogenesis.
In 2000, the benefits of  DHEA in assisted reproduction 
for the treatment of  poor responders to ovarian stimulation 
were  first  presented  by Casson  et al.[3]   This was  later 
confirmed  by  studies  from Barad  and Gleicher.[4]  In  a 
prospective randomized controlled study in 2010. Wiser 
et al.[5] showed higher pregnancy rates in poor responders 
after  a  6 weeks  75 mg daily DHEA  treatment  prior  to 
ovarian stimulation (23.1% vs. 4%, P = 0.05).
Over the  last decade, DHEA has gained the  interest of  
numerous specialists for the treatment of  POI, premature 
ovarian aging or diminished ovarian reserve sufferers 
wishing to achieve pregnancy. Only, few cases have been 
reported  concerning  the  interest  of  DHEA  in  POI 
patients. Mamas and Mamas[6] demonstrated that the use 
of  DHEA lowers endogenous FSH. A 37‑year‑old woman 
with a baseline FSH of  102 mIU/mL had a spontaneous 
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pregnancy after a 3 month of  treatment with 50 mg daily of  
DHEA. Her FSH dropped to 18.9 mIU/mL. Other similar 
cases were reported from the same team.[7] This opens the 
door for a therapeutic use of  DHEA for POI patients.
When compared to other androgen preparations 
(e.g. testosterone), DHEA gives more physiological serum 
androgen levels. This avoids follicular arrest in the antral 
stage that usually follows an androgen excess. However, we 
have to keep in mind that POI patients have 5‑10% chance 
of  spontaneous pregnancy.[2]
It  is  important  to  cease DHEA  administration when 
pregnancy is confirmed since animal studies have shown 
a 100% miscarriage rate in rats.[8] However, no side‑effect 
or congenital anomaly has been reported in the previously 
mentioned human studies.[5]
For patients with POI  for whom egg donation  remains 
the main treatment, an adjuvant DHEA treatment coupled 
with a mnIVF cycle can represent an original alternative. 
Further, randomized controlled studies are needed to assess 
this practice.[9] 
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Abstract
Purpose A retrospective cohort study was conducted in a sin-
gle academic center to determine if modified natural cycle
in vitro fertilization (mnIVF) is an acceptable treatment for
the infertile couple.
Methods Cycles performed between July 2005 and December
2011 were included. In our center’s mnIVF protocol, a GnRH
antagonist, gonadotrophin, as well as Indocid are given on a
daily basis from detection of a dominant follicle until ovula-
tion induction. The primary outcomes were clinical pregnancy
rates (CPR) per cycle started and per embryo transfer (ET).
Outcomes were stratified by female patient age (≤35 years and
≥36 years). They were further stratified in each age group by
ovarian response status according to the 2011 Bologna
criteria.
Results A total of 1503 cycles of mnIVF, performed in 782
patients, were analyzed. CPRs were 13.7 % per started cycle
and 32.5 % per ET. Stratification by ovarian response status
(normal or poor) in each age group showed similar CPRs in
patients ≤35 years (p=0.373), and divergent CPRs per ET in
patients ≥36 years old (26.26 vs 6.25 %).
Conclusion MnIVF is an acceptable treatment option for pa-
tients considering IVF, particularly for women ≤35 years old
and for women ≥36 years old with normal ovarian response.
Keywords Assisted reproduction .Modified natural IVF .
Clinical pregnancy rates
Introduction
Conventional stimulated IVF involves various different ovar-
ian stimulation protocols to increase the yield of retrieved
oocytes to then increase the chance of fertilized embryos and
ultimately to increase the chance of pregnancy. This stimulat-
ed form of IVF carries with it a physical and psychological
burden for the patient, high cost, a risk of ovarian hyperstim-
ulation syndrome (OHSS), and a risk of multiple pregnancies
when more than one embryo is transferred at once. Although
the increasing use of antagonist cycles in IVF with a GnRH
agonist trigger and a freeze-all strategy has lowered the risk of
OHSS, reports in the literature of severe OHSS in these cases
are still appearing [1–3]. Also, repeated stimulated IVF cycles
are not usually performed in consecutive menstrual cycles in
order to allow time for ovaries to recover. For these non-
negligible reasons, natural cycle IVF has regained popularity
in recent years. Despite the ideal advantages it offers, natural
cycle IVF is also associated with high risk of cancelation,
which varies in the literature from 15 to 71 % [4]. As this type
of IVF revolves around a single follicle, there are several
reasons for which the cycle can be canceled: abnormal follic-
ular maturation, premature ovulation of the single follicle,
failed oocyte retrieval or empty follicle at retrieval, as well
as failed fertilization. However, in contrast to conventional
stimulated IVF, repeated cycles can be performed in consec-
utive months.
Capsule Modified natural IVF is a low-cost, patient-friendly treatment
and is a reasonable option for infertile couples considering IVF, particu-
larly for women ≤35 years old.
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Several variations have been put on the spectrum of natural
IVF, as described in the literature. These range from a purely
natural cycle with no additional medication involved, to a
modified natural cycle with the addition of certain agents to
prevent premature ovulation and tomaintain follicular growth,
to mild or minimal stimulation IVF where there is some form
of ovarian stimulation with clomiphene citrate or letrozole.
Modified natural IVF (mnIVF), which is used in our center,
follows the course of the natural female menstrual cycle. The
addition of a GnRH antagonist will help in preventing prema-
ture ovulation, and the addition of a gonadotropin will aid in
maintaining estradiol concentrations and avoid dominant fol-
licle atresia induced by the GnRH antagonist [5]. Indometha-
cin has also proved to be beneficial in mnIVF by decreasing
premature ovulation rates, and this is when it is initiated prior
to the LH surge [6–8]. It does so probably by delaying or
preventing spontaneous ovulations through cyclooxygenase
blockade, which plays an important role in follicle rupture.
Our fertility clinic is a leading center in North America
performing modified natural IVF [9], and this technique rep-
resents more than 25 % of the IVF activity in this center [10].
It is still vague in the literature which patients should be
selected for mnIVF. Evidently, only those with regular cycles
should be considered since mnIVF depends on the natural
dominant follicle. The indication for mnIVF does not seem
to affect efficacy of the treatment [11]. Several studies show
that natural IVF yields favorable results in poor responders
[12–15]. A randomized controlled trial by Morgia et al. [16]
comparing purely natural IVF with controlled ovarian stimu-
lation in poor responders demonstrates that natural cycle IVF
is a suitable option especially in the younger patients. In 2011,
the Bologna criteria for poor ovarian response were
established [17] to make it possible to compare different stud-
ies on this subject. Following this, a retrospective cohort trial
[18] comparing poor responders, defined by the Bologna
criteria, to normal responders in natural cycle IVF showed
contradictory results to the studies previously stated. Also, a
recent study looking at outcomes of mnIVF in poor re-
sponders, with a protocol very similar to the one used in our
center, showed that this treatment yields poor outcomes in this
patient population [19].
The objective of the present study is to describe the out-
comes of a large number of cycles of mnIVF cycles performed
in our center and then analyze them according to patients’ age
and ovarian response status as per Bologna criteria.
Materials and methods
Study design
A single-center retrospective cohort study was performed
using all mnIVF cycles performed between July 2005 and
December 2011, according to the current mnIVF protocol
used in our center. Cycles that diverged from this protocol
were excluded.
The decision to undertake mnIVF is a shared decision be-
tween the healthcare professional and the patient. Some pa-
tients had undergone stimulated cycles beforehand, and some
patients were undergoing mnIVF as their first IVF treatment.
In our practice, mnIVF is strongly recommended as a first-line
treatment for young patients with poor ovarian reserve testing
and with an indication for IVF [9, 20].
The primary end points studied were clinical pregnancy
rates per cycle started and per embryo transfer. A clinical
pregnancy was defined as the visualization of a positive fetal
heartbeat on ultrasound. Secondary endpoints were cancel-
ation rates, successful oocyte retrieval rates, fertilization rates,
and embryo transfer (ET) rates.
Outcomeswere stratified by female patients’ age (≤35 years
and ≥36 years) and were further stratified in each age group by
poor ovarian response according to the 2011 Bologna criteria
(Ferraretti et al., 2011). Women are classified as poor re-
sponders when at least two of three criteria are met: (i) ad-
vanced maternal age (≥40 years) or any risk factor for poor
ovarian response, (ii) a previous poor ovarian response (≤3
oocytes with a conventional stimulation protocol), (iii) an ab-
normal ovarian reserve test (i.e., antral follicle count <5–7
follicles or AMH <0.5–1.1 ng/ml). Patients who had under-
gone previous stimulated IVF cycles were evaluated based on
all three criteria, and patients not having done so were evalu-
ated based only on the first and third criteria.
Details of the cycle protocol
In our mnIVF protocol, an ultrasound is performed on day 9 of
the cycle to detect the presence of a dominant follicle. Moni-
toring is then continued with ultrasound. Once the dominant
follicle reaches 15 mm, a 0.25-mg subcutaneous injection of a
GnRH antagonist (Orgalutran®—MSD Canada or
Cetrotide®—EMD Serono Canada), a 150-IU subcutaneous
injection of a gonadotrophin (Repronex® or Menopur®,
Ferring Canada), as well as a 50-mg suppository of Indocid
(Merck Canada) three times daily are given on a daily basis
until ovulation induction day. Ovulation is induced by a 5000-
IU hCG injection when the dominant follicle attains maturity
(18–19 mm). Oocyte retrieval is then performed 34 h later
under minimal or no sedation according to patient preference,
and the embryo is transferred at cleavage stage on day 2.
Patients were offered ICSI if male factor contributed to the
infertility. Cycles were canceled when an ovarian cyst was
detected during follicular surveillance, if the dominant follicle
failed to progress normally, or if ovulation happened prior to
oocyte retrieval. Luteal phase support was given in the form of
intravaginal progesterone.
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Statistical analysis
Proportion comparisons were performed by chi-squared test
or Fisher’s exact test when indicated. A p value <0.05 was
considered to be statistically significant. Statistical analysis
was performed using STATAversion 10.0 (Stata Corporation,
College Station, TX, USA).
This retrospective study was approved by the institutional
Research Ethics Committee on 4 January 2012.
Results
Overall outcomes
A total of 1503 cycles of mnIVF were included in this analy-
sis, which were performed in 782 patients. Baseline patient
characteristics are shown in Table 1. Primary infertility was
the case in 494 patients, and the most frequent cause of infer-
tility was male factor. The mean number of days that the
antagonist, gonadotrophin, and indocid were given was
2.61 days, with a range of 1 to 8 days. A maximum of 5 cycles
was performed per patient; however, the number of cycles
performed decreased from 782 to 21 from the first to the fifth
rank.
Of the 1503 cycles, 279 were canceled (18.6 %). The two
most common causes of cancelation were absent or abnormal
follicular recruitment in 94 cycles and premature ovulation in
86 cycles. The rest were due to other causes (e.g., cyst forma-
tion) or not specified.
Table 2 presents the overall cycle outcomes, as well as per
patient cycle. Overall, oocyte retrieval was attempted in
1224 cycles (81.4 %) and was successful in retrieving an oo-
cyte in 1090 cycles (89.1 %). Successful fertilization was
achieved in 729 cycles (66.9 % per successful oocyte retriev-
al), and embryo transfer was performed in 628 cycles
(41.8 %). Single-embryo transfer (SET) was performed in all
cases. The clinical pregnancy rate per cycle started, per oocyte
retrieval, and per embryo transfer was 13.7, 18.9, and 32.5 %,
respectively.
Results by patients’ age
There were 625 patients in the group 35 years or younger who
completed 1238 cycles, and there were 125 patients in the
group 36 years or older who completed 265 cycles. There
was a higher cancelation rate in the group of patients over
35 years old (23.8 vs 17.4 %), but this difference did not reach
statistical significance (p=0.12). The rate of successful oocyte
retrieval per attempt was equivalent in both groups (89 vs
89.1 %). There was a slightly higher fertilization rate in the
older group of patients (65.8 vs 72.2 %), which was not sig-
nificant. There was an almost equivalent rate of ET per cycle
in both groups (41.6 vs 43 %). In the younger group, the
clinical pregnancy rates per cycle started, per oocyte retrieval,
and per embryo transfer were 14.5, 19.7,and 34.5 %, respec-
tively. These rates, which were all lower in the older group,
were 10.2, 15, and 23.5 %, respectively. The differences that
were significant between the two age categories were the clin-
ical pregnancy rates per oocyte retrieval and per ET (p=0.02).
Results by Bologna criteria
There were a total of 704 normal responders and 78 poor
responders. In each age category (≤35 years old, ≥36 years
old), we stratified patients and their respective cycles by poor
or normal ovarian response. In the group ≤35 years old
(Table 3), 1119 cycles came from patients with normal ovarian
response and 119 from patients with low ovarian response.
The cancelation rates in normal responders were lower than
in poor responders (16.7 vs 24.3 %); however, this difference
was not significant (p=0.152). The remainder of patients went
on to have oocyte retrieval, and the success rates in both cat-
egories were similar (89.4 vs 84.4 %), as were the rates of ETs
per started cycle (41.2 vs 45.4 %). In regard to clinical preg-
nancies, there were 163 pregnancies among normal re-
sponders and 16 among poor responders, giving rates of
14.6 and 13.5 %, respectively, per started cycle, and 35 and
29.6 %, respectively, per ET. These differences were not
significant.
In the group of patients aged ≥36 years (Table 3), there
were 214 cycles from normal responders and 51 cycles from
poor responders. The cancelation rate among normal
Table 1 Characteristics of patients undergoing up to five cycles of
mnIVF
Number of patients (N) 782
Female patient age, mean (SD) 32.5 (3.2)
≤35 years old, n (%) 657 (84.0)
≥36 years old, n (%) 125 (16.0)
Male patient age, mean (SD) 36.7 (6.0)
Type of infertility, n (%)
• 1°
• 2°
494 (63.4)
286 (36.6)
Ovarian reserve by Bologna criteria, n (%)
• Normal
• Poor
704 (90)
70 (10)
FSH (IU/L), mean (SD)
• FSH<10 IU/L, n (%)
• FSH≥10 IU/L, n (%)
8.5 (5.5)
598 (76.5)
184 (23.5)
Cause of infertility, n (%)
• Tubal
• Endometriosis
• Male factor
• Low ovarian reserve
• Unexplained
• Other (implantation failure, pcos)+mixed
71 (8.9)
36 (4.6)
272 (34.78)
85 (10.87)
129 (16.5)
189 (24.17)
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responders was, once again, not significantly lower than
among poor responders (22.9 vs 27.5 %). The two categories
had similar successful oocyte retrieval rates (89.1 vs 86.8 %).
There was a trend toward a higher ET rate in normal versus
poor responders (46.3 vs 31.4 %), which was on the limit of
statistical significance (p=0.05). There were 26 clinical preg-
nancies among normal responders, and only 1 pregnancy
among poor responders, resulting in clinical pregnancy rates
of 12.2 and 1.96 %, respectively, per started cycle (p=0.04)
and 26.3 and 6.25 %, respectively, per ET (p=0.06).
Discussion
To our knowledge, this is the largest series of mnIVF cycles
and the first from a North American center. This is a
representative sample, as consecutive patients were included.
A total of 74 cycles were excluded for diversion from the
current protocol. We provide the results for all patients com-
bined and then distinguished by indication for IVF, by age,
and by ovarian response. Overall, the clinical pregnancy rate
per cycle was 13.7 and 32.5 % per ET.
The cancelation rate of 18.6 % in our cohort is com-
parable to the 19.3 % of another large study of 1048 cy-
cles of mnIVF which had a similar cycle protocol [21]
and lower than the 28.9 % cancelation rate described in
purely natural IVF cycles [4]. This further highlights the
value of the short course of GnRH antagonists, gonad-
otrophins, and Indocid, which have been proven benefi-
cial in lowering premature ovulation rates [6, 7, 22]. We
had a fairly high number of cycles canceled due to
abnormal or absent follicular recruitment (6.3 %), and
Table 2 Overall cycle outcomes according to cycle number of mnIVF
Cycle number 1 2 3 4 5 Total
Cycles started 782 436 189 75 21 1503
Cycles canceled, n (% per cycle) 141 (18.0) 85 (19.5) 36 (19.0) 11 (14.7) 6
(28.6)
279 (18.6)
• Premature ovulation 38 (4.8) 26 (6.0) 13 (6.9) 7 (9.4) 2 (9.5) 86 (5.7)
• No dominant follicle 52 (6.6) 31 (7.1) 8 (4.2) 3 (4.0) – 94 (6.3)
• Cyst 20 (2.6) 10 (2.3) 6 (3.2) – 1 (4.8) 37 (2.5)
• Other 31 (4.0) 18 (4.1) 9 (4.7) 1 (1.3) 3 (14.3) 62 (4.1)
ORs (oocyte retrieval) performed, n (%/cycle) 641 (90.6) 351 (80.5) 153 (81.0) 64 (85.3) 15 (71.4) 1224
(81.4)
Successful OR, n (% per attempt) 581 (74.3) 305 (86.9) 132 (86.3) 57 (89.1) 15 (100) 1090 (89.1)
Cycles with fertilization, n (% per successful OR) 390 (67.1) 200 (65.6) 87 (65.9) 41 (71.9) 11 (73.3) 729 (66.9)
Embryo transfers (ET), n (% per cycle) 334 (42.7) 170 (40) 80 (42.6) 37 (49.3) 7 (33.3) 628 (41.8)
Clinical pregnancies per cycle, % 15.0 13.5 10.1 10.7 14.3 13.7
Clinical pregnancies per OR, % 20.1 19.3 14.4 14.0 20.0 18.9
Clinical pregnancies per ET, % 34.5 34.7 23.5 21.6 42.9 32.5
Table 3 Outcomes stratified by Bologna criteria in patients ≤35 and ≥36 years old
≤35 years old ≥36 years old
Ovarian response Normal Low p value Normal Low p value
Cycles started, n (%) 1119 (90.4) 119 (9.61) 214 (80.8) 51 (19.25)
Cycles canceled, n (%) 188 (16.8) 29 (24.3) 0.152 49 (22.9) 14 (27.5) 0.143
OR (oocyte retrieval) performed, n (% per cycle) 933 (83.34) 90 (75.63) 165 (77.1) 38 (72.55)
Successful OR, n (% per attempt) 834 (89.39) 76 (84.44) 0.15 147 (89.09) 33 (86.84) 0.65
Cycles with fertilization,
n (% per successful OR)
541 (64.87) 58 (76.32) 0.044 109 (74.15) 21 (63.64) 0.22
Embryo transfers (ET), n (% per cycle) 461 (41.20) 54 (45.38) 0.349 99 (46.26) 16 (31.37) 0.054
Clinical pregnancies, n
• % per cycle started
• % per successful OR
• % per ET
163
14.57
19.57
35.05
16
13.45
21.05
29.63
0.404
0.014
0.373
26
12.15
17.69
26.26
1
1.96
3.13
6.25
0.040
0.035
0.064
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this may be influenced by the inclusion of several pa-
tients with irregular periods (i.e., anovulatory cycles).
Our pregnancy rate per started cycle of 13.7 % is higher
than that of 7.9 % described by Pelinck et al. [21] (p<0.001).
It is interesting to note that the cycles were performed only in
patients aged 18–36 years. Differences in the indication of
mnIVF or in the selection of patients for mnIVF in their cen-
ters may explain this disparity.
In our study, most patients were 35 years or younger
and had a normal ovarian response, leaving few patients
and evidently few cycles in the groups ≥36 years old
and poor ovarian response. The clinical pregnancy rate
in women aged ≤35 years was 14.5 % per cycle and
34.5 % per embryo transfer. In women aged ≥36 years,
these rates were 10.2 % per cycle and 23.5 % per ET.
This observation that outcomes are better in younger
patients is not surprising as follicular quality decreases
with increasing age, and it confirms those of several
other studies [23–25, 15].
We then further stratified the two age groups by
ovarian response status according to the 2011 Bologna
criteria, as clinically, this population often poses a man-
agement quandary. The results of our current analysis
cannot easily be compared to most other studies involv-
ing poor responders, as the definition of poor re-
sponders is inconsistent among these. However, there
are two more recent studies which use these latest Bo-
logna criteria to evaluate natural cycle IVF treatment in
poor responders [18, 19]. The earlier one by Polyzos
et al. [18] concludes that poor responders do not re-
spond well to natural cycle IVF, with ongoing pregnan-
cy rates per cycle under 3 % in all age groups in this
category. On the contrary, patients classified as normal
responders gave significantly better results with a live
birth rate per cycle of 8.9 % (ongoing pregnancy rates
not mentioned). The results of our study differ in that
the poor responders ≤35 years old seem to respond
equally as well as the normal responders, with respec-
tive clinical pregnancy rates of 13.45 and 14.57 % (p=
0.373). However, we concur that poor responders
≥36 years old do not benefit from this treatment. These
latter results we present are also in line with those of
Kedem et al. [19], who studied the outcomes of a sim-
ilar mnIVF protocol in poor-responder women with an
average age of 39 years old and show very poor out-
comes in this group. Proposed theories to support the
advantage of natural IVF over stimulated IVF are that
the follicle naturally selected is of better quality and the
endometrium is more receptive. In older patients, as
follicular quality naturally declines so does the response
to any kind of assisted reproductive technique [26],
which explains the negligible chance of pregnancy when
combined with poor ovarian response.
We note that the selection of patients for natural cy-
cles in our center may create a bias in the results. In
other words, given that the majority of patients did not
undergo stimulated IVF prior to mnIVF, their eligibility
for one of the three Bologna criteria is removed. It is
possible that had they undergone a stimulated IVF cy-
cle, a certain number may have responded poorly, in-
creasing the number of poor responders in this study,
and shifting the results either more or less favorably
toward the poor responders.
A weakness of our study is that due to its retrospective
design, patients who decided not to undergo further treatments
despite unsuccessful attempts were lost to follow-up. These
dropouts may have been due to patients changing fertility
centers, reaching spontaneous pregnancy, or proceeding to
stimulated IVF.
We consider that including male factor infertility had
no impact on our results. A previous report evaluating
results of mnIVF-ICSI cycles using ejaculate or surgi-
cally retrieved sperm for male factor infertility and per-
formed in women under 37 years of age showed similar
clinical pregnancy rates per ET to those reported in our
study (31.0 and 35.1 % with ejaculated and surgically
retrieved sperm, respectively) [27].
A strength of this large series is that all cycles were per-
formed according to one protocol which allows conclusions to
be drawn about modified natural IVF specifically—an aspect
that is especially relevant when counseling patients before
treatment. Studies which combine both natural and minimal
stimulation IVF cannot be interpreted in the same way in this
regard [23, 25].
The attractiveness of modified natural IVF evidently comes
from its easy accessibility, minimal risk of ovarian hyperstim-
ulation, low rate of multiple pregnancies, and low cost. Also,
these cycles have the advantage of being able to perform the
oocyte retrieval with minimal or no sedation as it is quite a
short procedure requiring only one needle passage through the
vagina. However, the challenge remains selecting the right
patient population. Our study shows that mnIVF is a reason-
able treatment option for patients considering IVF, specifically
for those ≤35 years old with normal or poor ovarian
response, possibly for those ≥36 years old with normal
ovarian response, and may even be considered as a first
approach in these patients. As single-embryo transfer
gains popularity in IVF, mnIVF may be a less aggres-
sive but effective approach to attain this embryo in the-
se good prognosis patients. However, in poor responders
≥36 years old, mnIVF is not justified, and this confirms
findings of recent studies. Randomized trials are neces-
sary to determine the optimal conditions for mnIVF,
such as the timing of ovulation induction or endometrial
thickness at induction, in order to maximize chance of
pregnancy and to minimize chance of cancelation. Also,
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further analyses by indication are necessary as current
as evidence on this matter is not uniform.
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CASE REPORT
Ongoing twin pregnancy after ICSI of PESA-retrieved
spermatozoa into in-vitro matured oocytes
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The recovery of immature oocytes from unstimulated ovaries followed by in-vitro maturation (IVM) is an attractive
alternative to conventional IVF in the treatment of female infertility. Similarly, surgical recovery of spermatozoa
from the epididymis by percutaneous sperm aspiration (PESA) has simplified the retrieval of the male gamete in
treatment of men with obstructive azoospermia. We report the first ongoing clinical twin pregnancy resulting from
intracytoplasmic sperm injection (ICSI) of spermatozoa retrieved by PESA into IVM oocytes. In the treatment of
a 24-year old woman, 12 immature oocytes were retrieved. Six oocytes matured (maturation rate 50%) after
24-hour incubation and were inseminated by ICSI. Four oocytes had two pronuclei (fertilization rate 67%) and 3
good quality embryos were transferred. A viable twin pregnancy was confirmed by ultrasound scan. This report
illustrates the use of a combination of less invasive assisted reproductive techniques in overcoming barriers to
infertility.
Key words: In-vitro maturation/human oocytes/polycystic ovaries/percutaneous sperm aspiration
Introduction Case report
In in-vitro maturation (IVM) treatment cycles, immature A 24-year old woman and her 30-year old husband presented
oocytes retrieved from unstimulated ovaries are cultured over- to our clinic with a 3-year history of primary infertility. She
night. Subsequently, matured oocytes are fertilized (Trounson had regular menstrual cycles and normal, early follicular and
et al., 1994; Barnes et al., 1995). IVM treatment has several mid-luteal phase serum hormone concentrations. A transvaginal
advantages including lower treatment cost, reduced health risks ultrasound examination performed during the early follicular
and increased patient convenience compared with conventional phase diagnosed bilateral polycystic ovaries (Adams et al.,
IVF treatment. Recent reports of live births following IVM 1985).
treatment of women during unstimulated cycles (Cha et al., Her partner had normal sized testes and had previously been
2000, Chian et al., 2000a) have emphasised the significant treated in another unit with surgical excision of a varicocoele
that was believed to be the cause of his severe oligozoospermia.potential of IVM treatment, especially for women with poly-
cystic ovaries. Similarly, the treatment of male infertility with Unfortunately, no spermatozoa were found on repeated post-
operative semen analysis. His serum concentrations of FSH,the use of intracytoplasmic sperm injection (ICSI) has benefited
many couples (Palermo et al., 1992). Both ejaculated spermato- LH, testosterone and prolactin were normal. The cause of his
azoospermia was considered to be obstructive. The couple hadzoa and those retrieved from the testis and epididymis have
been utilized in insemination of oocytes using ICSI (Temple- no history of assisted reproduction treatment.
Treatment options including surgical sperm retrieval com-Smith et al., 1985; Craft and Shrivastav, 1994).
To the best of our knowledge, this is the first report of an bined with either IVF or IVM, or donor insemination were
discussed with the couple. They opted for IVM treatmentongoing clinical pregnancy resulting from ICSI of spermatozoa
retrieved by percutaneous sperm aspiration (PESA), into with PESA.
On day 3 of a spontaneous menstrual cycle the womanIVM oocytes.
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underwent a baseline transvaginal ultrasound scan to exclude 24 h culture in maturation medium and were inseminated by
ICSI. Upon examination of the injected oocytes 18 h later,ovarian cysts and to estimate the number of retrievable oocytes.
A total of 35 ovarian follicles between 4–6 mm diameter were four had two pronuclei (fertilization rate 67%). No additional
mature oocytes were obtained after 48 h culture. Three goodcounted. A second ultrasound scan was performed on day 7
to exclude the development of a dominant follicle and to quality embryos (one embryo 4 cells, grade 1; 2 embryos 4
cells, grade 2) were transferred 48 hours after ICSI. The serummeasure the endometrial thickness. A total of 10 000 IU HCG
(Profasi; Serono, Oakville, Ontario, Canada) was administered β-HCG concentration 14 days after transfer was 1824 IU/ml.
Two weeks later, a clinical twin pregnancy was confirmed36 hours before oocyte retrieval (Chian et al., 2000a). On
cycle day 9, transvaginal ultrasound-guided oocyte collection with two fetal hearts seen at transvaginal ultrasonography. A
subsequent scan at 12 weeks gestation confirmed viability ofwas performed using a specially designed 17G single-lumen
aspiration needle (K-OPS-1235-Wood, Cook, Queensland, both fetuses.
Australia) with a reduced aspiration pressure of 7.5 kPa.
Aspiration of all small follicles was performed without flushing.
DiscussionOocyte retrieval was performed under i.v. sedation (2 mg
Midazolam and 175 µg Fentanyl) and a paracervical block The collection of immature oocytes from unstimulated ovaries,
followed by in-vitro oocyte maturation and subsequent insem-with 10 ml of 1% lidocaine. Oocytes were collected in 10 ml
culture tubes containing 2 ml warm 0.9% saline with 2 IU/ml ination, has received increasing attention as an alternative to
conventional IVF treatment (Cha and Chian, 1998; Chianheparin (Baxter, Toronto, Ontario, Canada). Cumulus-oocyte
complex (COC) were identified, washed and incubated in et al., 2000a). The benefits of IVM compared with IVF include
reduced cost [less drugs and monitoring), reduced healthan organ tissue culture dish (6015 mm; Falcon, Becton
Dickinson Labware, Franklin Lakes, NJ, USA) containing 1 ml risks (no gonadotrophin associated ovarian hyperstimulation
syndrome (OHSS) or putative future ovarian cancer risk],of maturation medium. The IVM medium consisted of
TCM-199 (Sigma Chemical Co., St Louis, MO, USA) supple- and increased patient acceptability (reduced blood test and
ultrasonographic monitoring and no daily injections). IVM ismented with 75 mIU/ml FSH and LH (Humegon; Organon,
Scarborough, Ontario, Canada), 25 mol/l pyruvic acid (Sigma particularly useful for patients with polycystic ovaries, who
have an increased risk of developing OHSS (MacDougall et al.Chemical Co.) and 20% heat-inactivated maternal serum.
The oocytes were incubated in an incubator at 37°C in an 1993) and who produce a significant number of immature
oocytes following ovarian stimulation (Dor et al., 1990)atmosphere of 5% carbon dioxide and 95% air with high
humidity. resulting in lower fertilization rates (MacDougall et al., 1993;
Kodama et al., 1995, Aboulghar et al., 1997).Twenty-four hours post-collection, the oocytes were denuded
with hyaluronidase (Scandinavia IVF Science, Gothenburg, Though Cha et al. (1991) were first to describe the successful
use of IVM in a donor oocyte programme (Cha et al., 1991),Sweden) and mechanical pipetting. Mature (metaphase II)
oocytes were identified by the presence of the first polar body. Trounson and colleagues (1994) placed IVM in the clinical
realm when they first reported a pregnancy using oocytesImmature oocytes were further cultured in IVM medium, and
examined prior to ICSI and 48 hours post-collection. retrieved by transvaginal ultrasound-guided follicle aspiration
from a patient with polycystic ovaries (Trounson et al., 1994).On the day of ICSI, the husband produced two ejaculated
semen samples, but no spermatozoa were found in either Since then, there have been a number of reports of the
successful use of IVM, but pregnancy rates and live birthsspecimen. A percutaneous epididymal sperm aspiration (PESA)
procedure was performed. Epididymal fluid was collected with associated with IVM have remained relatively low (Barnes
et al., 1995; Cha and Chain, 1998). Recently, our group showeda syringe connected to a 21G butterfly needle, which was
inserted directly through the skin and the epididymal tubule. that the maturation rate can be improved by the addition of
HCG priming before immature oocyte retrieval in women withThe aspirated fluid from the right testis was examined under
the microscope. Motile spermatozoa were observed, isolated polycystic ovaries (Chian et al., 1999, 2000a). High maturation,
fertilization and cleavage rates were obtained, resulting in aand then washed (200 g for 12 min) and resuspended in IVF-
20 medium (Scandinavia IVF Science). The spermatozoa were clinical pregnancy rate of 39% per cycle commenced. Several
live births following IVM treatment of women during unstimu-incubated (37°C, 5% carbon dioxide) until use. Mature oocytes
were inseminated by ICSI and cultured in organ tissue culture lated cycles have been reported (Cha et al., 2000, Chian
et al., 2000a).dish (6015 mm; Falcon). After the ICSI procedure, surplus
spermatozoa were cryopreserved. It was appropriate that the patient selected IVM as her
treatment option since she had a large number of follicles inFor endometrial preparation, the patient was given 6 mg of
oestradiol valerate (Estrace; Roberts Pharmaceutical, Mis- both ovaries. Her prognosis during the treatment cycle was
excellent as she did not develop a dominant follicle (Cobosissauga, Ontario, Canada) in divided doses starting on the
day of oocyte retrieval. Endometrial thickness on the day of et al., 1999) by the time of HCG administration and she had
a good endometrial thickness of 7.5 mm on the day of oocyteoocyte collection was 7.5mm. Luteal support was provided in
the form of 400 mg of progesterone twice a day for 16 days collection (unpublished observation). The thickness of the
endometrial lining was achieved by priming with exogenousstarting on the day of ICSI until 12 weeks gestation.
Twelve immature oocytes were retrieved at oocyte collection. oestradiol to assist in the proper synchronization of embryo
and endometrium development.Six mature oocytes (50% maturity rate) were obtained after
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A Comparison of In Vitro Maturation and In Vitro
Fertilization for Women With Polycystic Ovaries
Tim J. Child, MD, MRCOG, Simon J. Phillips, BSc, Ahmad Kamal Abdul-Jalil, MS,
Bulent Gulekli, MD, and Seang Lin Tan, MD, FRCOG
OBJECTIVE: To establish the relative success of treatment by
unstimulated in vitro maturation (IVM) of oocytes or stim-
ulated in vitro fertilization (IVF) in women with polycystic
ovaries undergoing assisted conception treatment.
METHODS: The case-control study included 107 IVM and
107 IVF cycles matched for age and cause of infertility. In
vitro maturation patients underwent transvaginal recov-
ery of immature oocytes during an unstimulated cycle, in
vitro oocyte maturation, and fertilization. Those in the IVF
group underwent ovarian stimulation after pituitary sup-
pression. Embryos were transferred in the same cycle in
both groups. Main outcome measures included numbers of
mature oocytes and embryos produced, and rates of im-
plantation, pregnancy, live birth, and complications.
RESULTS: In the IVM group after in vitro culture, 7.8
mature oocytes and 6.1 embryos were obtained per re-
trieval. With IVF, 12.0 mature oocytes (P < .01) and 9.3
embryos (P < .01) were obtained. The IVM pregnancy and
live birth rates per retrieval were 26.2% and 15.9% com-
pared with 38.3% and 26.2% for IVF (nonsignificant). The
implantation rate of IVF-derived embryos was higher
(17.1% versus 9.5%) than that for IVM (P < .01). There
were 12 cases (11.2%) of moderate or severe ovarian hyper-
stimulation syndrome in IVF patients, compared with
none in the IVM group (P < .01).
CONCLUSION: Our results suggest that for women with
polycystic ovaries who require assisted conception, IVM is
a promising alternative to conventional IVF treatment.
(Obstet Gynecol 2002;100:665–70. © 2002 by The Amer-
ican College of Obstetricians and Gynecologists.)
Conventional in vitro fertilization (IVF) treatment re-
quires gonadotropin ovarian stimulation to increase the
numbers of mature oocytes retrieved, embryos available
for transfer, and, consequently, pregnancy rates. How-
ever, there are numerous disadvantages with gonadotro-
pin stimulation including high drug costs, need for daily
injections and frequent monitoring, and potential side
effects such as abdominal bloating, breast tenderness,
mood swings, and nausea. More importantly, ovarian
stimulation is associated with a potential risk of ovarian
hyperstimulation syndrome. Women who have poly-
cystic ovaries visualized on ultrasound examination, re-
gardless of whether there are clinical (amenorrhea, oli-
gomenorrhea, hirsutism) or endocrine (raised luteinizing
hormone [LH] and androgen levels, elevated LH/follicle-
stimulating hormone [FSH] ratio) features of polycystic
ovarian syndrome (PCOS), are at particularly high risk
of developing ovarian hyperstimulation syndrome.1 Fi-
nally, there is concern over a possible link between
ovarian stimulation and the long-term risk of ovarian
cancer.2 Consequently, there is an increasing desire for
less aggressive ovarian stimulation using lower amounts
of gonadotropins or, ideally, dispensing with ovarian
stimulation altogether.3
In vitro maturation (IVM) of immature oocytes re-
trieved from unstimulated ovaries is a reproductive tech-
nology of increasing interest. In IVM, immature oocytes
are retrieved transvaginally from 2- to 8-mm diameter
antral follicles within unstimulated ovaries and matured
in vitro for 24–48 hours.4 Mature oocytes are then
fertilized and multiple embryos transferred to the uterus
2–3 days later. Although IVM success rates have in the
past been relatively low, recent studies have reported
much higher pregnancy rates, particularly for women
with polycystic ovaries.4–8 However, data are required
comparing the relative success of IVM or IVF treatment
for infertile women with polycystic ovaries. Because
around a quarter of women attending assisted concep-
tion clinics have polycystic ovaries,9,10 such data are vital
if patients are to have reliable information on which to
base their choice of treatment. The aim of this study was
to compare the numbers of mature oocytes and embryos
produced and the rates of embryo implantation, preg-
nancy, live birth, and complications between women
with polycystic ovaries undergoing IVM and those un-
dergoing IVF treatment.
From the McGill Reproductive Center, Department of Obstetrics and Gynecology,
Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
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MATERIALS AND METHODS
We identified all IVM and IVF treatment cycles per-
formed at the McGill Reproductive Center between
February 1998 and November 2000 from our unit data-
base for this case-control study. Cases were defined as
IVM cycles in which the patient had a diagnosis of
polycystic ovaries. There were a total of 169 IVM cycles
performed during the study period, of which 107 were
for women with polycystic ovaries. An ovary was con-
sidered polycystic if there were ten or more small cysts or
follicles visualized that were arranged around the periph-
ery or scattered through an enlarged ovarian stroma on
transvaginal ultrasound scan performed during the early
follicular phase of the menstrual cycle.
The control for each IVM cycle was defined as the
preceding IVF cycle for which the patient was within the
same age group (younger than 30, 30–34, 35–39, and
older than 39), had the same infertility diagnosis, and
had polycystic ovaries on ultrasound examination. All
patient files were then manually checked to confirm the
polycystic ovaries diagnosis and to assess whether there
had been complications such as ovarian hyperstimula-
tion syndrome, pelvic infection, or bleeding during or
after the treatment cycle.
During the study period women with polycystic ova-
ries who required assisted conception were offered, after
full explanation, the option of either IVM or IVF treat-
ment. The patient commenced the treatment of her
choice after having given written informed consent. The
characteristics of women choosing IVM or IVF could
have been different. However, by using a case-control
study design we were able to match patients for two
important baseline variables that may affect outcome—
namely, age and diagnosis.
Women with amenorrhea received vaginal progester-
one (Prometrium; Schering, Pointe-Claire, Quebec,
Canada), 300 mg once daily for 10 days, to induce
withdrawal bleeding. All women underwent a baseline
ultrasound scan on days 2–4 of menstrual bleeding,
whether spontaneous or induced, to ensure that no
ovarian cysts were present. No ovarian stimulation was
used during the treatment cycle. Transvaginal ultra-
sound scans were repeated on the day of human chori-
onic gonadotropin (hCG) administration (2 days before
immature oocyte retrieval) to exclude the development
of a dominant follicle. All patients received 10,000 IU of
hCG (Profasi; Serono, Oakville, Ontario, Canada) sub-
cutaneously 36 hours before oocyte retrieval. We previ-
ously demonstrated, in a randomized controlled trial,
that hCG priming increases both the percentage and rate
of immature oocyte maturation.6 All follicles had to be
less than 10 mm in diameter on the day of hCG to
proceed to oocyte retrieval, which was performed be-
tween days 9 and 11 of the cycle for women with
ovulatory cycles and days 9 and 14 for anovulatory
patients. Data suggest that the presence of a dominant
follicle at the time of immature oocyte retrieval is delete-
rious to outcome in IVM.11,12
Transvaginal ultrasound–guided oocyte collection
was performed using a specially designed 17-gauge sin-
gle-lumen aspiration needle (K-OPS-1235-Wood; Cook
IVF, Eight Mile Plains, Queensland, Australia) with a
reduced aspiration pressure of 7.5 kPa. Aspiration of all
small follicles was performed using either spinal anesthe-
sia or intravenous fentanyl and midazolam with or with-
out a paracervical block of 10 mL of 1% lidocaine.
Follicular flushing was not performed.
The oocyte IVM technique used in this study has been
reported in detail previously.6 Oocytes were collected in
culture tubes containing warm 0.9% saline with 2-IU/mL
heparin. The oocytes were evaluated for the presence or
absence of a germinal vesicle in the cytoplasm of the
oocyte, and the immature oocytes were then transferred
into maturation medium for culture. All oocyte-handling
procedures were conducted on warm stages and plates at
37C.
The immature oocytes were incubated in culture
dishes containing 1 mL of maturation medium, TC-199
medium supplemented with 20% heat-inactivated mater-
nal serum, 0.25-mmol/L pyruvic acid (Sigma Chemical
Co., St. Louis, MO), 50-mg/mL penicillin, 75-mg/mL
streptomycin, and 75-mIU/mL FSH and LH (Humegon;
Organon, Scarborough, Ontario, Canada) at 37C in an
atmosphere of 5% CO2 and 95% air with high humidity.
After culture, the maturity of the oocytes was deter-
mined under the microscope at 24 h and 48 h. Mature
oocytes were determined by the presence of first polar
body extrusion. Oocytes that were mature at the time of
checking were denuded of cumulus cells ready for intra-
cytoplasmic sperm injection. A single spermatozoon was
injected into each metaphase II oocyte. After intracyto-
plasmic sperm injection, each oocyte was transferred
into a 20-L droplet of 1.2 medium G (Vitrolife, Go¨te-
borg, Sweden). Fertilization was assessed 18 h after
intracytoplasmic sperm injection for the appearance of
two distinct pronuclei and two polar bodies.
Embryos were transferred on day 2 or 3 after intracy-
toplasmic sperm injection. Because the oocytes were not
matured and inseminated at the same time after matura-
tion in culture, the developmental stages of embryos at
the time of embryo transfer often varied. Before transfer,
all embryos for each patient were pooled and selected for
transfer based on standard embryological criteria such as
cleavage stage and morphological quality.13
For endometrial preparation, patients received estra-
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diol valerate (Estrace; Roberts Pharmaceutical, Missis-
sauga, Ontario, Canada), starting on the day of oocyte
retrieval, depending on the endometrial thickness on
that day. If the endometrial thickness was less than
6 mm, a 10-mg dose was given, and if it was greater than
6 mm, a 6-mg dose was administered. If the endometrial
thickness was less than 7 mm on the day of embryo
transfer, the recommendation was cryopreservation of
all embryos for replacement in a later cycle. Luteal
support was provided by 200 mg of intravaginal proges-
terone (Prometrium) twice daily starting on the day of
intracytoplasmic sperm injection and continued, along
with estradiol, until 12 weeks’ gestation.
Women underwent a long gonadotropin-releasing
hormone (GnRH) agonist protocol with a follicular
phase start. Patients were pretreated with either the oral
contraceptive pill for 2 weeks before GnRH agonist14 or
oral progesterone (Norlutate; Pfizer, New York, NY) for
5 days from the first day of menstruation.15 Ovarian
stimulation with urinary or recombinant FSH began
after pituitary suppression was confirmed. An appropri-
ate daily FSH dose was selected based on patient age,
early follicular phase serum FSH concentration, and any
previous response to ovarian stimulation. Human chori-
onic gonadotropin was administered when there were at
least three follicles of at least 18 mm average diameter.
Transvaginal ultrasound–guided oocyte collection was
performed 36 hours later. Intracytoplasmic sperm injec-
tion was performed as required, and cleaving embryos
replaced in the uterus 2–4 days later. Patients in both the
IVM and the IVF groups were offered the option to
cryopreserve any remaining best-quality embryos. Lu-
teal support was provided with progesterone pessaries
(Prometrium), 200 mg twice daily, until 12 weeks’ gesta-
tion.
For the purposes of this study, patients with ovarian
hyperstimulation syndrome were classified into three
groups: mild, moderate, and severe.16 Using this classi-
fication, mild ovarian hyperstimulation syndrome in-
cludes abdominal distension and discomfort, enlarged
ovaries, and/or nausea, vomiting, or diarrhea. Moderate
ovarian hyperstimulation syndrome is diagnosed when
there is, in addition, ultrasonographic evidence of as-
cites. Severe ovarian hyperstimulation syndrome is diag-
nosed when there are clinical ascites, hydrothorax,
and/or biochemical or hematological abnormalities.
A pregnancy test was considered positive when a
serum hCG taken 16 days after oocyte fertilization had a
concentration of greater than 25 IU/L. The implantation
rate was calculated by dividing the total number of
gestation sacs present on transvaginal ultrasound 4
weeks after oocyte retrieval by the total number of
embryos transferred within a treatment group.
Statistical comparisons between categoric data were
performed using the 2 test. Because none of the
oocyte and embryo outcome variables displayed a nor-
mal distribution (Kolmogorov-Smirnov test), the non-
parametric Mann-Whitney U test was used to analyze
differences between unpaired data. All P values quoted
are two sided, and values below .05 were taken to
indicate statistical significance. Analyses were per-
formed using the SPSS statistical package (SPSS Inc.,
Chicago, IL).
RESULTS
One hundred seven IVM and 107 IVF cycles were
identified as cases and controls, respectively. There were
83 women in the IVM group and 81 in the IVF. There
were no differences in mean age, previous number of
IVF cycles undertaken, or infertility diagnosis between
the treatment groups, indicating satisfactory matching
for these variables.
Two cycles in each treatment group failed to reach
embryo transfer. Causes were failure to retrieve
oocytes in one IVM cycle and maturation failure of
the four retrieved immature oocytes in the other. There
was no transfer in two IVF cycles because of 1) cross-
contamination with Candida albicans from the patient to
the embryo culture system and 2) a high estradiol
level on the day of hCG administration requiring all
embryos to be frozen for transfer in a later cycle because
of concern over the risk of ovarian hyperstimulation
syndrome.
One thousand one hundred two viable immature oo-
cytes were collected in the IVM group. By 48 hours of
culture 835 oocytes had matured to metaphase II (mat-
uration rate 76%). After intracytoplasmic sperm injec-
tion of the in vitro–matured oocytes, the fertilization rate
was 78% and the cleavage rate was 74%. The fertilization
and cleavage rates of IVF oocytes were 78% and 72%,
respectively (nonsignificantly different from IVM val-
ues).
There were significantly fewer oocytes collected,
metaphase II oocytes, fertilized oocytes, and cleaving
embryos in the IVM group (P .01) (Table 1). A total of
336 and 284 embryos were transferred to the uterine
cavity in the IVM and IVF groups, respectively. Conse-
quently, the mean number transferred in the IVM group
(mean  SD 3.2  0.9, range 1–5) was significantly
greater than that in the IVF group (2.7 0.8, range 1–6)
(P  .01), though the median number transferred was
three in both groups.
In vitro maturation cycles appeared less likely to result
in pregnancy, clinical pregnancy, and live birth than IVF
cycles, though the 95% confidence intervals for these
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outcomes just crossed unity, confirming nonsignificance.
The implantation rate was significantly lower in the IVM
group (9.5%) than in the IVF (17.1%) (P  .01). There
were seven multiple live births in the IVM group (41.2%)
and 10 in the IVF (37.0%) (nonsignificant), including one
set of triplets in each.
There were 12 cases (11.2%) of moderate or severe
ovarian hyperstimulation syndrome in the IVF group as
defined using the classification of Golan.16 Seven of these
(6.5%) were moderate ovarian hyperstimulation syn-
drome, and five (4.7%) severe. One patient required
admission for 1 night for intravenous hydration, and
another underwent transvaginal drainage of ascites, per-
formed as an outpatient procedure. As was expected,
there were no cases of ovarian hyperstimulation syn-
drome in the IVM group (P  .01).
There were no cases in either group of hemorrhage or
pelvic infection requiring antibiotic treatment. One pa-
tient in each group was diagnosed with ectopic preg-
nancy. Both women were treated successfully with sys-
temic methotrexate.
DISCUSSION
The results suggest that for women with polycystic ova-
ries who require assisted conception treatment, IVM is a
promising alternative to stimulated IVF. Although the
numbers of oocytes and embryos are significantly less,
on average, at least five cleaving embryos were available
per oocyte retrieval through IVM treatment. These em-
bryos were produced without the need for prolonged,
expensive, intrusive, and potentially dangerous gonado-
tropin ovarian stimulation. The rates of fertilization and
embryo cleavage were similar whether or not the oocytes
were matured in vitro or in vivo.
We found the implantation rate of embryos derived
from in vitro–matured oocytes to be significantly lower
than that of IVF embryos. From our data it is not
possible to determine whether the lower implantation
rate of IVM embryos is a result of reduced oocyte
potential, reduced endometrial receptivity, or a combi-
nation of both factors.
Explanations for reduced in vitro–matured oocyte
developmental potential could include suboptimal cul-
ture conditions or defective oocytes due to inadequate
cytoplasmic maturation.17 Both nuclear and cytoplasmic
maturation, which involve a complex cascade of events,
need to be closely integrated to ensure developmental
competence. It is possible that, in in vitro–matured oo-
cytes, nuclear maturation may be complete, as evidenced
by extrusion of the first polar body, whereas cytoplasmic
maturation is incomplete. Previous data suggest that,
compared with in vivo–matured oocytes, those matured
in vitro have a reduced embryo development rate, with
increased blockage of cleavage at the zygote stage.18 Our
data do not support this finding. However, we did not
attempt to culture IVM embryos to the blastocyst stage
during the study period, and so cannot comment on
developmental blockage beyond day 3 of embryo cul-
Table 1. Results of 107 Age- and Diagnosis-Matched IVM and IVF Treatment Cycles in Infertile Women With Polycystic
Ovaries
IVM IVF OR (95% CI)
No. of cycles 107 107
Age (y) 32.8 4.2 33.1 4.1
Total injected units (ampoules) of follicle-stimulating
hormone
0 2355 833 (31.4 11.1)*
Oocytes collected 10.3 7.6 14.9 6.5*
Metaphase II stage oocytes 7.8 4.9 12.0 5.4*
Fertilized 2PN embryos 6.1 3.8 9.3 4.4*
Cleaving embryos 5.8 3.7 8.6 4.2*
Embryos transferred (range) 3.2 0.9 (1–5) 2.7 0.8 (1–6)*
Embryos cryopreserved (range) 0.8 2.3 (0–14) 1.2 3.0 (0–16)
Pregnant [n (%)] 28 (26.2) 41 (38.3) 0.57 (0.31, 1.06)
Implantation rate (%) 9.5 17.1* 0.51 (0.31, 0.84)
Clinical pregnancy [n (%)] 23 (21.5) 36 (33.7) 0.54 (0.28, 1.04)
Live birth [n (%)] 17 (15.9) 28 (26.2) 0.53 (0.26, 1.10)
Multiple live births [n (% of total live births)] 7 (41.2) 10 (37.0) 1.26 (0.30, 5.11)
Twins 6 9
Triplets 1 1
Moderate or severe ovarian hyperstimulation syndrome 0 12 (11.2%)*
IVM  in vitro maturation; IVF  in vitro fertilization; OR  odds ratio; CI  confidence interval.
Results are means  standard deviations unless stated.
* P  .01.
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ture. In the IVF study group blastocysts were transferred
in 11 cycles.
We have recently shown that the pregnancy rate in
IVM treatment is related to uterine factors such as
endometrial thickness on the day of embryo transfer
(Child TJ, Gulekli B, Sylvestre C, Tan SL, unpublished
data). This supports data from the majority of IVF
studies.19 In IVM treatment, endometrial priming using
oral estrogen is commenced from the day of oocyte
retrieval, because administration from earlier in the cycle
may be deleterious to outcome.11 Because follicular
puncture for oocyte retrieval is performed before domi-
nant follicle development, the endometrium is exposed
to low levels of estradiol until priming is commenced.
Consequently, the endometrium is exposed to raised
serum estradiol concentrations for only a few days be-
fore embryo transfer. This contrasts with the situation
during standard IVF where supraphysiologic estradiol
concentrations exist for 10 days or more before embryo
transfer. If the lower implantation rate in IVM is indeed
partly related to endometrial receptivity, then improve-
ments in IVM endometrial priming regimens through
pharmacological or other methods may lead to im-
proved outcomes.
We routinely administered 10,000 IU of hCG
36 hours before immature oocyte retrieval to all women
undergoing IVM. This is based on data from a trial that
we performed in which women were randomized to be
primed with 10,000 IU of hCG before the retrieval or not
to be primed.6 In no cycles were mature metaphase II
oocytes retrieved. However, hCG priming significantly
increased the numbers of oocytes matured at 24 hours
(78.2% versus 4.9%) and 48 hours (85.2% versus 68.0%)
of culture. This study was based on the observation that
immature oocytes retrieved from small follicles (less than
10 mm diameter) in women undergoing ovarian stimu-
lation respond to hCG. More recently we have found
that similarly high rates of oocyte maturation are ob-
tained when hCG priming is used in women undergoing
IVM who have normal ovaries, ovulatory polycystic
ovaries, or anovulatory PCOS.4
Maturation media containing FSH significantly in-
crease fertilization and early embryo development and
consequently are routinely used in published IVM stud-
ies.7 We have achieved good results using Humegon,
containing 75 mIU/mL each of FSH and LH, in the
culture media.6 Extremely low fertilization rates are usu-
ally obtained after standard insemination of in vitro–
matured oocytes, suggesting that intracytoplasmic sperm
injection is the best option, even when the sperm param-
eters are not impaired.20 Qualitative changes, including
zona hardening, occur in the zona pellucida during oo-
cyte maturation in vitro and may reduce the fertilization
rates using conventional IVF.21 We therefore routinely
used intracytoplasmic sperm injection for fertilization of
in vitro–matured oocytes.
In our age-matched population the rates of pregnancy
and clinical pregnancy per cycle with IVM treatment
were 26.2% and 21.5%, respectively, compared with
38.3% and 33.7% for IVF. Similar proportions of cycles
with positive serum pregnancy tests in both treatment
groups continued on to live birth or an ongoing preg-
nancy (IVM 61%, IVF 68% [nonsignificant]). Although
success rates appear lower, IVM treatment costs less
than IVF because less monitoring, both hormonal and
ultrasonographic, is needed and no FSH is required. On
average, 31.4  11.1 ampoules of FSH were adminis-
tered per IVF cycle. During an IVM cycle only five clinic
visits are needed—namely, two ultrasound scans, the
oocyte collection, embryo transfer, and serum preg-
nancy test—resulting in greater treatment simplicity and
less disruption to patients’ lives.
The potential risks of ovarian stimulation, particu-
larly for women with polycystic ovaries, are illustrated
by the fact that 12 of the IVF cycles (11.2%) resulted in
moderate or severe ovarian hyperstimulation syn-
drome as per the classification of Golan et al.16 This
rate of ovarian hyperstimulation syndrome at first
seems particularly high. However, it should be recog-
nized that all of the women had polycystic ovaries and
were young, with an average age of 33.1 years. Both of
these factors significantly increase the risk of developing
ovarian hyperstimulation syndrome. Indeed, two previ-
ous studies examining the outcome of IVF in women
with polycystic ovaries reported rates of moderate or
severe ovarian hyperstimulation syndrome that were
very similar to those in the present study: 10.5%1 and
10.3%.22 Although five women in the current study were
classified as having severe ovarian hyperstimulation syn-
drome, only one required hospital admission, and an-
other had drainage of her ascites as an outpatient proce-
dure.
From 107 IVM cycles, 25 infants were born (seven
multiple live births), and from an equal number of IVF
cycles, 39 infants (ten multiple live births) were deliv-
ered. There was one set of triplets born in each treatment
group. There were no reported cases of congenital ab-
normality in the infants. It is vital that data be collected
on infants born after IVM treatment to allow full assess-
ment of this new technology. We are currently engaged,
in collaboration with pediatricians, in a prospective trial
assessing the normality and neurodevelopmental devel-
opment of IVM children conceived in our center. Results
will be reported in due course, but at present IVM
infants appear no different than those conceived through
IVF.
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Abstract 
A 19 years old patient with primary amenorrhea was referred to our center. 
Based on discrepancy between high follicle stimulating hormone (FSH) level 
and normal ovarian reserve parameters, follicle stimulating hormone receptor 
(FSHR) mutation was screened. The patient was homozygous in exon 6 of the 
FSHR gene for the new variant c.479T > C and predicted to result in an ami-
noacid substitution p.Ile160Thr. One year later, her anti-müllerian hormone 
(AMH) level inexplicably decreased. Oocyte vitrification was thus offered for 
fertility preservation. After 17 days of recombinant follicle stimulating hor-
mone (recFSH) (900 IU daily), no follicular growth was seen and estradiol le-
vels remained low. In vitro maturation (IVM) was then suggested. Ten oo-
cytes were successfully vitrified. 
Keywords 
FSH Receptor Mutation, Fertility Preservation, in Vitro Maturation, 
AMH, Primary Ovarian Insufficiency 
1. Introduction
Primary ovarian insufficiency patients represent a major challenge for obstetri-
cians and gynecologist in terms of fertility management. Even if it is rare, when 
POI is combined with a FSHR mutation, helping patient in her family planning 
looks almost impossible. If POI is most often of unknown etiology, the incidence 
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of family-related cases can achieve a percentage from 4% to 31%, suggesting a 
genetic etiology in a large proportion of patients [1] [2]. 
In 1995, Aittomäki et al. observed a particular Finnish population presenting 
with elevated gonadotropin levels and primary amenorrhea but a normal karyo-
type, ending in a POI [3]. Associated with streaks ovaries, this condition is called 
ovarian dysgenesis (ODG). Actually, Aittomäki et al. linked for the first time the 
ODG to a special FSH receptor (FSHR) mutation. They reported that a C566T 
transition in exon 7 of FSHR, predicting an Ala to Val substitution at residue 189 
in the extracellular ligand-binding domain, was congruent with the ovarian dys-
genesis observed in the Finnish population for homozygous women. More pre-
cisely, the locus segregating the disease can be mapped on chromosome number 
2p, which corresponds to the locus for both FSHR and luteinizing hormone re-
ceptor (LHR) [4]. Other research in the western countries couldn’t find the same 
mutation in women with the same phenotype, suggesting that the finish case was 
very peculiar [5]. Beau et al. yet, identified another FSHR mutation in a woman 
with a secondary amenorrhea, elevated gonadotropins, a subnormal estrogenic 
activity and normal ovaries, a different phenotype than the ODG [6]. Since then, 
a few FSHR mutation studies were reported in the literature, and most of them 
highlight the link between FSHR mutation or polymorphism and an ovarian 
dysfunction that could present under different forms [4] [7]. 
To date, when such a mutation was suspected, ovarian biopsy was often sug-
gested as the diagnostic tool and virtually no fertility treatment could be offered, 
but we now seem to have more to offer to these patients. 
2. Case Presentation
A 19 years old patient with primary amenorrhea was referred to our center. She 
measured 166cm and weighed 57 kgs (body mass index 21.8). She had mod-
erately developed secondary sex characteristics interesting particularly breasts, 
and diminished sized ovaries and uterus. She had normal axillary and pelvic 
hair, and had no morphotypic abnormalities. At this time, the antral follicular 
count (AFC) was 16 (8 + 8) and the anti-müllerian hormone (AMH) was 1.59 
ng/ml. 
Based on a discrepancy between high early follicular phase FSH level (72.5 
IU/L) (ref. range 3.1 - 7.9 IU/L) and normal other ovarian reserve parameters, 
such as AMH levels and AFC, a FSHR mutation was suspected and searched for. 
A genetic screening was also performed for Fragile X Mental Retardation 1 gene 
(FMR1) premutation and for her karyotype. We furthermore completed an in-
vestigation of the classic auto-immune and endocrinologic causes of POF. 
We found no FMR1 mutation or premutation and the karyotype was 46XX. 
The biological investigations were all normal. However, the patient was homo-
zygous in exon 6 of the FSHR gene for a variant defined as c.479T > C and pre-
dicted to result in the amino acid substitution p.Ile160Thr. Her parents were 
non-consanguineous French Canadians and were carrying the same mutation. 
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They were healthy and the mother had no complications during her pregnancy 
or delivery. 
One year later, her AMH level decreased from 1.59 to 0.62 ng/ml and her AFC 
from 16 to 9 for unexplained reason, so that a fertility preservation using oocyte 
vitrification was offered. Being aware of the FSHr mutation, we started with a 
stimulated cycle nonetheless. After 17 days of 900 IU daily doses of recombinant 
FSH (recFSH), no follicular growth was seen and estradiol levels remained low. 
Therefore an in vitro maturation (IVM) was done, with the use of subcutaneous 
hCG (10.000 IU) 34 hours before the ovarian function.  
Three Further IVM cycles were carried out to maximize the number of vitri-
fied mature oocytes. She firstly underwent five days of stimulation with daily 
doses of recFSH (300 IU) and recombinant luteinizing hormone (recLH) (300 
IU) before the ovulation induction. 
In vitro maturation was carried out using the following technique: follicular 
fluid was aspirated from small follicles (between 3 mm and 8 mm), the fluid was 
assessed by the embryologist using a 22 µm filter to maximise oocyte retention. 
Once the oocyte collection was completed, immature oocytes were washed using 
Global Total (IVFonline, Canada) and then transferred into the prepared IVM 
media. IVM media was made up on the morning of the oocyte collection, one 75 
IU ampoule of Repronex (Ferring, Canada) was diluted and using to produce a 
0.75 IU solution for the oocyte culture.  
Immature oocytes were cultured for 25 hours in the maturation media and 
then assessed for cumulus expansion and extrusion of the first polar body; this 
was facilitated by sliding the oocyte. Sliding refers to visualizing the oocyte in a 
very thin layer of media created by tipping the dish gently to the side leaving the 
oocyte to flatten in the dish. Oocytes judged to be mature were denuded of their 
cumulus cells using recombinant hyaluronidase (Cumulase, Origio) and sub-
jected to ICSI. Immature oocytes were further cultured for an additional 24 
hours and assessed for maturation at which time they were denuded and ICSI 
was performed. Following ICSI, oocytes were transferred into our standard cul-
ture media system (Global, IVFonline, Canada). 
In this 19 years old patient with a hypergonadotropic hypogonadism and a 
primary amenorrhea, we retained the diagnostic of FSHr-linked POI, taking in 
account the sudden diminution of her ovarian reserve.  
With the fertility cryopreservation by oocyte vitrification, a total of 8 meta-
phase II oocytes (24 hours post IVM) and 2 metaphase I oocytes (post oocyte re-
trieval) were successfully vitrified and cryopreserved. A total of 3 IVM cycles 
were necessary for the obtention of a total of 10 oocytes. 
3. Discussion
To our knowledge, this is the first reported successful fertility preservation by 
combining oocyte-IVM and vitrification for a POI patient. The main purpose of 
our case report is thus to suggest an opportunity for fertility preservation using 
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IVM in the management of patients with confirmed POI in the frame of a FSHR 
mutation. Grynberg et al. already mentioned that there is a place for IVM in pa-
tients with ovarian resistance to FSH. They reported two cases of live birth after 
IVM in such a patient [8]. Even if their FSHR status was not specified, these 
successes are another argument in favor of IVM for POI patients with FSHR 
mutations. Our enthusiasm should probably be tempered by the fact that our 
patient is still far from delivery, but considering the number of cryopreserved 
eggs (a total of 10 eggs) and her young age, her predicted probability of having 
one child is over 60%, based on the work of Doyle et al. [9]. 
Being able to obtain mature oocytes in this clinical context is not a surprise. 
The pathway that prevents germinal vesicle (GV) and oocyte maturation is well 
characterized to comprise signaling from the granulosa cells (GC) that ultimate-
ly keeps cAMP high in the oocyte until communication with the GC is lost. In 
vivo this loss of communication normally happens because of the LH surge. But 
physical removal of GV oocytes from the follicle, as in our situation, has the 
same effect, lowering oocyte cAMP, and thus triggering oocyte maturation. This 
approach is used routinely experimentally to trigger oocyte maturation in many 
mammalian systems. Thus, it is no surprise that, even in the context of altered 
FSH signaling, any oocytes that managed to make it to a threshold size were ca-
pable of resuming meiosis [10] [11] [12]. 
Before aiming for fertility preservation, one should first obtain the correct di-
agnosis of POI and, possibly, more precisely the rare condition of FSHR muta-
tion in order to anticipate an ulterior ovarian failure in these unusual patients 
with amenorrhea. As for our patient, the diagnosis of POI was first suspected 
when a primary amenorrhea was associated with a hypergonadotropic hypogo-
nadism, a normal AFC and a normal AMH. Such situations were formerly in-
vestigated with invasive techniques like an ovarian biopsy [13], in the certainty 
of a negative screening for FMR1 mutation or permutation [14] and a normal 
karyotype [15], trying to characterize a histological anomaly that could explain 
the clinical presentation. Of course, the possibility of genetic testing and the po-
tential association of genetic mutation with POI open a new window of oppor-
tunity in the diagnosis and the support of these patients [16] [17]. In our case, 
no ovarian biopsies were available, thus no correlation was possible between the 
mutated receptor function and the ovarian histology. 
Beau et al. have already and for the first time mentioned the reported mis-
sense mutation of our patient in 1998. It has to be clarified that their patient was 
found to carry a compound heterozygotic mutation affecting the FSHr gene and 
resulting in an Ile160Thr and an Arg573Cys substitutions. These substitutions 
were located, respectively, in the extracellular domain and in the third intracel-
lular loop of the receptor. Their patient presented with another phenotype as she 
had secondary amenorrhea and normal sized ovaries [6] [18]. Also, Binder et al. 
[19] found that heterozygotic mutation Ile160Thr was carrying in 5.6% - 6.1% of
infertile patients. But our patient is the first reported case of a homozygosity for
the variant c.479T > C, suggesting that this condition could also lead to a POI.
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Of course, amenorrhea or even POI are not obligatorily caused by a FSHR 
mutation. Achrekar et al. screened the entire FSHR gene in a population of In-
dian women with primary amenorrhea and found none of the known mutations. 
They identified a particular polymorphism that was more often present in 
women with elevated gonadotropins [20]. 
More recently, Desai et al. summarized the known FSHR mutation, their ef-
fect on the receptor function and the repercussion on the reproductive system 
for the affected woman [4]. This work suggests that the mutations are activating 
or inactivating. Inactivating mutations impair either the extracellular domain of 
the FSHR, resulting in the diminution of its expression at the ovarian cell sur-
face, its ability to bind the ligand being not affected, or the affinity of the recep-
tor to the ligand [4] [21]. In both situations, the formation of the receptor-ligand 
complex or the FSH signals transduction pathway would be altered ending to a 
diminution of the FSH induced cAMP production. But, in case of a diminished 
affinity, a higher gonadotropin concentration could partially solve the problem, 
which is not the case if the expression itself is impaired. If activating, the muta-
tion was related to OHSS or even spontaneous OHSS. 
Being convinced that IVM is worth considering as fertility preservation in 
young patients with POI, another interesting approach suggested by Suzuki et al. 
deserves attention. They report ovarian tissue cryopreservation by vitrification, 
followed by in vitro activation (IVA) of dormant follicles in POI patients with 
residual ovarian follicles. After activation, pieces of ovarian tissue are grafted 
back in the mesosalpinx and stimulated to obtain mature follicles. Out of their 
initial 37 patients, 20 had residual follicles. 9 of the 20 showed a follicular growth 
as a response to the post graft stimulation, and 24 oocytes were collected from 6 
patients. Finally, 2 term pregnancies were obtained from these oocytes [22]. 
4. Conclusion
POI patients secondary to FSHR mutation are probably underdiagnosed due to 
the lack of readily available testing. FSHR mutation should be considered in pa-
tients with normal-high ovarian reserve (AMH and AFC) and discrepant FSH/LH 
results. We suggest that genetic analysis and further diagnosis precision should 
be more often investigated in these situations. 
New hope is arising for patients carrying the FSHR gene mutation with POI, 
since we and others are showing encouraging results of fertility preservation for 
these patients. Being the first to report a case of successful oocyte vitrification 
following IVM in a patient with FSHr mutation, we call for further studies to as-
sess this original approach and improve its success. 
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Abstract In August 2010, the provincial government of Que´bec, Canada introduced funding of assisted reproduction treatment
through the provincial health programme. Alongside this benefit, legislation was introduced to control assisted reproduction treat-
ment activities in the province, including restrictions on the number of embryos that could be transferred in any one cycle. The aim
of the programme was to transfer a single embryo in every cycle; multiple embryos could be transferred under suboptimal conditions
but required physician justification. In the first 3 months of this programme, 1353 cycles of IVF were performed in five Que´bec
assisted reproduction centres, with an overall clinical pregnancy rate of 32% per embryo transfer and 50% of transfers used elective
single-embryo transfer (eSET). The multiple-pregnancy rate was only 3.7% per clinical pregnancy. In 2009, prior to the introduction
of the programme, eSET was used in only 1.6% of embryo transfers, resulting in a multiple-pregnancy rate of 25.6%. These data dem-
onstrate that providing provincially funded assisted reproduction treatment created an environment in which the aggressive use of
eSET was not only possible, but also rapidly implemented. The result was a dramatic drop in multiple-pregnancy rates, approaching
those for natural pregnancies. RBMOnline
ª 2011, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
KEYWORDS: cumulative pregnancy rate, eSET, funding, IVF, multiple pregnancies
Introduction
Huge advances have been seen in IVF success rates over the
more-than 30 years that this treatment has been applied
clinically. Improvements in laboratory practices, ovarian
stimulation protocols, cryopreservation techniques and
genetic aspects of treatment have all served to increase
implantation and live-birth rates. However, despite these
1472-6483/$ - see front matter ª 2011, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.rbmo.2011.05.020
Reproductive BioMedicine Online (2011) 23, 500–504
www.sc iencedi rec t .com
www.rbmonl ine .com
advances, one major drawback of IVF has remained con-
stant: the disproportionately high rates of multiple pregnan-
cies, including high-order multiple pregnancies, and the
associated risks seen with such outcomes.
In Canada, professionals working in the field of assisted
human reproduction meet under the auspices of the Cana-
dian Fertility and Andrology Society (CFAS). For the last
11 years, the CFAS has managed a registry of assisted repro-
duction cycles performed across the country. Participation
in the Canadian ART Register (CARTR) is not mandatory
but all Canadian assisted reproduction clinics participate
and provide funding for this initiative. The registry allows
Canadian clinics to monitor the outcome measures associ-
ated with treatment in the country. Although only aggregate
data are released to participants and the general public, the
CARTR outcome-improvement committee has confidential
access to clinic-specific data, permitting them to identify
and offer help to clinics whose results fall below the
national standard.
Looking at published data from 2005, it is clear that
North America has the greatest problem with multiple births
from assisted reproduction treatment; Canada and the USA
topped the statistics with >30% multiple-birth rates,
whereas the lowest rates were seen in countries with state
coverage for assisted reproduction treatment, such as Swe-
den (6%), Australia/New Zealand (14%) and Belgium (13%)
(Assisted Human Reproduction Canada, 2011).
Data from CARTR shows the progression of the
multiple-birth rate compared with the live-birth rate in Can-
ada from 2001 to 2008 (Figure 1) (Gunby et al., 2010). The
live-birth rate has improved gradually over the years, but
the multiple-pregnancy rate fluctuates consistently around
the 30% rate. Although the use of elective single-embryo
transfer (eSET) for assisted reproduction in Canada has been
slowly increasing, by 2009 it remained at a very low rate
(Figure 2). The low use of eSET can be attributed to the fact
that, when patients are paying for their treatment, the
pressure to achieve a pregnancy with as few attempts as
possible becomes a driving force for both the patient and
treating physician. In the absence of strict guidelines, a
clinic may be tempted to transfer more embryos to improve
its pregnancy rate.
Table 1 shows comparative data for 2009 between Que´-
bec and the rest of Canada, according to CARTR. It is clear
that, although the multiple-pregnancy rate in Que´bec was
slightly lower than the rest of Canada (25.6% versus 29.3%),
the use of eSET was more popular in the rest of Canada
(6.5% of embryo transfers) than in Que´bec (1.6%).
A large number of studies have discussed the potential
benefits of eSET and the financial issues, comparing ongoing
costs associated with multiple pregnancies and repeated IVF
cycles due to reduced pregnancy rate when using eSET (Bro-
mer et al., 2011; Fauque et al., 2010; Gerris, 2009; McLer-
non et al., 2010; Moustafa et al., 2008; Van Peperstraten
et al., 2008).
In Canada, health care is the responsibility of the individ-
ual provinces; thus, each province determines healthcare
coverage. In Que´bec, the provincial government decided
to include assisted reproduction treatment for infertility
under the provincial health plan starting on 5 August 2010.
The policy provides for any woman of reproductive age to
have to up to three cycles of IVF with ovarian stimulation
or up to six cycles of natural or modified natural cycle IVF
at no charge; this applies whether the cycles are performed
within a hospital unit or a privately owned facility. A cycle
counts once an embryo transfer has been performed.
Patients who have excess embryos cryopreserved following
an IVF cycle are obliged to have those embryos thawed for
transfer before embarking on another ovarian stimulation
cycle, but frozen–thawed embryo transfers do not count
against their three attempts.
In exchange for this coverage, the government imposed a
limit on the number of embryos that could be transferred in
any one cycle. In effect, the law states that only one
embryo should be transferred in either a fresh or frozen
IVF cycle. However, an option to transfer up to two embryos
in a woman aged 36 years or younger and up to three
embryos (including no more than two blastocysts) in a
woman aged 37 years or older is available, but the physician
must justify his decision (An Act Respecting Clinical and
Research Activities related to Assisted Procreation, 2010).
The purpose of this study is to report on the outcomes
(pregnancy rates and multiple-pregnancy rates) of IVF
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Figure 1 Change in multiple-birth rate compared with
live-birth rate in Canada between 2001 and 2008 (data from
the Canadian ART Register).
El
ec
tiv
e 
si
ng
le
-e
m
br
yo
 tr
an
sf
er
s 
(%
)
Figure 2 Change in percentage of embryo transfers using
elective single-embryo transfer in Canada between 2001 and
2009 (data from the Canadian ART Register).
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cycles in Que´bec from the first 3 months of provincially
funded assisted reproduction treatment.
Materials and methods
All IVF cycles started in Que´bec assisted reproduction cen-
tres from 5 August to 5 November 2010 were recorded.
The average patient age was 37 years, with patients ranging
from 22 to 46 years old. Each of the five centres applied its
own standard protocols for ovarian stimulation and labora-
tory procedures. Ovarian-stimulation protocols, including
long gonadotrophin-releasing hormone (GnRH) agonist,
short GnRH agonist and GnRH antagonist, were selected
based on physician preference and patient characteristics.
Egg retrieval was performed 34.5–36 h after the administra-
tion of human chorionic gonadotrophin, based on individual
clinic policy. Insemination was performed using standard IVF
or intracytoplasmic sperm injection. Embryo culture was
performed using Cook Sydney IVF media (Cook, Canada) in
all centres.
Embryo transfer was performed in all centres under
ultrasound guidance on either day 2, day 3 or at the blasto-
cyst stage depending on cycle-specific characteristics. Two
clinics performed the majority of their embryo transfers at
the blastocyst stage, one clinic transferred equally on day 2,
day 3 and at the blastocyst stage, one clinic performed the
majority of their transfers on day 3 and one clinic per-
formed transfers on both day 3 and at the blastocyst stage.
Each clinic applied their own internal policies for embryo
quality and selection as well as when it was judged perti-
nent to transfer more than one embryo. In general, the
patient’s age and quality of the embryos were primary fac-
tors in any decision to transfer multiple embryos as well as
previous IVF history. Embryo-quality characteristics were
applied when selecting suitable embryos for cryopreserva-
tion based on individual clinic protocols. Oocyte and embryo
development parameters were strictly applied in order to
eliminate embryos with very low potential.
Pregnancy was assessed by serum human chorionic
gonadotrophin concentration 15 days after egg retrieval
and clinical pregnancy was determined by ultrasonographic
evidence of intrauterine fetal heartbeat at 8 weeks’
gestation.
Results
From 5 August to 5 November 2010, a total of 1353 IVF
cycles were started in Que´bec centres, 1276 cycles had
egg retrieval and 1103 cycles resulted in embryo transfer.
For comparison, only 517 IVF cycles were started in the
same time period in 2009.
Overall, the clinical pregnancy rate was 32% and eSET
was used in 50% of embryo transfers (Table 2). In the youn-
ger patient group (<35 years old), eSET was used in 79% of
embryo transfers and resulted in a clinical pregnancy rate
of 40%. There were a total of only 13 twin pregnancies
and no triplet pregnancies. All twin pregnancies resulted
from the transfer of two embryos, either elective
double-embryo transfer (eDET) where two embryos were
selected from more than two available embryos or non-
elective DET where only two embryos were available for
transfer. This equates to a multiple-pregnancy rate of 3.7%.
Table 3 describes the outcomes based on the number of
embryos transferred, grouped by female age. For all age
groups combined, pregnancy rates per embryo transfer
were highest with eSET (38%), compared with non-elective
SET (21%), eDET (32%), non-elective DET (21%) and transfer
of more than two embryos (25%). Twin pregnancy rates were
0% for eSET and non-elective SET, 13% for eDET, 17% for
non-elective DET and 0% for transfer of more than two
embryos.
Overall, 42% of patients had supplementary embryos
cryopreserved following their IVF cycle, with an average
of 3.4 embryos per patient. For patients <35 years of age,
60% of patients had cryopreservation, with an average of
3.7 embryos per patient (Table 4).
A summary of the results seen in Que´bec prior to and
after the implementation of the programme can be seen
in Table 5.
Discussion
Multiple pregnancies are, undoubtedly, the major negative
side effect of assisted reproductive therapies and, in coun-
tries where patients are responsible for the total cost of
treatment, the multiple-pregnancy rate is often higher. An
assumption that the transfer of multiple embryos will sub-
stantially increase the chance of pregnancy and, therefore,
reduce the number of expensive attempts to achieve the
desired live birth, places pressure on patients who, in turn,
transfer this pressure to healthcare professionals charged
with their reproductive care.
In Que´bec, the government decided that provincially
funded assisted reproduction was the correct direction to
take. This policy provides access to treatment for all mem-
bers of society, regardless of income and resources. In addi-
tion, by imposing limitations on the number of embryos that
Table 1 IVF cycle data for Que´bec and Canada 2009 (from the Canadian ART Register).
Variable Que´bec Canada except Que´bec Canada
IVF cycles 1831 8524 10,355
Embryo transfers 1618 7417 9035
Clinical pregnancies (rate per ET) 692 (42.8) 3164 (42.7) 3856 (42.7)
eSET (rate per ET) 26 (1.6) 484 (6.5) 510 (5.6)
Multiple pregnancies (rate per pregnancy) 177 (25.6) 927 (29.3) 1104 (28.6)
Values are n or n (%). eSET = elective single-embryo transfer; ET = embryo transfer.
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can be transferred in any one cycle, a reduction in
multiple-pregnancy rates should occur. Although the policy
has the implicit aim of single-embryo transfer in as many
cases as possible, the Que´bec government had been listen-
ing to clinicians who stated that there are situations that
justify the transfer of more than one embryo. The costs
associated with the ongoing care of multiple pregnancies,
both during the pregnancy itself and for the care of
premature infants, possibly with life-time increased health
costs, can be exorbitant. By reducing the number of
multiple pregnancies and multiple births, the subsequent
reduction in associated health costs can be used to pay
for the assisted reproduction treatment. This appears to
be a more positive use of provincial health funds since it
is aimed at producing healthy babies rather than needing
to support babies with health issues.
Although other countries have introduced similar poli-
cies, the authors believe that this case demonstrates the
quickest realization of the aim of almost eliminating
multiple pregnancies in response to state-sponsored IVF.
Que´bec fertility specialists are very motivated to make this
programme work and have adopted stricter criteria than
those imposed by government. In Que´bec, the
multiple-pregnancy rate was reduced from 25.6% to only
3.7% by using 50% eSET, compared with only 1.6% eSET pre-
viously, in only 3 months. The correct application of the law
can be demonstrated by the fact that in those cycles where
two embryos were transferred the twin rate is very low and
that there are no triplets from cycles where three embryos
were transferred. This indicates that the appropriate selec-
tion of patients needing more than eSET can be achieved if
clinicians apply careful criteria in patient selection. If this is
Table 3 Results from elective and non-elective single- and double-embryo transfers in IVF cycles started
in the first 3 months of assisted reproduction treatment funding in Que´bec.
Variable <35 Years 35–39 Years 40 Years Overall
eSET 348 175 33 556
eSET clinical pregnancies (rate per ET)a 144 (41) 61 (35) 8 (24) 213 (38)
Non-elective SET 48 54 49 151
Non-elective SET clinical pregnancies* (rate per ET)a 15 (31) 13 (24) 3 (6) 31 (21)
eDET 17 74 81 172
eDET clinical pregnancies (rate per ET) 9 (53) 27 (36) 19 (23) 55 (32)
eDET twin pregnancies (rate per ET) 1 (11) 4 (15) 2 (11) 7 (13)
Non-elective DET 30 72 70 172
Non-elective DET clinical pregnancies (rate per ET) 9 (30) 18 (25) 9 (13) 36 (21)
Non-elective DET twin pregnancies (rate per ET) 1 (11) 3 (17) 2 (22) 6 (17)
>Two embryos transferred 0 13 39 52
Clinical pregnancies > Two embryosa 0 5 (38) 8 (21) 13 (25)
Values are n or n (%). DET = double-embryo transfer; cDET = elective double-embryo transfer; eSET = elective
single-embryo transfer; ET = embryo transfer; SET = single-embryo transfer.
aAll singleton pregnancies.
Table 2 Results from IVF cycles started in the first 3 months of assisted reproduction
treatment funding in Que´bec.
Variable <35 Years 35–39 Years 40 Years Overall
Cycles started 522 491 340 1353
Egg retrievals 500 458 318 1276
Embryo transfers 443 388 272 1103
Clinical pregnancies (rate per ET) 177 (40) 124 (32) 47 (17) 348 (32)
eSET (rate per ET) 348 (79) 175 (45) 33 (12) 556 (50)
Multiple pregnancies (rate per pregnancy) 2 (1.1) 7 (5.6) 4 (8.5) 13 (3.7)
Values are n or n (%). eSET = elective single-embryo transfer; ET = embryo transfer.
Table 4 Proportion of patients having embryo cryopreservation.
Variable <35 years 35–39 years 40 years Overall
Patients with embryo cryopreservation (n(%)) 286 (60) 144 (37) 57 (21) 487 (43)
Embryos cryopreserved per patient (mean) 3.7 3.2 2.7 3.4
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done it means that legislative terms such as those created in
Que´bec, whereby the clinician has some flexibility to trans-
fer multiple embryos if deemed truly necessary, can be suc-
cessfully applied. It is clear that buy-in by the clinics is
necessary with a programme such as this where the option
to transfer more than one embryo is permitted. Whilst this
option is important to allow for those cases where multiple
embryo transfer is required to maintain pregnancy potential
for the patient, it opens the door to potential abuse; if only
one clinic in the state continues to unnecessarily transfer
multiple embryos, the aim of the programme to reduce
multiple pregnancies will not be achieved.
Furthermore it is noted that there is a higher-than-usual
rate of cycles with no embryo transfer. This may be
explained by the fact that all the centres applied their
own internal policies on embryo selection criteria but that
the criteria were strictly applied, so that the elimination
of suboptimal embryos led to a higher cancellation rate.
This was carried out in an attempt to maintain clinical preg-
nancy rates with eSET and ensure that only suitable embryos
were considered for cryopreservation.
The major concern when using eSET liberally is that the
pregnancy rate will be negatively affected. The implemen-
tation of this programme saw the overall clinical pregnancy
rate fall from 42.8% to 31.6%; however, it is important to
remember that nearly 50% (48.7%) of patients under
40 years of age had at least one embryo cryopreserved fol-
lowing their fresh IVF cycle, with an average of 3.5 embryos
each. Although this may seem a high proportion of patients
having a high number of embryos cryopreserved, it is
believed that this relates to the fact that when transferring
only one embryo the chance that at least one other embryo
will be available for cryopreservation increases.
With the improvement of outcomes in cryopreserved
embryos, especially with the introduction of vitrification,
it is logical to use the cumulative pregnancy rate or cumu-
lative live-birth rate per initiated cycle, combining results
from transfer of fresh and frozen embryos, as the standard
measure of a patient’s chances for a baby. Certainly, in this
programme, where the use of cryopreserved embryos is
included and does not reduce the patient’s number of
funded cycles, it is clear that the cumulative pregnancy rate
and cumulative live-birth rate must be considered.
Further analysis will need to be performed as more data
becomes available to ensure that the patterns demon-
strated by the initial analysis remain constant and also to
assess the cumulative pregnancy rate once sufficient
frozen–thawed embryo transfers have been performed. It
is believed that once this data is included the cumulative
pregnancy rate for patients under 40 years of age will dem-
onstrate that the policy of ‘one embryo at a time’ can be
successfully implemented in the right environment.
Acknowledgements
The authors would like to thank the clinical teams from all
five Que´bec assisted reproduction treatment centres for
their hard work in achieving these results in such a short
period of time.
References
An act respecting clinical and research activities related to assisted
procreation, 2010. (2009, c.30) – Coming into force of certain
provisions of the Act. O.C. 643-2010, 7 July 2010. Gazette
Officielle du Que´bec, July 21, 2010, vol. 142, No. 29.
Assisted Human Reproduction Canada, 2011. Prevention of multiple
births associated with infertility treatments: building a Canadian
framework. Available from: <http://www.ahrc-pac.gc.
ca/v2/pubs/births-multiple-naissances-eng.php#a212> (accessed
15 Jan 2011).
Bromer, J.G., Ata, B., Seli, M., Lockwood, C.J., Seli, E., 2011.
Preterm deliveries that result from multiple pregnancies asso-
ciated with assisted reproductive technologies in the USA: a cost
analysis. Curr. Opin. Obstet. Gynecol. (Epub ahead of print).
Fauque, P., Jouannet, P., et al., 2010. Cumulative results including
obstetrical and neonatal outcome of fresh and frozen–thawed
cycles in elective single versus double fresh embryo transfers.
Fertil. Steril. 94 (3), 927–935.
Gerris, J., 2009. Single-embryo transfer versus multiple-embryo
transfer. Reprod. Biomed. Online 18 (Suppl. 2), 63–70.
Gunby, J., Bissonnette, F., Librach, C., Cowan, L., 2010. IVF
Directors Group of the Canadian Fertility and Andrology Society.
Assisted reproductive technologies (ART) in Canada: 2007 results
from the Canadian ART Register. Fertil. Steril. (Epub ahead of
print).
McLernon, D.J., Harrild, K., et al., 2010. Clinical effectiveness of
elective single versus double embryo transfer: meta-analysis of
individual patient data from randomised trials. BMJ 341, c6945.
doi:10.1136/bmj.c6945.
Moustafa, M.K., Sheded, S.A., El Aziz Mousta, M.A., 2008. Elective
single embryo transfer versus double embryo transfer in assisted
reproduction. Reprod. Biomed. Online 17 (1), 82–87.
van Peperstraten, A.M., Nelen, W.L., et al., 2008. Why don’t we
perform elective single embryo transfer? A qualitative study
among IVF patients and professionals. Hum. Reprod. 23 (9),
2036–2042 (Epub 2008 Jun 18).
Declaration: The author reports no financial or commercial
conflicts of interest.
Received 21 January 2011; refereed 29 April 2011; accepted 10 May
2011.
Table 5 Summary of impact of the state coverage of IVF cycles in Que´bec.
Before programme
(2009)
After programme
(August–November 2010)
Embryo transfers performed using eSET 1.6 50.4
Clinical pregnancy rate 42.8 31.6
Multiple-pregnancy rate 25.6 3.7
Values are %. eSET = elective single-embryo transfer.
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Abstract Public financing of IVF aims at increasing access to treatment while decreasing the expenses associated with multiple
pregnancies. Critics argue that it is associated with lower pregnancy rates. This study compared cycles performed during 2009
(before implementation of Quebec’s public IVF programme; period I) to those performed in the year following implementation
(period II) in a single IVF centre. First fresh cycles in period I (499 women) and first fresh cycles (815 women) along with their cor-
responding first vitrified–warmed transfer (271 women) in period II were evaluated. From period I to period II, single-embryo trans-
fer increased from 17.3% to 85.0% (P < 0.001), multiple ongoing pregnancy rate decreased from 25.8% to 1.6% (P < 0.001) and
ongoing pregnancy rate decreased from 31.9% to 23.3% (P = 0.001). During period II, the ongoing pregnancy rate per
vitrified–warmed embryo transfer was 19.2%, leading to a cumulative ongoing pregnancy rate per initiated cycle of 29.7%, which
was not different to the pregnancy rate per fresh cycle during period I (31.9%). To conclude, Quebec’s public IVF programme
decreased multiple pregnancy rates while maintaining an acceptable cumulative ongoing pregnancy rate, a more precise outcome
to evaluate the impact of public IVF programmes. RBMOnline
ª 2013, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
Public financing of assisted reproductive technology is
intended to increase access to fertility treatments by reduc-
ing the financial burden to patients. In counterpart, govern-
ments aim to reduce the health expenses associated with
multiple pregnancies attributable to the use of assisted
reproductive technology. Although comprehensive govern-
ment initiatives are associated with greater utilization of
fertility treatments and lower rates of multiple pregnancies
(Bissonnette et al., 2011), critics of public financing argue
that public programmes are also associated with lower
1472-6483/$ - see front matter ª 2013, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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pregnancy rates (Gleicher, 2011). Many countries have
implemented legislation to regulate assisted reproductive
technology, encouraging the practice of single-embryo
transfer (SET) through public funding (Maheshwari et al.,
2011). In Canada, the only province that totally covers the
costs of treatment is Quebec (Bissonnette et al., 2011).
The subject of how many embryos is safe and proper to
transfer and the best way to regulate this decision continues
to generate debate and no unanimity has been reached to
date (Gleicher, 2011; Johnson et al., 2011; Khalaf et al.,
2011).
SET is the most effective approach to reduce the inci-
dence of multiple pregnancies after assisted reproductive
treatment (ESHRE, 2001). However, most of the studies
evaluating the outcomes of SET have shown lower preg-
nancy rates when comparing with double-embryo transfer
(DET; Pandian et al., 2009). Nonetheless, the principal
weakness of these studies is not taking into account that
most SET are not elective. Elective SET requires the selec-
tion of good prognosis patients and the transfer of the best
high quality embryo (De Sutter et al., 2003). Studies that
have compared elective SET with DET have not found dif-
ferences in terms of pregnancy rates among both groups
(De Sutter et al., 2003; Dhont, 2001; Gerris et al., 2004).
Moreover, in regards to health expenses, a prospective
economic study demonstrated that the transfer of a single
top-quality embryo is substantially cheaper than DET in
women <38 years of age in their first IVF cycle (Gerris
et al., 2004).
Public financing of assisted reproductive technology usu-
ally covers three or more treatment cycles. Therefore, to
evaluate the effectiveness of these programmes, cumula-
tive pregnancy rates per initiated cycle are more relevant
than the pregnancy rates per fresh cycle (Thurin-Kjellberg
et al., 2009). As part of this strategy, DET should be com-
pared with SET including the resulting first cryopreserved
embryo transfer.
Starting on 5 August 2010, all costs related to IVF have
been covered by the Quebec Public Health Insurance Plan.
The programme covers three stimulated cycles of IVF or
up to six cycles in the case of modified natural cycles. The
law states that only one embryo may be transferred at a
time. Under very specific conditions (embryo quality and
age) the law does allow for clinicians to transfer a maximum
of two embryos if the woman is aged 36 and a maximum of
three embryos or two blastocysts if the woman is aged 37 or
over (Gouvernement de Que´bec, 2010). The objective of the
programme was to reduce the number of multiple pregnan-
cies resulting from IVF from 30% to 5% (Gouvernement de
Que´bec, 2012).
OVO clinic is a private centre affiliated with the Univer-
sity of Montreal. The Quebec funding programme leaves the
patient with the choice of going to a private or
hospital-based centre with no difference in the cost to the
couple.
The aim of the present study is to evaluate the impact of
the Quebec public IVF programme with emphasis on a strict
SET policy, in terms of utilization, pregnancy rates and
multiple pregnancies comparing those IVF cycles performed
in the OVO clinic during 2009 to those cycles performed dur-
ing the first year following implementation of the new Que-
bec public IVF programme.
Materials and methods
Study population
Two time periods were compared. Period I includes infor-
mation from IVF cycles performed at the OVO clinic during
2009, before implementation of the new public IVF
programme. Period II comprises IVF cycles performed at
OVO clinic during the first year following implementation
of the new Public IVF programme (from 5 August 2010 to 4
August 2011). Excluded from the analysis are the 6 months
between the two periods because the treated population
changed considerably as the programme was announced
and many couples decided to wait for gratuity.
OVO clinic is a leading centre in North America
performing modified natural IVF (Kadoch et al., 2011)
and this technique represents more than 25% of the IVF
activity in this centre. Nonetheless, for the purpose of cal-
culating time-limited cumulative pregnancy rates including
the resulting first cryopreserved embryo transfer cycle
(Daya, 2005), only the first cycles of stimulated IVF cycle
during both periods, additional to the first cryopreserved
cycle in period II, were analysed. Around 30% of the cou-
ples had previous undergone IVF cycles before the studied
periods; nonetheless, the number of previous cycles did
not differ between both periods. In addition, cycles result-
ing in the cryopreservation of all embryos were excluded
from the analysis since their inclusion would underestimate
the per cycle pregnancy rates (i.e. 13/512 (2.5%) during
period I and 62/877 (7.1%) during period II; Yovich and
Junk, 1999).
Stimulation protocol, oocyte retrieval and
embryology procedures
Ovarian stimulation protocols, including long
gonadotrophin-releasing hormone (GnRH) agonist, short
GnRH agonist and GnRH antagonist, were selected based
on physician preference and patient characteristics. The
long GnRH agonist was mainly used during the first period
(53.4%), while the GnRH antagonist was the main protocol
prescribed during period II (52.2%). Egg retrieval was per-
formed 36 h after the administration of human chorionic
gonadotrophin. Insemination was performed using standard
IVF or intracytoplasmic sperm injection when indicated.
Embryo culture was performed using standardized proce-
dures. Embryo transfer was performed under ultrasound
guidance on day 3 or at the blastocyst stage depending on
cycle-specific characteristics.
Cryopreservation
Embryo quality characteristics were applied when selecting
suitable embryos for cryopreservation based on individual
clinic protocols. Embryo development parameters were
strictly applied in order to eliminate embryos with very
low potential (ALPHA-ESHRE, 2011; Steer et al., 1992). Vit-
rification was used for cryopreservation. Cleavage-stage
vitrified–warmed embryos were transferred in 98.2% of
the cases.
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Outcomes
Pregnancy was assessed by serum human chorionic gonado-
trophin (HCG) concentration 15 days after egg retrieval.
Biochemical pregnancy was defined by HCG 25 IU/l; and
clinical pregnancy was determined by ultrasonographic evi-
dence of intrauterine fetal heart beat at 7 weeks of gesta-
tion (Zegers-Hochschild et al., 2009). Pregnancy rates
were calculated on a per woman basis and defined as the
proportion of women achieving pregnancy out of the total
number who started treatment. Pregnancy rates after the
first fresh IVF cycle performed during period I, a period
where DET was prevalent, were compared with cumulative
pregnancy rates of period II, a period where SET was prevail-
ing. The time-limited cumulative pregnancy rate for period
II was defined as the proportion of clinical pregnancies after
the first fresh IVF cycle, including the resulting first
vitrified–warmed embryo transfer cycle (Daya, 2005).
Multiple pregnancies were defined according to the number
of embryos with a positive heart beat. Cryopreserved
embryos were defined as the number of surplus embryos
available for cryopreservation.
Statistical analysis
Proportion comparisons were performed by chi-squared test
or Fisher’s Exact test when indicated. Student’s t-test and
ANOVA were used to compare means. A P-value <0.05 was
considered to be statistically significant. Statistical analysis
was performed using STATA version 10.0 (Stata Corporation,
College Station, TX, USA).
This retrospective study was approved by OVO research
and development scientific board on 4 January 2012.
Results
A total of 499 women started a cycle of stimulated IVF at
OVO clinic during 2009 (period I), while 815 women started
a cycle of stimulated IVF during the first year following
implementation of the new Quebec government legislation
(period II), representing an increase of 64% on utiliza-
tion/access rates.
The age of the women was similar in both periods:
mean ± SD, 35.2 ± 4.4 years for period I and 35.4 ± 4.4 years
for period II. In addition, no differences were seen in the
distribution of women per categories of age (Table 1).
The proportion of oocyte retrievals was higher in period II,
while no differences were seen on the number of mature
eggs retrieved. Although the proportion of women having
embryo transfer was similar between both periods, the
mean number of embryos transferred during period I was
higher than the cumulative number of embryos transferred
during period II. The overall ongoing clinical pregnancy rate
after the first fresh cycle of stimulated IVF was higher dur-
ing period I than in period II (P = 0.001). Nonetheless, no dif-
ference was seen when period I was compared with the
cumulative ongoing pregnancy rate of period II. After strat-
ifying by categories of age, the difference between the
fresh cycles was present only in women younger than
37 years, while no difference was seen in women aged 37
and older. In both categories of age, the CPR during
period II was similar to the ongoing pregnancy rate per fresh
cycle during period I.
Figure 1 shows the modalities of embryo transfer per-
formed during both periods. SET increased during the sec-
ond period (P < 0.001), while DET and the transfer of
more than two embryos decreased (P < 0.001).
Table 2 presents clinical pregnancy rates according to
the number of embryos transferred during both periods.
After SET, the ongoing clinical pregnancy rate per embryo
transfer was higher in period II compared with period I. In
contrast, DET resulted in a lower ongoing pregnancy rate
during period II compared with period I. No differences in
clinical pregnancy rates per embryo transfer were found
between both periods when more than two embryos were
transferred.
Multiple pregnancies following the first fresh IVF
cycle
The multiple pregnancy rates decreased considerably during
period II. According to the modalities of embryo transfer, no
multiple pregnancies were reported after SET in period I,
while one monozygotic twin pregnancy was observed during
period II (Table 3). In contrast, the prevalence of multiple
pregnancies after DET decreased from period I to period
II. Of note, during the first period very few pregnancies
were the result of SET, with the majority issued from DET;
in contrast, during the second period the vast majority of
pregnancies resulted from SET (Table 3).
Cryopreserved embryos
Overall, the proportion of cryopreserved embryos per cycle
started significantly increased from period I to period II
(P < 0.001). Table 4 shows the proportion of women having
cryopreserved embryos according to age. Younger women
had a higher proportion of cryopreserved embryos than
older women in both periods. Additionally, the number of
cryopreserved embryos per patient was higher in period II
compared with period I (Table 4).
Discussion
This study supports that the access to IVF, as measured by
the number of cycles performed at OVO clinic after imple-
mentation of the public IVF programme, increased. It also
finds that the proposed objective of the public IVF
programme of reducing multiple pregnancies was met.
Additionally, although the per cycle pregnancy rate after
the first stimulated IVF cycle was lower in period II com-
pared with period I, the cumulative pregnancy rate in period
II (i.e. up to one IVF cycle, including the first resulting cryo-
preserved embryo transfer) was similar to the pregnancy
rate per cycle during period I. Furthermore, the programme
resulted in a higher proportion of women having cryopre-
served embryos than in period I, a difference that can fur-
ther impact on cumulative pregnancy rates.
Lack of public funding has a major role in the unequal
access of women to clinically appropriate infertility treat-
ment in Canada (Nisker, 2008). The proportion of infertile
couples who had access to IVF treatment in the province
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of Quebec before the public IVF programme has not been
assessed in a formal manner. Data from this study clinic
indicates that before the public IVF programme only
one-quarter of the infertile population had access to IVF
and that this was mainly because of the cost of treatment.
Utilization/access to fertility treatment is determined by
factors such as the number of centres available, the cost
to the individual, and distance and opening hours (Collins,
2002). In the year following implementation of the
programme, the number of IVF clinics in Quebec, as well
as their distance and opening hours was the same as before
the public funding. Thus, the increase in access to IVF after
the public programme was mainly through the impact on the
cost of treatment for all women, with certainly greatest
benefit to the least advantaged infertility patients.
In addition, this study supports that regulated access to
public funded IVF also decreases multiple pregnancies.
The reduction of multiple pregnancies is the result of a judi-
cious policy of the number of embryos to transfer. In fact,
after the programme, SET increased significantly and the
transfer of more than two embryos was seldom indicated.
Consequently, most of the pregnancies were the result of
SET during the second period, whereas only a few resulted
after DET, supporting that SET is presently the most
Figure 1 Modalities of embryo transfer. SET = single-embryo
transfer; DET = double-embryo transfer; >DET = more than two
embryos transferred.
Table 2 Clinical pregnancy rates according to the
number of embryos transferred in first fresh cycles.
Variable Period I Period II P-
value
Transfers 423 666
Ongoing clinical
pregnancies
159 190
SET 11/73
(15.1)
172/566
(30.4)
0.01
DET 122/260
(46.9)
13/83
(15.7)
<0.001
>DET 26/90
(28.9)
5/17
(29.4)
NS
Values are n or n/total (%). P-values were obtained using
the Chi-squared test.
SET = single-embryo transfer; DET = double-embryo trans-
fer; >DET = more than two embryos transferred; NS = not
statistically significant.
Table 1 Outcomes of stimulated IVF cycles performed at OVO clinic preceding and following Quebec’s public IVF legislation.
Period I (499 women) Period II (815 women) P-value
First fresh cycle First fresh cycle First cryopreserved
cycle
Cumulative
Age (years)
<37 333 (66.7) 530 (65.0) NSa
37 166 (33.3) 285 (35.0)
Retrievals 446 (89.4) 764 (93.7) 0.004b
Mature eggs 10.9 ± 6.2 11.0 ± 6.5 NSc
Transfers 423 (84.8) 666 (81.7) 271 NSa,b
Embryos transferred 2.11 ± 0.81 1.18 ± 0.44 1.37 ± 0.55 1.23 ± 0.48 <0.001d
Ongoing pregnancies 159 190 52 242
Ongoing pregnancy
rate per cycle
31.9 23.3 19.2 29.7 NSa,d
Age <37 years 136 (40.8) 151 (28.5) 35 (19.2) 186 (35.1) NSa,d
Age 37 years 23 (13.9) 39 (13.7) 17 (19.1) 56 (19.7) NSa,d
Ongoing pregnancies
Single 118 (74.2) 187 (98.4) 48 (92.3) 235 (97.1) <0.001a,d
Multiple 41 (25.8) 3 (1.6) 4 (7.7) 7 (2.9)
Values are n (%), mean ± SD or n. Period I = from 1 January to 31 December 2009; period II = from 5 August 2010 to 4 August 2011.
NS = not statistically significant.
aChi-squared test.
bPeriod I compared with first fresh cycle in period II.
cStudent’s t-test.
dPeriod I compared with cumulative data in period II.
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effective strategy for reducing multiple pregnancies
(ESHRE, 2001).
The cumulative pregnancy rates after the programme are
in accordance with the ESHRE Campus Course for the pre-
vention of twin pregnancies after IVF/ICSI by SET, which
states that pregnancy rates higher than 30% are adequate
(ESHRE, 2001).
Regarding the modalities of embryo transfer, SET
resulted in a higher clinical pregnancy rate in period II com-
pared with period I, while the opposite was seen after DET.
In fact, patients selected for DET after the programme were
more likely to be poor-prognosis patients since there is a
direct requirement to consider transferring only one embryo
and the need to justify the transfer of more than one
embryo. It is also important to consider that the manner
in which patients use up their three insured cycles can influ-
ence the decision to transfer or not. Under the Quebec
programme, only cycles resulting in an embryo transfer
count against the three insured attempts and therefore,
unless a suitable embryo is available, there is always a con-
sideration to cancel the embryo transfer.
The success of a SET policy is correlated with a good
cryopreservation programme (Veleva et al., 2009). In the
Quebec public IVF programme, the subsequent transfer of
cryopreserved embryos is included in each cycle attempt
if no pregnancy is achieved after fresh embryo transfer. In
a randomized controlled trial (Thurin et al., 2004), the live
birth rate after SET followed by the transfer of a single
vitrified–warmed embryo was 38.8%, which is comparable
to this study centre’s results in women younger than
37 years. In the same trial, the cumulative live birth after
the inclusion of all vitrified–warmed cycles was 43.9%.
Thus, since the Quebec public IVF programme resulted in
a higher number of patients having cryopreserved embryos
and a higher number of cryopreserved embryos by patient
compared with period I, it is expected that the cumulative
pregnancy rates after transferring all available embryos, if
no live pregnancy occurred after a fresh IVF cycle, will be
even higher.
In conclusion, implementation of the Quebec public IVF
programme in this clinic attained the objective of decreas-
ing multiple pregnancy rates while maintaining acceptable
cumulative pregnancy rates, a more precise outcome to
evaluate the impact of public IVF programmes.
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studyquestion:Whatwas the clinical and economic impact of universal coverage of IVF inQuebec,Canada, during the ﬁrst calendar year
of implementation of the public IVF programme?
summaryanswer: Universal coverageof IVF increased access to IVF treatment, decreased themultiple pregnancy rate anddecreased the
cost per live birth, despite increased costs per cycle.
what is known already: Public funding of IVF assures equality of access to IVF and decreasesmultiple pregnancies resulting from this
treatment. Public IVF programmes usually mandate a predominant SET policy, themost effective approach for reducing the incidence of multiple
pregnancies.
study design, size, duration: This prospective comparative cohort study involved 7364 IVF cycles performed in Quebec during
2009 and 2011 and included an economic analysis.
participants/materials, setting, methods: IVF cycles performed in the ﬁve centres offering IVF treatment in Quebec
during 2009, before implementation of the public IVF programme, were compared with cycles performed at the same centres during 2011,
the ﬁrst full calendar year following implementation of the programme.Datawere obtained from theCanadian Assisted Reproductive Technolo-
gies Register (CARTR). Comparisons were made between the two periods in terms of utilization, pregnancy rates, multiple pregnancy rates and
costs.
main results and the role of chance: The number of IVF cycles performed inQuebec increased by 192% after the newpolicy
was implemented. Elective single-embryo transfer was performed in 1.6% of the cycles during Period I (2009), and increased to 31.6% during
Period II (2011) (P, 0.001). Although the clinical pregnancy rate per embryo transfer was lower in 2011 than in 2009 (24.9 versus 39.9%,
P, 0.001), the multiple pregnancy rate was greatly reduced (6.4 versus 29.4%, P, 0.001). The public IVF programme increased government
costs per IVF treatment cycle from CAD$3730 to CAD$4759. Despite increased costs per cycle, the efﬁciency deﬁned by the cost per live
birth, which factored in downstream health costs up to 1 year post delivery, decreased from CAD$49 517 to CAD$43 362 per baby conceived
by either fresh and frozen cycles.
limitations, reasons for caution: The costs described in the economicmodel are likely an underestimate as they do not factor
inmany of the long-term costs that can occur after 1 year of age. The information collected in theCanadianART register precludes the calculation
of cumulative pregnancy rates.
wider implications of thefindings:Our study conﬁrms that the implementation of a public IVF programme favouring eSET not
only sharply decreases the incidence of multiple pregnancy, but also reduces the cost per live birth.
study funding/competing interest(s): M.P.V. holds a fellowship award from the Canadian Institutes of Health Research
(CIHR). The economic analysis performed by M.P.C. was supported by an unrestricted grant from Ferring Pharmaceutical.
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Introduction
Through public funding of in vitro fertilization (IVF), governments can
assure equality of access to this type of treatment while decreasing the
health-care expenses associated with multiple pregnancies, the main
drawback of the injudicious use of assisted reproductive technologies
(ART). Public IVF programmes usually mandate a predominant single-
embryo transfer (SET) policy, the most effective approach for reducing
the incidence of multiple pregnancy after ART (ESHRE, 2001), and the
practice of SET has been encouraged through public funding by many
countries (Maheshwari et al., 2011). In Canada, the only province that
universally covers the costs of IVF is Quebec (Bissonnette et al., 2011).
Nonetheless, disagreement persists worldwide on the number of
embryos that are safe and appropriate to transfer and on the best way
to regulate this decision (Gleicher, 2011; Johnson et al., 2011; Khalaf
et al., 2011).
In Canada, health care is the responsibility of the individual provinces.
In the Province of Quebec, until recently, the cost of all IVF procedures
was covered by the patient and partially reimbursed as a 50% tax rebate.
Therewas no regulation regarding the number of embryos to transfer or
the number of treatment cycles provided to each patient. On 5 August
2010, the Quebec government introduced a public IVF programme,
marking the beginning of a new era in the ﬁeld of ART in the province.
Theobjectivewas to increase access to IVF and lower the cost ofmultiple
pregnancies from ART, speciﬁcally by reducing the proportion of mul-
tiple pregnancies resulting from IVF from 30 to 5% (Gouvernement de
Que´bec, 2012). Under this programme, all costs related to IVF are
covered by Quebec’s universal health insurance plan. This includes the
cost of all medical procedures related to IVF for three stimulated
cycles, or up to six modiﬁed natural cycles (mnIVF). A cycle counts
only when an embryo transfer has been performed. Patients who have
excess embryos cryopreserved following an IVF cycle are obliged to
have those embryos thawed for transfer before embarking on another
ovarian stimulation cycle, but frozen/thawed embryo transfers (FET)
do not count against their three attempts. The cost of gonadotrophins
is reimbursed according to the individual’s public medication insurance
plan, which ranges between a 68% and a 100% reimbursement rate;
this medication reimbursement plan has not changed since the advent
of the public IVF programme. The new policy stipulates that only one
embryo may be transferred at a time. However, the law does allow for
clinicians to transfer a maximum of two embryos when the woman is
36 years old, and a maximum of three embryos or two blastocysts
when the woman is 37 years old or over (Gouvernement de Que´bec,
2010).
We previously reported the outcomes of IVF cycles in Quebec in
the ﬁrst 3 months of provincially funded ART (Bissonnette et al.,
2011). The aim of the present study was 2-fold: to demonstrate that
the sharp decrease in the multiple pregnancy rate remained constant
into the second year, and to assess the economic effect of full govern-
ment coverage of IVF treatment in Quebec.
Materials andMethods
Study population
Twoperiodswere compared inour study. Period I included information from
all IVF cycles performed in the ﬁve centres offering IVF treatment in Quebec
during 2009, the year prior to the start of theQuebec public IVF programme.
Period II comprises all IVF cycles performed in the same centres during 2011,
the ﬁrst full calendar year of the programme. IVF cycles involving donor
oocytes or gestational carriers and mnIVF were excluded. Data were
obtained from the Canadian Assisted Reproductive Technologies Register
(CARTR). CARTR collects treatment cycle data from Canadian fertility
centres that are using ART. Staff at each centre provide information for
each IVF cycle initiated. The completely anonymous case records are sent
electronically each year to the CARTR coordinating centre, where they are
checked for accuracy and completeness (Gunby et al., 2011).
Stimulation protocol, oocyte retrieval and
embryology procedures
As described in our previous evaluation of the ﬁrst 3 months of the Quebec
public IVF programme (Bissonnette et al., 2011), each centre applied its own
standard protocols for ovarian stimulation and laboratory procedures.
Ovarian stimulation protocols, including that of long gonadotrophin-
releasing hormone (GnRH) agonist, shortGnRHagonist andGnRHantagon-
ist, were selected based on physician preference and patient characteristics.
Oocyte retrieval was performed 34.5–36 h after the administration of
human chorionic gonadotrophin, according to individual clinic policy. Insem-
ination was performed using standard IVF or intracytoplasmic sperm injec-
tion. Embryo culture was performed using standardized procedures in all
centres.
Embryo transfer
Embryo transfer was performed in all centres under ultrasound guidance on
Day 2, Day 3, or at the blastocyst stage, depending on cycle-speciﬁc
characteristics. Each clinic applied its own internal policies with respect to
embryo quality and selection and regarding the pertinence of transferring
more than one embryo. In general, the woman’s age, her IVF history and
the quality of the embryoswere primary factors in a decision to transfer mul-
tiple embryos. Embryo quality characteristics were applied when selecting
suitable embryos for cryopreservation, based on the clinic’s internal proto-
cols. Oocyte and embryo development parameters were strictly applied to
eliminate embryos with very low implantation potential.
Modalities of embryo transfer
Elective single-embryo transfer (eSET) refers to the transfer of only one
embryo when at least one more embryo was available for cryopreservation
at the time of transfer.Non-elective single-embryo transfer (neSET) refers to
the transfer of the only embryo available at the time of transfer. Elective
double-embryo transfer (eDET) refers to the transfer of two embryos
when more than two embryos were available at the time of transfer.
Non-elective double-embryo transfer (neDET) refers to the transfer of the
only twoembryos available at the timeof transfer.More thandouble-embryo
transfer (.DET) refers to the transfer of more than two embryos.
Outcomes
Pregnancy was assessed by serum human chorionic gonadotrophin concen-
tration 15 days after oocyte retrieval (≥25 IU) and clinical pregnancy was
determined by ultrasonographic evidence of an intrauterine fetal heartbeat
between 7 and 8 weeks of gestation. Clinical pregnancies exclude ectopic
pregnancies. Multiple pregnancies were deﬁned according to the number
of fetuses with a positive heartbeat. Frozen embryos were deﬁned as the
number of surplus embryos available for cryopreservation.
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Economic analysis of the public IVF
programme
A decision-analytic model was developed to assess the economic effect of
the introduction of universal IVF coverage in Quebec by comparing the
cost implications of the former tax-credit reimbursement system with
those of the new public IVF system. The analytic framework for assessing
the efﬁciency of policy changes differs from a cost-effectiveness analysis,
which compares alternative treatment interventions among people with
similar medical conditions. Policy analyses are methodologically diverse
and seek to determine the policy goals and economics of different policy
alternatives. Because access to care can be inﬂuenced by reimbursement,
the populations considered in policy analysis may not be comparable. This
is particularly relevant in the analysis describedhere, as access to theuniversal
coverage of IVF in Quebec increased the demand for fertility services by
nearly 200% within the ﬁrst 12 months. Furthermore, complete reimburse-
mentwould likely allowaccess towomen froma lower socioeconomic status
who could not previously afford IVF treatment, a group of patients who also
have an increased risk of adverse birth outcomes (Blumenshine et al., 2010).
In order to estimate the downstream costs of treatment related to mul-
tiple pregnancies, we projected live birth rates from the clinical pregnancy
rates reported to CARTR by the ﬁve Quebec clinics providing IVF treat-
ment during 2009 and 2011. Additionally, the number of children born
from cryopreserved cycles was determined based on 177 and 670 frozen
cycles performed in 2009 and 2011, respectively, adjusted formiscarriages.
The median gonadotrophin dose reported in CARTR by the ﬁve centres
providing IVF treatment inQuebec was used to estimate the ovarian stimu-
lation costs during the years studied. All costs in themodel were adjusted to
2012 to compare outcomes based on comparable costs and to be able to
interpret efﬁciency metrics related to the reimbursement policy change.
Costs were inﬂated by 4%, based on current health cost inﬂation in
Canada over the past few years (Canadian Institute for Health Information,
2011).
Ourmodel accounted for costs attributed tomultiple pregnancy, preterm
labour, preterm birth, neonatal admissions, antenatal care, vaginal and Cae-
sarean delivery, miscarriage, cerebral palsy, neonatal care, and readmission
within the ﬁrst year of life. Probabilities for pregnancy-related events cap-
tured in the model are described in Table I. Cost data for each event were
obtained from published references in Canada (Canadian Institute for
Health Information, 2006; Chuck and Yan, 2009).
Statistical analysis
Proportion comparisons were performed by Chi-square test or Fisher exact
test when indicated. The Student t-test was used to compare means. A
P-value of,0.05 was considered to be statistically signiﬁcant. Statistical ana-
lysis was performed using the STATA 10.0 software (Stata Corporation,
College Station, TX, USA).
Because the data analysed are publicly available through the Canadian
Fertility and Andrology Society website and do not include patient-
speciﬁc information, this study did not require Institutional Review
Board approval.
Results
A total of 1875 fresh IVF cycles were performed in Quebec during 2009
and 5489 cycles were performed during 2011, representing an increase
of 192%. Characteristics of these cycles are presented in Table II. The
proportion of women aged 35–39 was similar in the years studied;
however, the proportion of women younger than 35 decreased in
2011, and the proportion of women aged 40 and older increased. The
proportion of women experiencing their ﬁrst IVF cycle was higher in
2009 than in2011, aswasthemeangonadotrophindose.Theproportion
of cycles progressing to oocyte retrieval remained constant, while the
proportion of cycles achieving embryo transfer decreased. The preg-
nancy rates were lower in 2011 compared with 2009 for all age categor-
ies. After the initiation of the programme, the multiple pregnancy rates
decreased to 1/8th of its previous value in women younger than 35,
and to less than half its previous value in women aged 35 and older
(Table II).
As shown in Fig. 1, elective single-embryo transfer (eSET) was per-
formed in only 1.6% of cycles during 2009, which dramatically increased
........................................................................................
Table I Medical probabilities applied in reimbursement
policy analysis.
Probability Source
Miscarriage
Rate of clinical pregnancy
loss
0.154 Gunby (2010)
Stillbirth
Singleton pregnancy 0.007 Gunby (2010)
Twin pregnancy 0.0132
Higher order pregnancy 0.0229
Preterm labour (no delivery)
Singleton pregnancy 0.046 Cassell et al. (2004)
Twin pregnancy 0.368
Higher order pregnancy 0.432
Preterm birth
Singleton pregnancy 0.152 Gunby (2010)
Twin pregnancy 0.673
Higher order pregnancy 1.0
Low birthweight
Singleton pregnancy 0.07 Canadian Institute for
Health Information
(2009)
Twin pregnancy 0.56
Higher order pregnancy 0.98
Neonatal deaths
Singleton pregnancy 0.00216 Gunby (2010)
Twin pregnancy 0.009
Higher order pregnancy 0.038
C-Section delivery
Singleton pregnancy 0.335 Katalinic et al. (2004)
and Pinborg et al.
(2004)
Twin pregnancy 0.6135a
High order pregnancy 1b
Re-hospitalization
Child re-hospitalization
based on premature
,37 weeks
0.0654 Martens et al. (2004)
Maternal re-hospitalization
C-section
0.031 Public Health Agency
of Canada (2008)
Maternal re-hospitalization
vaginal delivery
0.018
aBased on averageC-section rates reported by Pinborg et al. (2004) and Katalinic et al.
(2004).
bBased on Canadian expert opinion.
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to 31.6% in 2011 (P, 0.001). The proportions of elective double-
embryo transfer (eDET) and the transfer of more than two embryos
(.DET) revealed a sharp decrease in 2011 (P, 0.001).
Table III shows the outcomes of frozen/thawed embryo transfer
cycles performed inQuebecpreceding and following universal IVF cover-
age. Overall, the proportion of cycles having embryos frozen was similar
in both periods; however by age group, it was higher in the two younger
age groups during 2011. The mean number of frozen embryos per
patient was higher in 2009 compared with 2011, and this applied to all
age groups.
In 2009, 177 FET created from fresh cycles were performed, com-
pared with 670 in 2011. The proportion of cycles performed was
similar for all age categories. Although the mean number of frozen/
thawed embryos transferred in 2009was higher than in 2011, the clinical
pregnancy rate and themultiple pregnancy ratewere similar in both study
years.
Economics
The costs to the Quebec government associated with funding IVF
increased substantially in the ﬁrst years of the public IVF programme
from CAD$7 million to CAD$26 million (Table IV). The comparative
total cost, which factored in antenatal, birth and complication costs for
IVFpregnancies,wasCAD$31.4million for the formerpartial reimburse-
ment by tax-credit and CAD$49.1 million for universal IVF coverage.
The public IVF programme increased government costs per IVF treat-
ment cycle from CAD $3730 to CAD$4759. The health system efﬁ-
ciency per cycle, which considered all downstream care-related costs,
decreased with universal IVF coverage to CAD$8960 per cycle from
CAD$16 747 per cycle in 2009. Based on the number of projected chil-
dren born from2009 fresh and frozen cycles and the projected live births
from the 2011 cohort, the cost per baby surviving to 1 year of age
decreased fromCAD$49 517 toCAD$43 362 per live birthwith univer-
sal reimbursement.
Discussion
The Quebec public IVF programme immediately attained the objectives
of increasing access to IVF and reducing multiple pregnancy rates. There
was a decrease in the proportion of patients having embryo transfer in
2011. In fact, the manner in which patients use up their three insured
........................................................................................
Table II Outcomes of fresh IVF cycles performed in
Quebec preceding and following universal IVF coverage.
2009 2011 P-value
Number of cycles 1875 5489
Age ,0.001
,35 years 854 (45.5) 2032 (37.0)
35–39 years 673 (35.9) 1996 (36.4)
≥ 40 years 348 (18.6) 1461 (26.6)
Number of previous
IVF cyclesa
,0.001
None 944 (73.0) 3403 (62.0)
One 259 (20.0) 1317 (24.0)
Two or more 91(7.0) 789 (14.0)
Gonadotrophin
dose IU (mean, SD)
3675 (1992) 3521 (2224) 0.01
Oocyte retrievals 1743 (93.0) 5110 (93.1) 0.8
Embryo transfers 1660 (88.5) 4361 (79.4) ,0.001
Clinical pregnancies
per embryo transfer
663 (39.9) 1084 (24.9) ,0.001
,35 years 372/778 (47.8) 566/1677 (33.8)
35–39 years 239/607 (39.4) 384/1586 (24.2)
≥40 years 52/275 (18.9) 134/1098 (12.2)
Multiple pregnancies
per clinical pregnancy
195 (29.4) 69 (6.4) ,0.001
,35 years 124 (33.3) 22 (3.9)
35–39 years 60 (25.1) 35 (9.1)
≥40 years 11 (21.2) 12 (9.0)
Values are n (%), unless otherwise stated.
aMissing information in 31% of the cycles for 2009.
Figure 1 Proportion of cycles using different modalities of embryo transfer, in period I (2009) and period II (2011).
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cycles can inﬂuence the decision whether to transfer or not. Under the
Quebec public IVF programme, only cycles resulting in an embryo trans-
fer count against the three insured attempts, and therefore, unless a suit-
able embryo is available, there is always the option of cancelling the
embryo transfer.
The lower proportion of women with previous IVF cycles among the
women receiving treatment in 2009 compared with those receiving the
same treatment in 2011might demonstrate existing barriers in access to
ART before the public IVF programme. Unequal access to IVF treatment
in Canada is determined mainly by lack of public funding (Nisker, 2008).
In Quebec, the increase in access to IVF after implementing the public
programme was mainly achieved through the impact of the elimination
of the cost of treatment for all women. Indeed, during 2011, the
number of clinics offering IVF treatment, their relative proximity and
their opening hours, factors that, along with the cost of treatment, are
the main determinants of IVF utilization/access (Collins, 2002), had
been the same before the advent of the public funding.
Because the use of eSETwasmuch greater in the second period, a de-
crease in the pregnancy rate was seen, especially in younger women.
However, also as consequence of the new SET policy, the rate of
embryo cryopreservation was higher in the second period (although
this only applied to women under 40), thus permitting more FET in
womenwho did not become pregnant from their fresh embryo transfer.
We have already recommended that cumulative pregnancy rates should
be themain outcome considered in evaluating the impact of a SET policy
(Ve´lez et al., 2013).Unfortunately, theCanadianARTregister collects in-
formation per individual IVF cycle and not longitudinally per patient, pre-
venting the calculation of cumulative pregnancy rates.
There were fewer embryos available for cryopreservation per patient
during the secondperiod,which could beexplainedbya tendencyamong
physicians towards milder ovarian stimulation in recent years. There is a
2-year difference in our study; therefore treating physicians may be
stimulating their patients less aggressively than before, especially when
only one embryo is transferred, as is suggested by the lower gonado-
trophin dose prescribed during 2011 compared with 2009. There was
no signiﬁcant difference in the pregnancy rate per FET, although the
mean number of frozen/thawed embryos transferred in 2011 was
lower than in 2009. We hypothesize that because only one embryo is
transferred in most patients under the new policy, there may be one
or more other embryos of equal quality that will be frozen; previously,
these better-quality embryos would also have been transferred,
leaving only the poorer-quality embryos for freezing. At the present
time, no information is availableonembryoquality to test this hypothesis.
The reduction of multiple pregnancies was similar to that reported in
other countries after the implementation of the public funding of IVF
programmes (Debrock et al., 2005; Gordts et al., 2005; Saldeen and
........................................................................................
Table III Outcomes of frozen/thawed embryo transfer
cycles performed in Quebec preceding and following
universal IVF coverage.
2009 2011 P-value
Proportion of women with
embryos available for
cryopreservation (%)
34.3 34.8 0.7
,35 years 47.8 54.0
35–39 years 28.5 32.7
≥40 years 12.6 11.1
Frozen embryos per patient,
mean (SD)
4.54 (3.0) 3.34 (2.7) ,0.001
,35 years 4.70 (3.1) 3.54 (2.8)
35–39 years 4.16 (2.6) 3.10 (2.7)
≥40 years 4.70 (3.7) 2.99 (2.5)
Frozen/thawed embryo transfer
cycles (FET)a, n (%)
177 670 0.8
,35 years 103 (58.2) 393 (58.7)
35–39 years 55 (31.1) 216 (32.2)
≥40 years 19 (10.7) 61 (9.1)
Number of frozen/thawed
embryos transferred, mean (SD)
2.40 (0.7) 1.47 (0.6) ,0.001
Clinical pregnancy rate per FET,
n (%)
45 (25.4) 130 (19.4) 0.1
,35 years 26 (25.2) 84 (21.4)
35–39 years 18 (32.7) 39 (18.1)
≥40 years 1 (5.3) 7 (11.5)
Multiple pregnancies per clinical
pregnancy, n (%)
7 (15.6) 17 (13.1) 0.7
,35 years 4 (15.4) 12 (14.3)
35–39 years 3 (17.7) 3 (12.8)
≥40 years 0 2 (28.6)
aEmbryos created from fresh cycles performed during the same calendar year.
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Table IV Costs to the Quebec government of
implementing universal IVF coverage and changes in
efﬁciency based on differences in outcomes achieved
for the two policies.
50% tax rebate
policy 2009
Universal IVF
policy 2011
Number of fresh IVF cycles 1875 5489
Number of FET 177 670
Sum of all costs C$31 402 410 C$49 184 098
Total costs of IVF
treatment
C$6 995 164 C$26 120 797
IVF pregnancy medical
costs
C$24 407 246 C$23 063 301
Pregnancy costs,
miscarriage, preterm labour
C$1 691 941 C$2 056 421
Hospitalization costs
including NICU
C$15 699 392 C$15 775 241
First year costs and CP
cases
C$7 015 913 C$5 231 639
Total cost per cycle C$16 747 C$8960
IVF treatment costs per
cycle
C$3730 C$4759
Medical costs per cyclea C$13 017 C$4201
Cost per babyb C$49 517 C$43 362
aIncludes all downstream related maternity and child costs to 1 year.
bSum of all costs per cycle/1 year survivors.
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Sundstrom, 2005; Van Landuyt et al., 2006). This is the result of a judi-
cious policy regarding the number of embryos to transfer. In our case,
single-embryo transfer increased signiﬁcantly after the programme was
instituted, and more than two embryos were seldom transferred, sup-
porting the hypothesis that single-embryo transfer is presently the
most effective strategy towards reducing multiple pregnancies (ESHRE,
2001).
Over the past 10 years, conventionalwisdom in fertility policy has held
that thepublic fundingof IVFwill ﬁnance itself due to the reductionofmul-
tiple pregnancies and their high cost to the health system. This fails to
account for the prevailing unmet need for IVF treatment that often
exists in society and the increase in demand that can occur following
such changes in funding. In Quebec, the demand for IVF treatment
increased by nearly 200% following the inclusion of the treatment in
the universal coverage system. This brought a dramatic increase in cost
to the government, as noted above,with the cost per IVF cycle increasing
from CAD$3730 to CAD $4759. Although savings were achieved in
terms of reduced neonatal care, re-hospitalization and complications,
therewerealso increases in antenatal anddelivery costs due tomore chil-
dren being conceived and born by means of IVF treatment.
A better measure of a policy’s success can be assessed by estimating
efﬁciency outputs which rationalize costs in relation to the outcomes
achieved in alternative policy scenarios. In Quebec, the introduction of
universal IVF coverage increased the number of clinical pregnancies
and projected live births. The reduced medical cost per cycle and
reduced cost per live birth indicate that savings are being achieved with
the new public IVF programme. Despite the surge in demand due to
the newly available possibility for many to fulﬁl a previously unmet
need, and despite the increased cost of IVF treatment compared with
the former tax-credit reimbursement system, the efﬁciency of the
policy to reduce cost per baby has been achieved. The costs described
here are likely anunderestimate, as theydonot factor inmanyof the long-
term costs that can arise from complications. Furthermore, as the em-
phasis is exclusively on health-care costs, our analysis fails to take into
account the long-term contribution that children offer to society, and
their contribution to ﬁscal sustainability (Connolly et al., 2010).
Increasingly, modelling is used to bridge gaps in available evidence to
be able to understand the long-term implications of policy changes and
medical treatment practices. In our study, the collection of longitudinal
data on patientswas not possible due to the privacy and ethical concerns
that have prevented the establishment of a central register that reports
the outcomes of IVF treatments. Moreover, collecting such information
wasnot feasible in this study, as the costof collecting primary data related
to the recent policy change would have been prohibitively high. In such
instances, modelling can be an informative bridge to establish links
between ongoing pregnancies and their likely outcomes based on previ-
ously reported probability outcomes in comparable populations. To
reﬂect the increased risks associated with IVF-conceived children, we
considered probabilities and rates reported in studies conducted in
other ART populations. However, in some instances, it was not possible
to ﬁnd data speciﬁc to ART-conceived children, and therefore, the cost
estimates of our analysis should be viewed as conservative.
It should be stressed that the implementation of a public IVF pro-
gramme can only be adequately assessed by means of a comprehensive
health-surveillance tool. The Canadian ART register was established for
the collectionof treatment cycledata from fertility centresusingARTand
is ﬁnancially supported by voluntary participating ART centres (Gunby,
2012). Although this register addresses important aspects of IVF, the in-
formation needs to be expanded and integrated into a comprehensive
health-care monitoring system that includes the follow-up of women
treated by ART, and the health of children born after these treatments.
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 Chapter 22 
 The Quebec Experience—One Plus One 
Equals Two at Once: Presenting Cumulative 
Pregnancy Rates as the Ideal Outcome 
in Elective SET Programmes 
 Maria  P.  Vélez ,  Isaac-Jacques  Kadoch ,  Simon  J.  Phillips , 
and  Francois  Bissonnette 
 Introduction 
 Single Embryo Transfer (SET) is the most effective approach to reduce the inci-
dence of multiple pregnancies associated with Assisted Reproductive Technologies 
[ 1 ]. Although the pregnancy rate after one fresh SET is reported to be lower com-
pared with one fresh double embryo transfer (DET), no difference exists when one 
DET is compared with elective SET followed by one Frozen embryo Transfer (FET) 
[ 2 ]. Elective SET requires the selection of good prognosis patients and the transfer 
of the best high quality embryo [ 3 ]. As noted elsewhere in this volume, sophisti-
cated molecular techniques continue to be refi ned for evaluation of the chromo-
somal competencies of embryos, thus permitting an improved selection process to 
enable SET. Of note, several observational studies comparing elective SET with 
DET have not found differences in terms of pregnancy rate among both groups [ 3 –
 5 ]. The few Randomized Controlled Trials that have compared a single cycle of 
DET with one cycle of fresh SET followed by one frozen/thawed SET have shown 
that there is no signifi cant difference in terms of cumulative live birth rates [ 2 ]. 
Moreover, in regard to health expenses, elective SET embryo is substantially 
cheaper than DET in women younger than 38 years with a good prognosis [ 5 ]. 
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 Public fi nancing of assisted reproductive technologies (ART) is intended to 
increase access to fertility treatments by reducing the fi nancial burden to patients. 
In counterpart , governments aim to reduce the health expenses associated with mul-
tiple pregnancies attributable to the use of ART. Although comprehensive govern-
ment initiatives are associated with greater utilization of fertility treatments and 
lower rates of multiple pregnancies [ 6 ,  7 ], critics of public fi nancing argue that 
public programmes are also associated with lower pregnancy rates [ 8 ]. 
 In Canada, health care is the responsibility of the individual provinces. In the 
Province of Quebec, the cost of all IVF procedures was covered by the patient and 
partially reimbursed as a 50 % tax rebate before 2010. There was no regulation 
regarding the number of embryos to transfer or the number of treatment cycles pro-
vided to each patient. On 5 August 2010, the Quebec government introduced a pub-
lic IVF programme, marking the beginning of a new era in the fi eld of ART here. 
Under this programme, all costs related to IVF are covered by Quebec’s universal 
health insurance plan. This includes the cost of all medical procedures related to IVF 
for three stimulated cycles, or up to six modifi ed natural cycles (mnIVF) [ 9 ,  10 ]. 
 We previously assessed the clinical outcomes and the economic effect of the IVF 
cycles performed in Quebec during the fi rst year of provincially funded ART [ 6 ,  7 ]. 
We reported that the implementation of a public IVF programme favouring elective 
SET not only sharply decreases the incidence of multiple pregnancy but also reduces 
the cost per live birth [ 7 ]. In addition, we have shown that the cumulative pregnancy 
rate per initiated cycle (i.e. the proportion of clinical pregnancies after the fi rst fresh 
IVF cycle, including the resulting fi rst frozen/thawed embryo transfer) was compa-
rable to DET before the public IVF programme in one of the IVF centres offering 
ART treatment in Quebec [ 11 ]. In this chapter, we aim to demonstrate that the preg-
nancy rate after one fresh elective SET plus one FET is comparable to the pregnancy 
rate after elective DET using data from the whole province of Quebec. We under-
score the importance of presenting cumulative pregnancy rates as the preferred out-
come to evaluate the impact of elective SET programmes. 
 Methods 
 Study Population 
 The methodology of this prospective comparative analysis has been previously 
described [ 7 ]. For this specifi c analysis, period I includes the elective DET per-
formed in the fi ve centres offering IVF treatment in Quebec during 2009, the year 
prior to the start of the Quebec public IVF programme. Period II comprises the elec-
tive SET performed in the same centres during 2011, the fi rst full calendar year of 
the programme, plus the fi rst FET from embryos created from fresh 2011 cycles. 
Elective Single Embryo Transfer (eSET) refers to the transfer of only one embryo 
when at least one more embryo was available for cryopreservation at the time of 
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transfer. Elective Double Embryo Transfer (eDET) refers to the transfer of two 
embryos when more than two embryos were available at the time of transfer. 
 Data were obtained from the Canadian Assisted Reproductive Technologies 
Register (CARTR). CARTR collects treatment cycle data from Canadian fertility 
centres that are using ART. Staff at each centre provides information for each IVF 
cycle initiated. The complete anonymous case records are sent electronically each 
year to the CARTR coordinating centre, where they are checked for accuracy and 
completeness [ 12 ]. 
 Clinical and Laboratory Procedures 
 Ovarian stimulation protocols, including long gonadotropin-releasing hormone 
(GnRH) agonist, short GnRH agonist, and GnRH antagonist, were selected based 
on physician preference and patient characteristics. Oocyte retrieval was performed 
36 h after the administration of human chorionic gonadotropin. Insemination was 
performed using standard IVF or intracytoplasmic sperm injection when indicated. 
Embryo culture was performed using standardized procedures. Embryo transfer 
was uniformly performed under ultrasound guidance on Day 2, Day 3, or at the 
blastocyst stage, depending on cycle-specifi c characteristics. Each clinic applied its 
own internal policies with respect to embryo quality and selection and regarding the 
pertinence of transferring more than one embryo. In general, the woman’s age, her 
IVF history, and the quality of the embryos were primary factors in a decision to 
transfer multiple embryos. Embryo quality characteristics were applied when 
selecting suitable embryos for cryopreservation, based on the clinic’s internal pro-
tocols. Oocyte and embryo development parameters were strictly applied to elimi-
nate embryos with very low implantation potential. 
 Outcomes 
 Pregnancy was assessed by serum human chorionic gonadotropin concentration 15 
days after egg retrieval (≥25 IU); and clinical pregnancy was determined by ultra-
sonographic evidence of intrauterine fetal heartbeat between 7 and 8 weeks of gesta-
tion. For this tabulation, clinical pregnancies excluded ectopic pregnancies. Multiple 
gestation was defi ned according to the number of embryos with positive cardiac 
action. Frozen embryos were defi ned as the number of surplus (non- transferred) 
embryos available for cryopreservation. 
 We estimated the time-limited cumulative pregnancy rate among patients under-
going a fresh eSET during 2011, plus the resulting fi rst FET performed during the 
same study period. The 2011 cumulative pregnancy rate was then compared with the 
pregnancy rate after eDET performed in 2009. Time-limited analyses using propor-
tions provide information on the likelihood of pregnancy per woman with a 
 predetermined number of IVF cycles in the time period defi ned. This method is an 
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alternative to life table analysis, which although frequently used may overestimate 
treatment effect [ 13 ]. We then conducted a sensitivity analysis to extrapolate the 
cumulative pregnancy rate for those women who following a negative pregnancy test, 
and having cryopreserved embryos, were unable to have their fi rst FET during 2011. 
 Statistical Analysis 
 Proportion comparisons were performed by chi-squared test or Fisher’s Exact test, 
as appropriate. Student’s  t -test and ANOVA were used to compare means. A  p -value 
<0.05 was considered to be statistically signifi cant. Statistical analysis was per-
formed using STATA version 10.0 (Stata Corporation, College Station, TX, USA). 
Because the data analysed for this investigation are publicly available through the 
Canadian Fertility and Andrology Society website and do not include patient- 
specifi c information, this study did not require Institutional Review Board approval. 
 Results 
 The mean age was similar in both groups [32.54 years (SD 3.69) in the eDET group 
versus 32.52 (SD 3.62) in the eSET group,  p = 0.92]. Additional characteristics are 
presented in Table  22.1 . The two groups were similar in terms of the distribution of 
age categories, number of prior pregnancies, and number of previous IVF cycles. 
There are some differences in the diagnosis of infertility, with some indication that 
the eSET group is at a disadvantage for some prognostic factors. As Table  22.2 
refl ects, the mean number of oocytes retrieved, cleaved embryos, and embryos cryo-
preserved was lower in the eSET group compared with the eDET (2009).
 Table  22.3 presents the outcomes of IVF cycles performed during both study 
periods according to the two modalities of embryo transfer. There were 514 eDET 
during 2009. The eDET pregnancy rate was 47.1 % in 2009, and the multiple preg-
nancy rate was 35.1 %. There were 1,375 eSET cycles in 2011, of which 466 
(33.9 %) resulted in a pregnancy, leaving 909 women to have transfer of cryopre-
served embryos (by defi nition, all women having eSET have at least one embryo for 
cryopreservation). Of these, 378 women had a fi rst FET during 2011 with a preg-
nancy rate of 21.2 %, which leads to a clinical pregnancy after one fresh eSET plus 
one FET of 39.7 % (Table  22.3 ).
 Next, we conducted a sensitivity analysis to extrapolate the cumulative preg-
nancy rate. Applying a conservative survival rate of 90 % to the remaining cryopre-
served embryos, 478 women still waiting for their fi rst FET after eSET will be able 
to undergo an FET. Extrapolating the 2011 FET pregnancy rate of 21.2 % to the 
remaining women, 101 more pregnancies would be expected. So the pregnancy rate 
after one fresh eSET plus one FET would be 47.1 % (647/1,375). This is equal to 
the 2009 eDET pregnancy rate, showing equivalence between the two approaches 
( p = 0.8). 
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 Table 22.1  Characteristics of the Quebec study population 
 2009 (eDET),  n = 514  2011 (eSET),  n = 1,375 
 p  n  %  n  % 
 Age  0.15 
 <35  367  71.4  943  68.6 
 35–39  132  25.7  405  29.5 
 ≥40  15  2.9  27  2.0 
 Prior pregnancy  0.99 
 No  266  51.7  620  45.1 
 Yes  134  26.1  313  22.8 
 Missing  114  22.2  442  32.1 
 Prior ART cycles  0.50 
 0  317  61.7  1,053  76.6 
 1  59  11.5  240  17.5 
 2  14  2.7  62  4.5 
 ≥3  6  1.1  20  1.4 
 Missing  118  23.0  0  0 
 Diagnosis category  0.01 
 Unexplained  90  17.5  247  18.0 
 Male factor only  224  43.6  544  39.6 
 >1 female factor  12  2.3  26  1.9 
 Male + female factor  71  13.8  133  9.7 
 Endometriosis only  37  7.2  96  7.0 
 Tubal only  41  8.0  122  8.9 
 Ovulatory only  27  5.3  107  7.8 
 DOR only  6  1.2  47  3.4 
 Other female only  4  0.8  22  1.6 
 Missing  2  0.4  31  2.3 
 Table 22.2  IVF outcomes in Quebec, as a function of ET strategy 
 2009 (eDET),  n = 514  2011 (eSET),  n = 1,375 
 p  Mean  SD  Mean  SD 
 Oocytes retrieved  14.7  6.5  13.3  6.3  <0.001 
 Cleaved embryos  8.9  4.1  7.80  4.2  <0.001 
 Embryos cryopreserved  4.2  2.9  3.18  2.5  <0.001 
 Table 22.3  Clinical pregnancies following elective DET (2009) vs. elective SET + one FET 
(2011) in Quebec 
 2009  2011 
 p 
 Fresh eDET 
cycles 
 Fresh eSET 
cycles 
 First FET 
after eSET  Cumulative 
 Transfers  514  1,375  378 
 Clinical pregnancies  242 (47.1)  466 (33.9)  80 (21.2)  546/1,375 (39.7)  0.004 
 Single pregnancies  157 (64.9)  458 (98.3)  70 (87.5)  528 (96.7)  <0.001 
 Multiple pregnancies  85 (35.1)  8 (1.7)  10 (12.5)  18 (3.3) 
 Note : All data presented as  n (%) 
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 Conclusion 
 Our goal was to present data regarding the implementation of a predominant eSET 
treatment strategy through public funding in the province of Quebec. One concept 
that was alluded to in the presentation of the initial data from this programme was 
that the transfer of two embryos, one at a time, would result in pregnancy rates simi-
lar to those seen when eDET was used prior to the programme [ 6 ]. This concept was 
recently supported with data from one of the fi ve centres offering IVF treatment in 
Quebec [ 11 ]. The present analysis, which includes data from the entire Quebec prov-
ince, goes towards the same direction. The extrapolated pregnancy rate after one 
fresh eSET plus one fi rst FET in 2011 was not different from that of fresh eDEt alone 
in 2009. Moreover, it is similar to the pregnancy rate of 47.7 % reported in a large 
randomized controlled trial comparing these two treatment strategies [ 14 ]. We recog-
nize the limitations of extrapolating clinical pregnancies, but this is our best estimate 
since the Canadian ART Register collects data per individual cycle, not longitudi-
nally per patient. We consider, however, that our results are valid and conservative. 
Indeed, some patients who won’t be pregnant after their fi rst FET will have cryopre-
served embryos still available, increasing even more the probability of pregnancy. 
Our data support, therefore, that cumulative pregnancy rates should be presented as 
the ideal outcome in the evaluation of the effectiveness of eSET programmes. 
 Confl ict of Interest  The authors declare no confl ict. 
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Abstract An analysis of national registry data for 5 years of in-vitro fertilization 
(IVF) funding in Quebec, Canada was compared with the previous complete year of 
non-funded IVF cycles, as well as the first complete year following the end of 
funding. The number of cycles, livebirth rates, age group of patients treated, use of 
donor gametes, multiple pregnancy rates and cycle cancellation rates were assessed. 
The total number of IVF cycles performed increased dramatically during the funded 
period, averaging over 10,000 cycles per year. There was no change in the age group 
distribution of patients treated, but less egg donation was performed. Interestingly, 
funding was also associated with an increase in the IVF cycle cancellation rate (17.0% 
versus 34.4%, P<0.001), a dramatic decline in the multiple pregnancy rate (25.6% 
versus 4.9%, P<0.001), and a decline in the livebirth rate per fresh embryo transfer in 
stimulated IVF cycles (32.3% versus 25.5%, P<0.001). Although the livebirth rate for 
stimulated IVF declined, over 9000 babies were born as a result of the coverage. 
Lessons learned from this experience could help develop a more fiscally responsible 
programme that still facilitates access to IVF care. 
 
KEYWORDS: IVF, public funding, multiple pregnancy rates 
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<A>Introduction 
In August 2010, the Provincial Government of Quebec introduced public coverage for 
assisted reproductive technology (ART) treatment (Gazette Officielle du Québec, 
2010). In parallel, the number of embryos that could be transferred was controlled. 
The law encouraged single embryo transfer (SET) in all cases, but permitted up to two 
embryos in women aged ≤36 years and up to three embryos in women aged ≥37 
years. The results of the first few months of the programme demonstrated a dramatic 
decrease in the multiple pregnancy rate due to the increased use of elective SET 
(Bissonnette et al., 2011). The law covered ART treatment for all residents of Quebec 
via the provincial health plan. There were no exclusion criteria in terms of age, 
previous history of tubal ligation/vasectomy, previous pregnancies, sexuality or 
marital status. The coverage provided for three stimulated in-vitro fertilization (IVF) 
cycles including medication, along with any associated procedures such as surgical 
sperm retrieval or donor semen, and the frozen embryo transfers (FET) resultant from 
those egg retrievals. Any frozen embryos had to be used before further ovarian 
stimulation could be undertaken. Egg donation was covered if the egg donor herself 
was a holder of a valid Quebec health card, but obtaining donor eggs from out of 
province or from an egg bank was not covered.  
An IVF cycle only counted towards the three attempts if an embryo transfer 
occurred. Therefore, any cycles cancelled prior to embryo transfer (poor ovarian 
stimulation, no eggs at retrieval, failed fertilization or no high-quality embryos 
available for transfer) were not counted. Furthermore, a successful live birth reset the 
counter.  
After a little more than 5 years of operation, on 15 November 2015, the 
programme was terminated (Gazette Officielle du Québec, 2015). A new law 
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removed the coverage of IVF, except in the case of fertility preservation for oncologic 
reasons, although only ovarian stimulation, oocyte retrieval and cryopreservation 
remained covered; fertilization by intracytoplasmic sperm injection, embryo culture 
and future use of the cryopreserved materiel were not included. Furthermore, the law 
increased restrictions on embryo transfer, mandating SET for all women aged <37 
years, while permitting two embryos to be transferred in patients aged ≥37 if written 
justification was provided in the patient file. In sharp contrast to IVF, intrauterine 
insemination (IUI) was covered to a maximum of nine attempts, including 
medication, monitoring, semen preparation and insemination. The purchase of donor 
semen for IUI was no longer covered.  
 
<A>Materials and methods  
In Canada, professionals working in the field of assisted human reproduction meet 
under the auspices of the Canadian Fertility and Andrology Society (CFAS). Since 
2000, CFAS has managed a registry of ART cycles performed across the country 
[Canadian Assisted Reproductive Technology Registry (CARTR)]. Since 2014, 
CARTR has been managed by the Better Outcomes Registry Network (BORN) 
Ontario. BORN is the province of Ontario’s registry for births within the province. 
Although based in one province, for the ART registry, BORN manages the data from 
all IVF clinics across Canada. BORN does not receive any patient identifying 
information from provinces other than Ontario, and is managed by very strict privacy 
regulations. 
Data from CARTR-BORN is available upon request for research purposes. 
There was no direct patient involvement in this study and data were already 
anonymized: as such, no ethical approval was required according to Canadian 
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Institutes of Health Research policy on ethical conduct for research involving humans. 
This study used CARTR-BORN data from August 2010 until November 2015, 
representing the period when ART was covered under Quebec provincial health 
insurance, and from 2009 and 2016 to compare data from years either side of the 
coverage when ART was within the private domain. 
Data are reported as livebirth rates per embryo transfer. During the 64 months 
of the programme, in addition to the live births that were reported to clinics, there 
were an additional 1310 clinical pregnancies for which the livebirth data were not 
reported by patients. As these pregnancies were confirmed by ultrasound at the 
clinics, a 15% loss of pregnancy (Avalos et al., 2012) was assumed, and the remaining 
85% of these lost-to-follow-up clinical pregnancies were added to the livebirth data. 
There were 27 similar cases in 2009 and 124 cases in 2016, of which 85% were also 
included in the livebirth data. 
Statistical analysis was performed using Chi-squared test, and the result was 
considered to be significant when P<0.05. No funding was obtained for this study. 
Ethical approval was not required for this study according to the Canadian Tri-
council Policy Statement on Ethical Conduct for Research Involving Humans, as data 
were obtained from a centralized anonymized databank.  
 
<A>Results 
The total number of cycles performed per year increased dramatically once the 
programme became established (see Figure 1). Interestingly, however, the proportion 
of patients treated by age was not affected by the availability of insured IVF 
treatments (see Figure 2). The number of fresh IVF cycles started decreased 
dramatically in 2016, while the number of frozen–thaw cycles started remained 
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relatively stable in 2016. It is important to note that upon termination of the 
programme in November 2015, all patients with cryopreserved embryos in storage 
from the programme still had coverage for their FET cycles until a pregnancy was 
obtained. In addition, all patients with a valid prescription for IVF obtained prior to 15 
November 2015 were also covered for their fresh IVF attempt and all FET cycles as a 
result of that attempt. Thus, despite the change in the law, some fresh and frozen–
thaw cycles performed in 2016 remained covered.  
 
<insert Figures 1 and 2 near here> 
 
The overall cancellation rate for fresh IVF cycles increased from 17% in 
2009/2016 (combined) to 34.4% during the programme (P<0.001) (Table 1). 
 
<insert Table 1 near here> 
 
<B>Use of donor gametes 
During the funded period, the percentage of IVF cycles that were combined with 
donor sperm decreased (8.2% versus 6.2%, P<0.001). The use of donor eggs in IVF 
also declined significantly during the insured period (4.5% versus 2.4%, P<0.001), 
and this reduction was seen for all age groups. 
 
<B>Livebirth rates 
The overall livebirth rate per fresh embryo transfer decreased during the funded 
period compared with 2009/2016 (33.9% versus 23.7% between 2010 and 2015, 
P<0.001) (Table 2). Although significant for both fresh and frozen IVF cycles, the 
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absolute percentage point decline was greater in fresh cycles. The complete results for 
stimulated cycles, natural modified cycles and FET cycles broken down by age are 
presented in Tables 3–5. The reduction in the livebirth rate per transfer for fresh 
embryo transfer following IVF with ovarian stimulation was significant in all age 
groups except for 39–40 years (Table 3).  
 
<insert Tables 2–5 near here> 
 
There were 9232 live births between 2010 and 2015, and although the multiple 
pregnancy rate was reduced significantly by the programme, as reported previously 
(Bissonnette et al., 2011), a small proportion of these live births involved the birth of 
more than one baby. Overall, more than 9232 babies were born as a result of the 
programme.  
 
<B>Use of single embryo transfer 
As should be expected from a programme twinned with legislation controlling the 
number of embryos to be transferred, the use of SET in stimulated IVF cycles and 
FET cycles increased significantly (Table 6) when comparing 2009 with 2010–2015 
(IVF 9.2% versus 64.3%, P<0.0001; FET 10.0% versus 73.5%, P<0.0001). 
Moreover, because the change in coverage in 2015 coincided with even tighter 
restrictions on the number of embryos that could be transferred, the use of SET 
increased further in 2016 (IVF 71.5%, FET 86.7%). Not surprisingly, there was no 
difference in the use of SET in the natural cycle IVF groups. Coincident with 
increased use of SET, the multiple pregnancy rate decreased from 25.6% in 2009 to 
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3.3–7% during the years of the programme, and was 4.5% in 2016 during the return to 
privately funded cycles (Table 7). 
 
<insert Tables 6 and 7 near here> 
 
<A>Discussion 
There was an enormous increase in the number of cycles performed during the 
insured period, with total cycle numbers reaching close to 12,000 in 2013, and 
averaging over 10,000 per year. This represented a five-fold increase compared with 
the number of cycles performed in 2009, despite the fact that the proportion of 
patients in each age group did not change. However, this coincided with a reduction in 
the livebirth rate per transfer during the funded period.  
Interestingly, this occurred despite an increase in the cycle cancellation rate. 
Although it is possible that the dramatic increase in the number of cycles performed 
without time to effectively increase capacity may have initially stressed the ability of 
IVF centres to expand and continue to provide the same high-level care, the types of 
patients seeking treatment also changed. Funding altered the balance between the cost 
of trying another cycle and the probability that the next cycle might succeed. 
Increasingly, patients with a poor prognosis returned for another cycle rather than 
considering alternatives, such as egg donation or adoption. Moreover, because 
government funding applied separately to ovarian stimulation, egg collection and 
embryo transfer, both patients and IVF centres had no real disincentive to start IVF 
cycles even if they were cancelled prior to retrieval, or cancelled after retrieval. Thus, 
it was not unusual for patients with a poor prognosis to initiate multiple stimulated 
IVF attempts before finally completing all of their funded embryo transfers. 
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The impact on the success rate per transfer in FET cycles is interesting. The 
data show that the proportion of SET increased even more for FET cycles than fresh 
IVF cycles. From 2009 to 2016, the use of blastocyst transfer increased. Coupled with 
the fact that cryopreservation was included in the overall cycle reimbursement, the 
years 2010–2015 saw more selective use of embryo cryopreservation and higher 
subsequent cryo–thaw transfer success rates. These factors may have mitigated the 
negative impact of funding on the success rates of frozen–thaw cycles compared with 
fresh cycles. 
In terms of the use of donor gametes within IVF cycles, a decrease in donor 
egg use during the programme was noted for all patient age groups. In terms of the 
use of donor eggs in Canada, it is important to note that, under Federal law, it is 
illegal to reimburse donors for their donation, and therefore almost all gametes from 
egg and sperm banks come from the USA. Although in the funded years, the purchase 
of donor sperm was covered by the programme, the purchase of donor eggs was not. 
Thus, those patients who may have most benefited from donor eggs had little to lose 
by attempting an IVF cycle using their own eggs, even when their prognosis was very 
poor. In a private setting, those patients may have chosen to put their money towards 
egg donation rather than spend it on an autologous attempt with a poor prognosis. As 
the data demonstrate, relatively few patients chose to spend additional money on 
treatments that were not covered in addition to or in place of the funded treatments. In 
terms of treatment age, although the law did not impose a maximum age limit, the 
clinics, using historical data from CARTR-BORN, applied a soft cut-off of 43 years 
of age for autologous IVF, so an increase in the use of donor eggs is seen after this 
age (49.2% of IVF cycles). 
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We have previously reported on the reduction in cost per live birth during the 
programme compared with previous years where a 50% tax deduction was possible in 
Quebec (Velez et al., 2014). It is important to note that the cost of the programme was 
the major reason cited for its untimely end. Although it is difficult to obtain precise 
details on the annual costs, they were widely presented in the media as being between 
$CAN 70 and 80 million per year. If one considers that the average lifetime 
contribution of an individual in terms of income tax in the province of Quebec is 
approximately $CAN 330,000 (StatsCanada), it can be estimated that the 9232+ 
babies born as a result of the programme will contribute over $CAN 3 billion. 
Therefore, at a cost of $CAN 400 million over the 5.5 years, it suggests that, in purely 
financial terms, the Provincial Government of Quebec achieved close to an eight-fold 
return on their investment.  
The design of the coverage encouraged the cancellation of cycles as only a 
cycle resulting in an embryo transfer counted towards the three insured cycles per 
patient. This is clearly demonstrated by the significant increase in cycle cancellations 
in all age groups. This clearly had an important impact on results as well as 
financially on the programme. Such a design leads to aggressive rejection of 
suboptimal embryos since the concept that a better outcome can be achieved in a 
future cycle leads to the desire to maximize the use of the three available embryo 
transfers. Furthermore, it creates pregnancy and livebirth rate per cycle data that are 
not comparable with other studies. Undoubtedly counting a cycle from the start of 
ovarian stimulation or egg collection would reduce cancellation rates. Data from 
2016, when the cancellation rate returned to <20%, confirms that this increased 
cancellation rate was associated directly with the funding design, and not, as could 
have been hypothesized, by development of new technologies such as time lapse or 
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pre-implantation genetic testing for aneuploidy which tend to ‘deselect’ embryos and 
can result in increased cancellation.   
There is substantial variation from country to country regarding IVF funding. 
A survey of patients, professionals and the general public in Germany concluded that 
the majority of people supported public coverage of IVF. However, the concept of 
patient co-payments varied depending on which group was interviewed: 33% of 
patients agreed with this idea compared with 75% of professionals and the general 
public. At the time of publication, patients contributed 50% of the costs in Germany 
(Rauprich et al., 2010). 
Some opponents to IVF funding have argued that infertility is a social rather 
than a medical issue
 
(Hughes et al., 2009). However, infertility is defined as a disease 
by the World Health Organization (Zegers-Hochschild et al., 2009). Furthermore, due 
to an increased presence in the media as well as its inclusion as storylines in movies 
and television series, the use of IVF has become more widely known and understood 
by the general public, and the ability to access this technology is increasingly desired. 
Of course, the associated expense creates challenges for public funding.  
There are certainly lessons that can be learned from Quebec’s experience with 
regard to the best manner in which a programme can be designed to maximize its 
potential whilst maintaining fiscal restraints. The study data suggest that funding 
design can influence the clinical results, as well as encourage changes in clinical 
practice. Based on this analysis, it is suggested that a programme should fund a 
limited number of egg collections per patient, should include all resulting fresh and 
frozen embryos, and should have strict inclusion/exclusion criteria.  
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Table 1. Cancellation rates of fresh in-vitro fertilization cycles between the insured period 
(2010–2015) and pre/post insured years (2009 and 2016). 
 
 
2009 
 
2016 
 
2009 and  
2016 
 
2010–2015 
 
P-value 
 
Overall  Total cycles started 
Cycles completed 
2055 
1769 
5353 
4380 
7408 
6149 
17.0% 
39,722 
26,064 
34.4% 
<0.001 
% 13.9% 18.2% 
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Table 2. Livebirth rates per embryo transfer (ET) for in-vitro fertilization (IVF), modified natural 
cycle IVF and frozen embryo transfers (FET) between the insured period (2010–2015) and 
pre/post insured years (2009 and 2016) in the province of Quebec. 
 
2009 2016 
 
2009 and 
2016 
 
2010–2015 
 
P-value 
 
IVF Total ET 
n live births 
1725 
616 
1398 
395 
3123 
1011 
23,765 
6066 
˂0.001 
% 35.7% 28.3% 32.3% 25.5%  
Natural IVF 
 
Total ET 
n live births 
44a 
16 
37a 
13 
81a 
29 
2062a 
520 
0.03 
% 36.4% 35.2% 35.8% 25.2% 
FET Total ET 
n live births 
492 
109 
2938 
765 
3430 
874 
12,924 
2824 
˂0.001 
 
% 22.2% 26.1% 25.5% 21.9% 
Overall Total ET 
n live births 
2261 
741 
3373 
1163 
5634 
1904 
38,955 
9232 
˂0.001 
 % 32.8% 34.5% 33.9% 23.7%  
a
<38 years old.  
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Table 3. Livebirth rates per embryo transfer (ET) using in-vitro fertilization with ovarian 
stimulation between the insured period (2010–2015) and pre/post insured years (2009 and 
2016) in the province of Quebec. 
 
 
2009 
 
2016 
 
2009 and 2016 
 
2010–2015 
 
P-value 
 
<30 years Total ET 
n live births 
197 
93 
144 
60 
341 
153 
2708 
968 
<0.001 
% 47.2% 41.7% 44.9% 35.7% 
30–34 
years 
Total ET 
n live births 
586 
246 
389 
140 
975 
386 
6754 
2260 
<0.001 
% 42.0% 36.0% 39.5% 33.5% 
35–38 
years 
Total ET 
n live births 
483 
179 
402 
117 
885 
296 
6732 
1760 
<0.001 
% 37.1% 29.1% 33.4% 26.1% 
39–40 
years 
Total ET 
n live births 
236 
53 
210 
42 
446 
95 
3288 
600 
0.12 
% 22.5% 20.0% 21.3% 18.2% 
41–43 
years 
Total ET 
n live births 
181 
32 
209 
25 
390 
57 
3839 
409 
0.017 
% 17.7% 12.0% 14.6% 10.7% 
Overall Total ET 
n live births 
1725 
616 
1398 
395 
3123 
1011 
23,765 
6066 
<0.001 
% 35.7% 28.3% 32.4% 25.5% 
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Table 4. Livebirth rates using in-vitro fertilization in a modified natural cycle between the 
insured period (2010–2015) and pre/post insured years (2009 and 2016) in the province of 
Quebec. 
 
 
 
2009 
 
2016 
 
2009 and 2016 
 
2010–2015 
 
P-value 
 
<30 
years 
Total ET 
n live births 
10 
3 
30.0% 
1 
1 
11 
4 
316 
101 
0.76 
% 100% 36.4% 32.0% 
30–34 
years 
Total ET 
n live births 
21 
10 
14 
5 
35.7% 
35 
15 
965 
253 
0.03 
% 47.6% 42.9% 26.2% 
35–38 
years 
Total ET 
n live births 
% 
13 
3 
23.1% 
22 
7 
31.8% 
35 
10 
781 
166 
0.3 
28.6% 22.2% 
Overall Total ET 
n live births 
44 
16 
37 
13 
81 
29 
2062 
520 
0.03 
% 36.4% 35.2% 35.8% 25.2% 
ET, embryo transfers. 
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Table 5. Livebirth rates using frozen embryo transfers between the insured period (2010–
2015) and pre/post insured years (2009 and 2016) in the province of Quebec. 
 2009 2016 2009 and 2016 
 
2010–2015 
 
P-value 
<30 
years 
Total ET 
n live births 
77 
15 
352 
106 
429 
121 
1754 
403 
0.02 
% 19.5% 30.1% 28.2% 23.0% 
30–34 
years 
Total ET 
n live births 
194 
47 
899 
262 
1093 
309 
4388 
1105 
0.04 
% 24.2% 29.1% 28.3% 25.2% 
35–38 
years 
Total ET 
n live births 
119 
28 
904 
241 
1023 
269 
3797 
838 
0.004 
% 23.5% 26.7% 26.3% 22.1% 
39–40 
years 
Total ET 
n live births 
51 
11 
301 
73 
356 
84 
1406 
236 
0.003 
% 21.6% 24.3% 23.6% 16.8% 
41–43 
years 
Total ET 
n live births 
34 
3 
333 
49 
367 
52 
1201 
164 
0.8 
% 8.8% 14.7% 14.1% 13.7% 
Overall Total ET 
n live births 
492 
109 
2938 
765 
3430 
874 
12,924 
2824 
<0.001 
% 22.2% 26.0% 25.5% 21.9% 
ET, embryo transfers. 
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Table 6. Proportion of use of single embryo transfers (SET) between 2009 and 2010–2015 in 
the province of Quebec. 
 
 
2009 
 
2010–2015 
 
 
2016 P-value 
 
IVF Total ET 
SET 
1769 
163 
26,064 
16,766 
1398 
999 
<0.001 
% 9.2% 64.3% 71.5% 
Natural 
IVF 
Total ET 
SET 
44 
42 
2299 
2251 
44 
44 
0.53 
% 95.0% 97.9% 100% 
FET  Total ET 
SET 
492 
49 
12,924 
9496 
2938 
2546 
<0.001 
% 10.0% 73.5% 86.7% 
IVF, in-vitro fertilization; FET, frozen embryo transfers; ET, embryo transfers. 
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Table 7. Multiple pregnancy rate from 2009 until 2016 in the province of Quebec. 
Year Multiple pregnancy rate 
 
2009 
 
 
25.6% 
 
2010 (partial year) 
 
 
3.7% 
 
2011 
 
 
7.0% 
 
2012 
 
 
6.0% 
 
2013 
 
 
3.3% 
 
2014 
 
 
3.4% 
 
2015 
 
 
5.2% 
 
2016 
 
 
4.5% 
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